Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
The CRISPR-Cas system gene editing technology targets the ANGPTL3 gene, which solves the problem of difficulty in reducing ANGPTL3 protein and lipid levels in the existing technology for a long time, and achieves a significant reduction in plasma ANGPTL3 protein levels, effectively treating ANGPTL3 related diseases.
Patent Information
- Application Number
- CN202380036652.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-10-21
- Filing Date
- 2023-02-28
- Publication Date
- 2024-11-26
Smart Images

Figure CN119032176A_ABST
Abstract
Description
Related Applications
[0001] This application claims priority to U.S. Provisional Patent Application Serial No. 63 / 315,372 filed on March 1, 2022, U.S. Provisional Patent Application Serial No. 63 / 332,234 filed on April 18, 2022, U.S. Provisional Patent Application Serial No. 63 / 352,747 filed on June 16, 2022, and U.S. Provisional Patent Application Serial No. 63 / 380,557 filed on October 21, 2022. The entire contents of these applications are hereby expressly incorporated by reference in their entirety. Reference to a sequence listing
[0002] This application is submitted with a sequence listing in electronic format. The sequence listing is provided as a file entitled 80EM-341711-WO_SeqListing, which was created on February 25, 2023 and is 375 kilobytes in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety. background
[0003] field The present disclosure relates generally to the fields of molecular biology and biotechnology, including gene editing. Description of Related Art
[0004] Angiopoietin-like 3 (ANGPTL3) is a member of the angiopoietin-like family of secreted factors that regulate lipid metabolism and is primarily expressed in the liver. ANGPTL3 dually inhibits the catalytic activity of lipoprotein lipase (LPL), which catalyzes the hydrolysis of triglycerides, and endothelial lipase (EL), which hydrolyzes high-density lipoprotein (HDL) phospholipids. ANGPTL3 has been associated with a variety of conditions, including disorders of lipid metabolism (e.g., hyperlipidemia).
[0005] Targeting DNA using the RNA-guided DNA targeting principle of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas (CRISPR-associated) systems has been widely used. CRISPR-Cas systems can be divided into two categories, where Class 1 systems utilize a complex of multiple Cas proteins (such as Type I, Type III, and Type IV CRISPR-Cas systems), and Class 2 systems utilize a single Cas protein (such as Type II, Type V, and Type VI CRISPR-Cas systems). Type II CRISPR-Cas-based systems have been used for genome editing, and require Cas polypeptides or variants thereof guided by customizable guide RNAs (gRNAs) for programmable DNA targeting.
[0006] There is a need to develop safe and effective therapies for treating ANGPTL3-associated diseases and disorders. Overview
[0007] Disclosed herein are methods, compositions, and kits for treating an ANGPTL3-related disease or disorder. In some embodiments, the method for treating an ANGPTL3-related disease or disorder comprises administering to a subject (e.g., a primate subject) more than one nanoparticle complexed with (a) a guide RNA (gRNA) targeting an ANGPTL3 gene or a nucleic acid encoding the gRNA and (b) a nucleic acid encoding an RNA-guided endonuclease, thereby treating the ANGPTL3-related disease or disorder in the subject. In some embodiments, more than one nanoparticle is administered to the subject two or more times. In some embodiments, each of the two or more administrations is separated by about 1 year, about 2 years, or about 5 years. In some embodiments, each of the two or more administrations is separated by about two weeks to about four weeks. In some embodiments, more than one nanoparticle is administered to a subject at a dose of about 0.01-5 mg / kg (determined by the total nucleic acid (e.g., the sum of ANGPTL3 gRNA and Cas9 mRNA) per administration, including 0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 0.7 mg / kg, 0.8 mg / kg, 0.9 mg / kg, 1 mg / kg, 1.1 mg / kg, 1.2 mg / kg, 1.3 mg / kg, 1.4 mg / kg, 1.5 mg / kg, 1.6 mg / kg, 1.7 mg / kg, 1.8 mg / kg, 1.9 mg / kg, 2 mg / kg, 2.1 mg / kg, 2.2 mg / kg, 2.3 mg / kg, 2.4 mg / kg, 2.5 mg / kg, 2.6 In some embodiments, more than one nanoparticle is administered to a subject at or about the following dose (determined by the sum of ANGPTL3 gRNA and SpCas9 mRNA): 0.1 mg / kg, 0.3 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 1 mg / kg, 1.5 mg / kg, 2 mg / kg, or 3 mg / kg.
[0008] ANGPTL3 expression (e.g., ANGPTL3 gene expression or ANGPTL3 protein expression) in a subject can be reduced after administration, e.g., by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70%. The concentration of ANGPTL3 protein in a subject (e.g., in the blood or plasma of the subject) can be reduced after administration, e.g., by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70%. The reduction can be relative to (a) ANGPTL3 expression or the concentration of ANGPTL3 protein in the subject's plasma prior to administration of more than one nanoparticle; (b) ANGPTL3 expression or the concentration of ANGPTL3 protein in one or more untreated subjects; and / or (3) a reference level of ANGPTL3 expression or the concentration of ANGPTL3 protein in a healthy subject.
[0009] The level (e.g., plasma level) of one or more of the non-high-density lipoprotein (non-HDL) lipids of the subject can be reduced by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% after administration. One or more non-HDL lipids can be triglycerides, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), or a combination thereof. In some embodiments, the reduction in non-HDL levels is relative to (a) the non-HDL level in the plasma of the subject before administration of more than one nanoparticle; (b) the non-HDL level in one or more untreated subjects; and / or (3) a reference non-HDL level in a healthy subject.
[0010] In some embodiments, the concentration of apolipoprotein B (ApoB) protein in the subject's plasma is reduced by at least 20%, at least 40%, or at least 70% after administration. In some embodiments, the reduction is relative to (a) the concentration of ApoB protein in the subject's plasma before administration of more than one nanoparticle; (b) the concentration of ApoB protein in one or more untreated subjects; and / or (3) a reference level of ApoB protein concentration in healthy subjects.
[0011] In some embodiments, the reduction in the concentration of ANGPTL3 protein, the level of one or more of non-high-density lipoprotein (non-HDL) lipids, and / or the concentration of ApoB protein is at least 20%, at least 40%, or at least 70% at three weeks, four weeks, five weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, or more after administration. In some embodiments, the concentration of ANGPTL3 protein, the level of one or more of non-high-density lipoprotein (non-HDL) lipids, and / or the concentration of ApoB protein is reduced by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or a number or range between any two of these values for three weeks, four weeks, five weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, eighteen months, two years, three years, four years, five years, six years, seven years, eight years, nine years, ten years, 12 years, 15 years, 20 years, or more after administration.
[0012] In some embodiments, a subject in need has a triglyceride level greater than 150 mg / dl. In some embodiments, a subject in need has a triglyceride level greater than 300 mg / dL, a non-high-density lipoprotein (HDL) level greater than 160 mg / dL, a low-density lipoprotein cholesterol (LDL-C) level greater than 100 mg / dL, an ApoB level greater than 100 mg / dL, or a combination thereof. The method may include measuring the blood level of one or more of ANGPTL3, ApoB, triglycerides, very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), LDL-C, HDL, and non-HDL lipids in the subject before, during, and / or after administration. The method may, for example, also include identifying a subject in need of treatment.
[0013] In some embodiments, the ANGPTL3-related disease or disorder is a metabolic disease, a cardiovascular disease, a lipid metabolism disease, or a combination thereof. In some embodiments, one or more symptoms of an ANGPTL3-related disease or disorder in a subject are alleviated or relieved. Non-limiting examples of ANGPTL3-related diseases or disorders include obesity, diabetes, atherosclerosis, dyslipidemia, coronary heart disease, non-alcoholic fatty liver disease (NAFLD), hyperfatty acidemia, metabolic syndrome, and combinations thereof. Dyslipidemia can be hyperlipidemia, such as hypercholesterolemia, hypertriglyceridemia, or both. In some embodiments, the ANGPTL3-related disease or disorder is familial hypercholesterolemia, familial combined hyperlipidemia, familial chylomicronemia syndrome, multifactorial chylomicronemia syndrome, elevated Lp(a), or a combination thereof. NAFLD can be hepatic steatosis or steatohepatitis. Diabetes can be type 2 diabetes or type 2 diabetes with dyslipidemia. In some embodiments, administering more than one nanoparticle to a subject reduces dyslipidemia, cardiovascular risk, likelihood of death related to a cardiovascular event, or a combination thereof.
[0014] In some embodiments, the nucleic acid encoding the RNA-guided endonuclease is an mRNA of the RNA-guided endonuclease. The RNA-guided endonuclease can be, for example, a Cas9 endonuclease. Non-limiting examples of Cas9 endonucleases include Streptococcus pyogenes (S. Pyogenes) Cas9, Staphylococcus aureus (S. aureus) Cas9, Neisseria meningitidis (N. meningitides) Cas9, Streptococcus thermophilus (S. thermophilus) Cas9, Streptococcus thermophilus 3 Cas9, Treponema denticola (T. denticola) Cas9 and variants thereof.
[0015] The gRNA can be, for example, a single guide RNA (sgRNA). In some embodiments, the gRNA targets exon 1 of the ANGPTL3 gene. In some embodiments, the gRNA comprises a spacer sequence of any one of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26. In some embodiments, the gRNA or a nucleic acid encoding the gRNA and the RNA-guided nuclease are encapsulated in a nanoparticle. The nanoparticle can be or include a lipid nanoparticle. In some embodiments, the subject is a primate subject. In some embodiments, the subject is a human.
[0016] In some embodiments, the method also includes determining the level of one or more of (i) alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transferase (GGT), bilirubin, alkaline phosphatase (Alk Phos) and albumin in the subject; (ii) prothrombin time (PT) and / or (iii) partial thromboplastin time (PTT). Determination can occur before administration, after administration, during administration, or any combination thereof. In some embodiments, determination includes determining (i), (ii) and / or (iii) once, twice, three times, four times or more in the subject during the desired duration. For example, determination may include determining (i), (ii) and / or (iii) once after administration, or determining daily up to (daily up to) the 7th day, the 14th day, the 21st day, the 28th day, the 35th day, the 42nd day, the 49th day, the 56th day, the 63rd day. In some embodiments, determining comprises determining (i), (ii) and / or (iii) in the subject daily, weekly or monthly for at least 3 months, at least 6 months or at least 12 months after administration. In some embodiments, more than one nanoparticle is administered to the subject at a single dose of about 0.1 mg / kg, 0.3 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 1 mg / kg, 1.5 mg / kg, 2.0 mg / kg, 2.5 mg / kg or 3.0 mg / kg of nucleic acid (a) and (b).
[0017] Disclosed herein include methods for treating an ANGPTL3-associated disease or disorder in a subject in need thereof, wherein the method comprises administering to the subject more than one nanoparticle complexed with (a) and (b) at a single dose of about 0.1 mg / kg, 0.3 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 1 mg / kg, 1.5 mg / kg, 2.0 mg / kg, 2.5 mg / kg or 3.0 mg / kg of nucleic acid (a) a gRNA targeting an ANGPTL3 gene (ANGPTL3gRNA) and (b) Cas9 mRNA, thereby treating the subject's ANGPTL3-associated disease or disorder.
[0018] In some embodiments, the methods disclosed herein include administering more than one nanoparticle to a subject in a single administration. For example, in some embodiments, more than one nanoparticle is administered to a subject in a single administration at or about the following doses: 0.5 mg / kg, 0.6 mg / kg, 1 mg / kg, 1.5 mg / kg, 2.0 mg / kg, 2.5 mg / kg or 3.0 mg / kg RNA content of (a) guide RNA (gRNA) or nucleic acid encoding a gRNA targeting an ANGPTL3 gene and (b) a nucleic acid encoding an RNA-guided endonuclease (e.g., Cas9). In some embodiments, the gRNA comprises a spacer sequence of SEQ ID NO: 3, SEQ ID NO: 20, or SEQ ID NO: 12. In some embodiments, the gRNA comprises a sequence of SEQ ID NO: 10 or SEQ ID NO: 13. In some embodiments, a single dose of more than one nanoparticle is complexed with (a) about 1.5 mg / mL of ANGPTL3 gRNA and (b) about 0.5 mg / mL of Cas9 mRNA. In some embodiments, a single dose of more than one nanoparticle is about 58.2 mg / mL.
[0019] In some embodiments, additional treatment is applied to the subject. In some embodiments, additional treatment includes administration of corticosteroids, anti-H1 antihistamines, anti-H2 antihistamines or any combination thereof. In some embodiments, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week or more before or after administering more than one nanoparticle to the subject. In some embodiments, additional treatment and more than one nanoparticle are administered simultaneously.
[0020] The present disclosure also includes compositions. In some embodiments, the composition comprises more than one nanoparticle complexed with (a) a guide RNA (gRNA) targeting an ANGPTL3 gene (ANGPTL3 gRNA) and (b) an mRNA encoding a Cas9 endonuclease, wherein the gRNA comprises a spacer sequence of SEQ ID NO: 3, SEQ ID NO: 20, or SEQ ID NO: 12. In some embodiments, the gRNA comprises a sequence of SEQ ID NO: 10 or SEQ ID NO: 13. In some embodiments, the Cas9 endonuclease is a Streptococcus pyogenes Cas9 endonuclease. In some embodiments, the concentration of the more than one nanoparticle is about 58.2 mg / mL and is complexed with a total of about 2 mg / mL of nucleic acids of (a) ANGPTL3 gRNA and (b) Cas9mRNA. In some embodiments, the concentration of the more than one nanoparticle is about 58.2 mg / mL and is complexed with (a) about 1.5 mg / mL of ANGPTL3 gRNA and (b) about 0.5 mg / mL of Cas9 mRNA.
[0021] In some embodiments, the Cas9 mRNA may comprise SEQ ID NO: 16. In some embodiments, two or more of the uracil residues of the Cas9 mRNA are N1-methyl pseudouridine. In some embodiments, the Cas9 mRNA comprises the sequence of SEQ ID NO: 18. In some embodiments, the Cas9 mRNA comprises the sequence of SEQ ID NO: 19.
[0022] The disclosure herein includes a method for treating an ANGPTL3-related disease or disorder in a subject in need thereof. In some embodiments, the method comprises administering to the subject more than one nanoparticle complexed with (a) a guide RNA (gRNA) targeting an ANGPTL3 gene (ANGPTL3 gRNA) or a nucleic acid encoding the gRNA, wherein the ANGPTL3 gRNA comprises a spacer sequence of SEQ ID NO: 20, and (b) a Cas9 mRNA comprising a sequence of SEQ ID NO: 16, thereby treating the subject's ANGPTL3-related disease or disorder. The disclosure herein provides a composition for use in treating an ANGPTL3-related disease or disorder. In some embodiments, the composition comprises more than one nanoparticle complexed with (a) a guide RNA (gRNA) targeting an ANGPTL3 gene (ANGPTL3 gRNA) or a nucleic acid encoding the gRNA, wherein the ANGPTL3 gRNA comprises a spacer sequence of SEQ ID NO: 20, and (b) a Cas9 mRNA comprising a sequence of SEQ ID NO: 16. In some embodiments, the ANGPTL3 gRNA comprises a spacer sequence of SEQ ID NO: 12. In some embodiments, the ANGPTL3 gRNA is a single guide RNA (sgRNA) comprising a sequence of SEQ ID NO: 13. Two or more uracil residues of the Cas9 mRNA can be modified uracil residues, such as N1-methyl pseudouridine. In some embodiments, the Cas9 mRNA comprises a sequence of SEQ ID NO: 18. In some embodiments, the method comprises administering to the subject more than one nanoparticle at a single dose of about 0.1 mg / kg, 0.3 mg / kg, 0.6 mg / kg, or 1.0 mg / kg of the total nucleic acid of (a) and (b). In some embodiments, the expression of ANGPTL3 in the subject is reduced by at least 20% after administration, the concentration of ANGPTL3 protein in the plasma of the subject is reduced by at least 20% after administration, or both. In some embodiments, the reduction is relative to (a) ANGPTL3 expression or concentration of ANGPTL3 protein in the subject's plasma prior to administration of more than one nanoparticle; (b) ANGPTL3 expression or concentration of ANGPTL3 protein in one or more untreated subjects; and / or (3) a reference level of ANGPTL3 expression or concentration of ANGPTL3 protein in healthy subjects. In some embodiments, the concentration of ANGPTL3 protein in the subject's plasma is reduced by at least 70% one month after administration. In some embodiments, the subject's plasma level of one or more of non-high-density lipoprotein (non-HDL) lipids is reduced by at least 20% after administration.In some embodiments, one or more of the non-HDL lipids are triglycerides, very low density lipoproteins (VLDL), low density lipoproteins (LDL), or a combination thereof. In some embodiments, the reduction in non-HDL levels is relative to (a) the non-HDL levels in the plasma of the subject before administering more than one nanoparticle; (b) the non-HDL levels in one or more untreated subjects; and / or (3) the reference non-HDL levels in healthy subjects. In some embodiments, the plasma triglyceride levels in the subject are reduced by at least 30% after administration for one month, two months, three months, six months, or more. In some embodiments, the concentration of apolipoprotein B (ApoB) protein in the plasma of the subject is reduced by at least 20% after administration. In some embodiments, the reduction is relative to (a) the concentration of ApoB protein in the plasma of the subject before administering more than one nanoparticle; (b) the concentration of ApoB protein in one or more untreated subjects; and / or (3) the reference level of ApoB protein concentration in healthy subjects. The reduction caused by the methods or compositions described herein can be, for example, sustained for at least four weeks, two months, six months, one year, two years, five years, ten years, or longer. In some embodiments, the subject in need thereof has a triglyceride level greater than 300 mg / dL, a non-high-density lipoprotein (HDL) level greater than 160 mg / dL, a low-density lipoprotein cholesterol (LDL-C) level greater than 100 mg / dL, an ApoB level greater than 100 mg / dL, or a combination thereof. The ANGPTL3-related disease or disorder can be, for example, a metabolic disease, a cardiovascular disease, a lipid metabolism disease, or a combination thereof. In some embodiments, the ANGPTL3-related disease or disorder is obesity, diabetes, atherosclerosis, dyslipidemia, coronary heart disease, non-alcoholic fatty liver disease (NAFLD), hyperfatty acidemia, metabolic syndrome, or a combination thereof. In some embodiments, the method comprises administering more than one nanoparticle to the subject at a single time. In some embodiments, a single dose of more than one nanoparticle is complexed with (a) ANGPTL3 gRNA and (b) Cas9 mRNA at a total RNA concentration of 2.0 mg / mL. In some embodiments, the total RNA comprises (a) about 1.5 mg / mL of ANGPTL3 gRNA and (b) about 0.5 mg / mL of Cas9 mRNA. In some embodiments, the lipid nanoparticle comprises one or more neutral lipids, charged lipids, ionizable lipids, steroids, and polymer-conjugated lipids. In some embodiments, the lipid nanoparticle comprises cholesterol, polyethylene glycol (PEG) lipids, or both. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 A non-limiting exemplary non-human primate (NHP) study design is depicted.
[0024] Figure 2 is a graph showing the percent change from baseline in plasma ANGPTL3 protein in Group 1 NHPs and Group 3 NHPs.
[0025] Figure 3A-3B Measurements of triglyceride levels are depicted. Figure 3A is a graph showing plasma triglyceride levels of NHPs in Group 1 before and after treatment. Figure 3B is a graph showing the percent change from baseline in plasma triglyceride levels of NHPs in Group 1.
[0026] Figure 4A-4B Non-limiting exemplary data related to plasma triglyceride levels are depicted. Figure 4A is a graph showing plasma triglyceride levels of NHPs in Group 3 before and after treatment. Figure 4B is a graph showing the percent change from baseline in plasma triglyceride levels of NHPs in Group 3.
[0027] Figure 5A-5D Non-limiting exemplary data related to triglyceride levels are depicted. Figure 5A-Figure 5B It shows that the first group ( Figure 5A ) and Group 3 ( Figure 5B ) are two graphs showing the maximum percent change in plasma triglyceride levels of NHPs. Figure 5C-5D It shows that the first group ( Figure 5C ) and Group 3 ( Figure 5D ) Graph of the percent change from baseline in plasma triglyceride levels on Day 36.
[0028] Figure 6A-6D It is a graph showing the ANGPTL3 gene editing efficiency in different organ tissues.
[0029] Figure 7 is a graph showing the percentage of ANGPTL3 gene editing in liver biopsies in Group 1 and Group 3 NHPs.
[0030] Figure 8A-8E Alanine aminotransferase (ALT) ( Fig. 8A )、Aspartate aminotransferase (AST) ( Figure 8B )、alkaline phosphatase (ALP) ( Figure 8C )、Albumin (ALB) Fig.8D ) and bilirubin (TBIL) ( Fig. 8E ) of liver function tests.
[0031] Fig. 9 A non-limiting exemplary NHP study design is depicted.
[0032] Figures 10A-10D It is shown that 0.5 mg / kg ( Fig. 10A )、1.5 mg / kg ( Fig. 10B ) and 3.0 mg / kg CTX310 formulation ( Fig. 10C ) Graph showing the percentage of ANGPTL3 gene editing in different organ tissues of treated NHPs. Fig. 10D Depicted are the percentages of ANGPTL3 gene editing in different organ tissues of NHPs treated with 0.5 mg / kg, 1.5 mg / kg, and 3.0 mg / kg CTX310 formulations approximately 3 months after administration.
[0033] Fig.11 is a graph showing the percentage of ANGPTL3 gene editing in hepatocytes of NHPs treated with 0.5 mg / kg, 1.5 mg / kg, and 3.0 mg / kg CTX310 formulations.
[0034] Figure 12A-12E Depicted are exemplary data relating to plasma ANGPTL3 levels. Fig. 12A is a graph showing plasma ANGPTL3 protein levels in cynomolgus monkeys treated with three different doses of CTX310 formulations (0.5, 1.5, and 3.0 mg / kg) compared to a control group. Fig. 12B is a graph showing the percent change from baseline in plasma ANGPTL3 protein levels in cynomolgus monkeys treated with three different doses of CTX310 formulations (0.5, 1.5, and 3.0 mg / kg) compared to the control group. Fig. 12C is a graph showing the percent change from baseline in plasma ANGPTL3 protein in cynomolgus monkeys on Day 37 following CTX310 treatment. Fig.12D is a graph showing the percent change in serum ANGPTL3 protein after CTX310 treatment. Fig.12E is a graph showing the percent change in plasma ANGPTL3 protein approximately 3 months after CTX310 treatment.
[0035] Figure 13A-13I Depicted are exemplary data related to triglyceride levels. Figure 13A-13C is a graph showing the percent change in plasma triglyceride levels normalized to baseline in cynomolgus monkeys following treatment with three different doses of CTX310 formulations: 0.5 mg / kg ( Fig.13A )、1.5 mg / kg ( Fig. 13B ) and 3.0 mg / kg ( Fig. 13C ). Fig.13D is a graph showing the percent change from baseline in plasma triglyceride levels in cynomolgus monkeys on Day 37 following CTX310 treatment. Fig.13Eis a graph showing the percent change from baseline in serum triglyceride levels one month after CTX310 treatment. Figure 13F-13H Depicted are changes in triglyceride levels in mg / dL in cynomolgus monkeys following treatment with three different doses of CTX310 formulations: 0.5 mg / kg ( Fig.13F )、1.5 mg / kg ( Figure 13G ) and 3.0 mg / kg ( Fig.13H ). Fig.13I is a graph showing the percent change from baseline in plasma triglyceride levels in cynomolgus monkeys approximately 3 months after CTX310 treatment.
[0036] Figure 14A-14B Data related to the correlation between lipid levels and gene editing are depicted. Fig.14A is a graph showing the correlation between triglyceride reduction in liver and the percentage of ANGPTL3 gene editing. Fig. 14B is a graph showing the correlation between ANGPTL3 protein reduction in liver and the percentage of ANGPTL3 gene editing.
[0037] Figure 15A-Figure 15C Figure 2 shows wild-type (WT), LDLR treated with two exemplary lipid nanoparticles (RIV-000005 and RIV-000006) with gRNA targeting the mouse ANGPTL3 gene. + / - Mouse (Het) and LDLR - / - Gene editing efficiency in liver of mice (Hom) Fig.15A ), Angptl3 protein level ( Fig. 15B ) and triglyceride levels ( Fig. 15C ns: not significant.
[0038] Figures 16A-16H Exemplary data related to the LDLR pathway are depicted. Figures 16A-16D Figure 3 depicts wild-type (WT), LDLR treated with three exemplary lipid nanoparticles (RIV-000004, RIV-000005, and RIV-000006) with gRNA targeting the mouse ANGPTL3 gene. + / - Mouse (Het) and LDLR - / - Gene editing efficiency in liver of mice (Hom) Fig.16A ), Angptl3 protein level ( Fig. 16B ), triglyceride levels ( Fig. 16C ) and LDL levels ( Fig.16D )’s picture. Figure 16E-16H Depicted are data from LDLR mutant mice one month after administration of RIV-000005. Fig.16EDepicts the editor in the liver, Fig.16F showed a decrease in ANGPTL3 protein levels, and Figure 16G Shown are plasma TG levels in both male and female groups following RIV-000005 treatment compared to untreated control mice. Fig.16H depicts that a moderate reduction in LDL was observed in female mice administered RIV-000005 compared to control female mice, but a similar effect was not observed in male mice administered RIV-000005.
[0039] Fig.17 A non-limiting exemplary design of a Phase 1 safety and tolerability clinical study for one or more of the ANGPTL3 gene editing nanoparticles described herein (e.g., CTX310) and a determination of how to proceed to a Phase 2 clinical study based on the results of the Phase 1 study is shown.
[0040] Fig.18 A non-limiting exemplary design of a Phase 1 safety and tolerability clinical study for one or more of the ANGPTL3 gene editing nanoparticles described herein (e.g., CTX310) and a determination of how to proceed to a Phase 2 clinical study based on the results of the Phase 1 study is shown.
[0041] Fig.19 A non-limiting exemplary clinical study Phase 2 patient population based on dose escalation results (eg, six months after treatment) is shown.
[0042] Figure 20A-20B Depicted are exemplary data associated with non-Good Laboratory Practice (non-GLP) toxicity studies. Fig. 20A AST levels in animals treated with the indicated doses up to about 3 months after administration are shown in . Fig. 20B Bilirubin levels in animals treated with the indicated doses up to about 3 months after administration are shown in .
[0043] Figure 21A-21B Depicted are exemplary data associated with a Good Laboratory Practice (GLP) toxicity study showing that AST ( Fig.21A ) and bilirubin ( Fig.21B ) levels. Data up to about 10 days after administration are shown.
[0044] Figure 22A-22B Describes the use of in vivo ( Fig.22A ) and in vitro studies ( Fig. 22B )Edited EC90 values.
[0045] Fig.23 An exemplary clinical trial study design is depicted.
[0046] Fig.24 Depicted are non-limiting exemplary data showing reduction in ANGPTL3 plasma protein (ng / mL) with and without pre-treatment. N = 4 animals per group. Means and SD are shown.
[0047] Fig.25 Depicted from Fig.24 Results of the same experiment shown in , as percent change reduction in ANGPTL3 plasma protein with and without pre-treatment. N = 4 animals per group. Means and SD are shown.
[0048] Fig.26 Data from 2 months post-administration are depicted. Reduction of ANGPTL3 plasma protein with and without pre-treatment is shown. N = 4 animals per group. Mean and SD are shown.
[0049] Fig. 27 Data from 2 months post-administration are depicted. Reduction in ANGPTL3 plasma protein with and without pre-treatment is shown (as percent change). N = 4 animals per group. Means and SD are shown.
[0050] Fig.28 An exemplary schematic diagram of a Phase I clinical trial design is depicted.
[0051] Fig.29 A non-limiting exemplary schematic diagram depicting the good laboratory practice (GLP) toxicity of CTX310 in a non-human primate (NHP) study design.
[0052] Fig.30 Non-limiting exemplary data showing dose-dependent reductions in ANGPTL3 total plasma protein following administration of CTX310. Data are shown in ng / mL. 0 to 1 month: 8-10 NHPs per group, 1 to 6 months: 5 NHPs per group; mean SD is shown.
[0053] Fig.31 Shown from Fig.30 Data (as percent change) 0 to 1 month: 8-10 NHPs per group, 1 to 6 months: 5 NHPs per group; mean SD is shown.
[0054] Fig.32 Shown Fig.31 1 month time point. 8-10 NHPs per group; mean SD is shown.
[0055] Fig.33 Shown Fig.31 6-month time point. 5 NHPs per group; mean SD is shown. Details
[0056] In the following detailed description, reference is made to the accompanying drawings which form a part of this document. In the accompanying drawings, similar symbols generally identify similar components unless the context otherwise indicates. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized and other changes may be made without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure as generally described herein and illustrated in the accompanying drawings can be arranged, replaced, combined, separated, and designed in a variety of different configurations, all of which are expressly contemplated herein and form a part of the present disclosure.
[0057] All patents, published patent applications, other publications, and sequences from GenBank, and other databases mentioned herein are incorporated by reference in their entirety with respect to the relevant art.
[0058] The angiopoietin-like 3 (ANGPTL3) protein is a secreted protein that regulates plasma lipid levels by affecting the hydrolysis of triglycerides and phospholipids mediated by lipoprotein lipase and endothelial lipase. In humans, ANGPTL3 is a determinant of high-density lipoprotein (HDL) cholesterol levels as well as non-HDL levels such as low-density lipoprotein (LDL) cholesterol, triglycerides, and very low-density lipoprotein (VLDL) cholesterol. ANGPTL3 is associated with diseases and disorders involving abnormal lipoprotein metabolism, such as dyslipidemia, hypobetalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, and coronary heart disease. ANGPTL3 may be a potential therapeutic target for the treatment of various ANGPTL3-related diseases and disorders.
[0059] Disclosed herein are methods, compositions, and kits for treating an ANGPTL3-associated disease or disorder in a subject (e.g., a primate). In some embodiments, the method comprises administering to a primate subject in need thereof more than one nanoparticle complexed with (a) a guide RNA (gRNA) or a nucleic acid encoding a gRNA targeting an ANGPTL3 gene and (b) a nucleic acid encoding an RNA-guided endonuclease, thereby treating an ANGPTL3-associated disease or disorder in the primate subject. definition
[0060] As used herein, the term "about" means plus or minus 5% of the provided value.
[0061] As used herein, the term "RNA-guided endonuclease" refers to a polypeptide that can bind to RNA (e.g., gRNA) to form a complex that targets a specific DNA sequence (e.g., in a target DNA). A non-limiting example of an RNA-guided endonuclease is a Cas polypeptide (e.g., a Cas endonuclease, such as a Cas9 endonuclease). In some embodiments, an RNA-guided endonuclease as described herein targets a specific DNA sequence in a target DNA through an RNA molecule to which it binds. The RNA molecule may include a sequence that is complementary to a target sequence within the target DNA and is capable of hybridizing with the target sequence, thereby allowing the bound polypeptide to be targeted to a specific location within the target DNA.
[0062] As used herein, the term "guide RNA" or "gRNA" refers to a site-specific targeting RNA that can bind to an RNA-guided endonuclease to form a complex and direct the activity of the bound RNA-guided endonuclease (such as a Cas endonuclease) to a specific target sequence within a target nucleic acid. A guide RNA can include one or more RNA molecules.
[0063] As used herein, the "secondary structure" of a nucleic acid molecule (e.g., an RNA fragment or a gRNA) refers to the base pairing interactions within the nucleic acid molecule.
[0064] As used herein, the term "target DNA" refers to a DNA including a "target site" or a "target sequence". The term "target sequence" is used herein to refer to a nucleic acid sequence present in a target DNA to which a DNA targeting sequence or segment (also referred to herein as a "spacer") of a gRNA can hybridize as long as there are sufficient hybridization conditions. For example, a target sequence 5'-GAGCATATC-3' in a target DNA is targeted (or can hybridize or be complementary to it) by an RNA sequence 5'-GAUAUGCUC-3'. The hybridization between the DNA targeting sequence or segment of a gRNA and a target sequence can be, for example, based on the Watson-Crick base pairing rules, which makes programmability in a DNA targeting sequence or segment possible. A DNA targeting sequence or segment of a gRNA can be designed, for example, to hybridize with any target sequence.
[0065] As used herein, the term "Cas endonuclease" or "Cas nuclease" refers to an RNA-guided DNA endonuclease associated with the CRISPR adaptive immune system.
[0066] Unless otherwise indicated, "nuclease" and "endonuclease" are used interchangeably herein to refer to an enzyme with endonucleolytic catalytic activity for polynucleotide cleavage.
[0067] As used herein, the term "constant region" of gRNA refers to the nucleotide sequence of the gRNA associated with the endonuclease guided by RNA. In some embodiments, the gRNA includes crRNA and trans-activating crRNA (tracrRNA), wherein crRNA and tracrRNA hybridize with each other to form a duplex. In some embodiments, crRNA includes 5' to 3': spacer sequence and minimal CRISPR repeat sequence (also referred to herein as "crRNA repeat sequence"); and tracrRNA includes a minimal tracrRNA sequence complementary to the minimal CRISPR repeat sequence (also referred to herein as "tracrRNA antisense repeat sequence") and 3' tracrRNA sequence. In some embodiments, the constant region of gRNA refers to the part of crRNA that is the minimal CRISPR repeat sequence and tracrRNA.
[0068] As used herein, the term "donor template" refers to a nucleic acid chain containing exogenous genetic material that can be introduced into the genome (e.g., by homology-directed repair) to cause targeted integration of the exogenous genetic material. In some embodiments, the donor template may not have a region homologous to the target position in the DNA, but can be integrated by NHEJ-dependent end connection after cleavage at the target site. The donor template can be single-stranded or double-stranded DNA or RNA, and can be introduced into the cell in a linear or circular form.
[0069] The terms "polynucleotide" and "nucleic acid" are used interchangeably herein and refer to a polymeric form of nucleotides (ribonucleotides or deoxyribonucleotides) of any length. A polynucleotide may be single-stranded, double-stranded, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids / triple helices, or polymers containing purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural or derivatized nucleotide bases.
[0070] As used herein, the term "binding" refers to a non-covalent interaction between macromolecules (e.g., between a protein and a nucleic acid). When in a non-covalent interaction state, the macromolecules are said to be "associated" or "interacting" or "bound" (e.g., when molecule X is said to interact with molecule Y, this means that molecule X binds to molecule Y in a non-covalent manner). The binding interaction can be characterized by a dissociation constant (Kd), such as a Kd of or less than: 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12 M, 10-13 M, 10 -14 M, 10 -15 M or a number or range between any two of these values. Kd may depend on environmental conditions, such as pH and temperature. "Affinity" refers to the strength of binding, and increased binding affinity is associated with a lower Kd.
[0071] As used herein, the term "hybridizing" or "hybridize" refers to the pairing of substantially complementary or complementary nucleic acid sequences within two different molecules. Pairing can be achieved by any process in which a nucleic acid sequence is joined to a substantially complementary or fully complementary sequence by base pairing to form a hybrid complex. "Hybridizing" or "hybridizing" can include denaturing a molecule to destroy one or more intramolecular structures (e.g., one or more secondary structures) in the molecule. In some embodiments, denaturing the molecule includes heating a solution containing the molecule to a temperature sufficient to destroy the intramolecular structure of the molecule. In some cases, denaturing the molecule includes adjusting the pH of the solution containing the molecule to a pH sufficient to destroy the intramolecular structure of the molecule. For the purpose of hybridization, if at least 80% of the individual bases of two nucleic acid sequences or sequence segments are complementary to each other, they are "substantially complementary". In some embodiments, the splint oligonucleotide sequence is no more than about 50% identical to one of the two polynucleotides (e.g., RNA fragments) designed to be complementary thereto. The complementary portions of each sequence may be referred to herein as "segments," and if the segments have 80% or greater identity, the segments are substantially complementary.
[0072] The terms "complementary" and "complementary" refer to the fact that a nucleic acid can form hydrogen bonds with another nucleic acid based on the traditional Watson-Crick base pairing rules, i.e., adenine (A) pairs with thymine (U), and guanine (G) pairs with cytosine (C). Complementarity can be complete (e.g., complete complementarity) or incomplete (e.g., partial complementarity). Complete or complete complementarity indicates that each and all nucleic acid bases of a chain can form hydrogen bonds with the corresponding bases in another antiparallel nucleic acid sequence according to the Watson-Crick standard base pairing. Partial complementarity means that only a certain percentage of continuous residues in a nucleic acid sequence can form Watson-Crick base pairing with the same number of continuous residues in another antiparallel nucleic acid sequence. In some embodiments, complementarity can be at least 70%, 80%, 90%, 100%, or a number or range between any two of these values. In some embodiments, complementarity is complete, i.e., 100%. For example, the complementary candidate sequence segment is completely complementary to the candidate sequence segment, and the sequence of the candidate sequence segment can be deduced from the candidate sequence segment using Watson-Crick base pairing rules.
[0073] As used herein, the terms "nucleic acid" and "polynucleotide" are interchangeable and refer to any nucleic acid, whether comprising phosphodiester linkages or modified linkages such as phosphotriester, phosphoramide, siloxane, carbonate, carboxymethyl ester, acetamide, carbamate, thioether, bridged phosphoramide, bridged methylenephosphonate, bridged phosphoramide, bridged phosphoramide, bridged methylenephosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sultone linkages, and combinations of such linkages. The terms "nucleic acid" and "polynucleotide" also specifically include nucleic acids composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil).
[0074] As used herein, the term "transfection" or "infection" refers to the introduction of a nucleic acid into a host cell, such as by contacting the cell with a liposome or nanoparticle (eg, lipid nanoparticle) as described herein.
[0075] As used herein, "treatment" refers to a clinical intervention for a disease, disorder or physiological condition that the patient exhibits or may be susceptible to. The purpose of treatment includes, but is not limited to, reducing or preventing symptoms, slowing or terminating the progress or worsening of a disease, disorder or condition, and / or alleviating a disease, disorder or condition. "Treatment" refers to one or both of therapeutic treatment and prophylactic measures or preventive measures. Subjects in need of treatment include those that have been affected by a disease or disorder or undesired physiological condition, and those that are to be prevented from disease or disorder or undesired physiological condition.
[0076] As used herein, the term "effective amount" or "pharmaceutically effective amount" or "therapeutically effective amount" refers to an amount sufficient to produce beneficial or desired biological and / or clinical results.
[0077] As used herein, the term "pharmaceutically acceptable excipient" refers to any suitable substance that provides a pharmaceutically acceptable carrier, additive, or diluent for administering a compound of interest to a subject. Pharmaceutically acceptable excipients may include substances known as pharmaceutically acceptable diluents, pharmaceutically acceptable additives, and pharmaceutically acceptable carriers.
[0078] As used herein, "subject" refers to an animal that expects diagnosis, treatment or therapy. In some embodiments, the subject is a mammal. "Mammal" as used herein refers to an individual belonging to the Mammalia class, and includes, but is not limited to, humans, domestic and farm animals, zoo animals, sports animals and pets. Non-limiting examples of mammals include mice; rats; rabbits; guinea pigs; dogs; cats; sheep; goats; cattle; horses; primates such as monkeys, chimpanzees and apes, and in particular humans. In some embodiments, the mammal is a primate. In some embodiments, the mammal is a human. In some embodiments, the mammal is not a human. In some aspects, the subject has or is suspected to have an ANGPTL3-related disease or disorder.
[0079]
[00136] The term "plasma level" as used herein in the context of a molecule refers to the concentration or amount of the molecule, eg, the number of moles or weight of the molecule present in a given volume of plasma.
[0080] ANGPTL3 is a secreted protein that regulates plasma lipid levels by affecting the hydrolysis of triglycerides and phospholipids mediated by lipoprotein lipase and endothelial lipase. ANGPTL3 is associated with diseases and disorders involving abnormal lipoprotein metabolism, such as dyslipidemia, hypobetalipoproteinemia, hyperlipidemia, hypertriglyceridemia, and familial hypercholesterolemia. There is still a need for a new gene therapy that can stably reduce the levels of ANGPTL3 protein and lipids (e.g., cholesterol, HDL, LDL, triglycerides, and non-HDL) in the blood over an extended period of time or permanently reduce the level of ANGPTL3 protein. The present disclosure provides a highly efficient gene editing method and related compositions and kits that directly target the ANGPTL3 gene or its variants and permanently reduce the expression, function or activity of the ANGPTL3 gene. In some embodiments, the methods, compositions, and kits described herein can reduce plasma ANGPTL3 protein levels by at least 70% or more. In some embodiments, lipid levels (e.g., triglycerides) after implementation of the method can be reduced to 40 mg / dL or less. The gRNA sequences used herein can also significantly minimize the number and frequency of off-target effects, thereby reducing the risk of genotoxicity.The methods, compositions, and kits described herein can be used to treat an ANGPTL3-associated disease or disorder in a subject.
[0081] Angiopoietin-like protein 3 (ANGPTL3) Provided herein include vectors, compositions, methods and kits for editing the ANGPTL3 gene or variants thereof in the genome of a cell to modulate (e.g., reduce) the expression, function or activity of the ANGPTL3 gene in the cell. The vectors, compositions, methods and kits described herein can be particularly useful for treating ANGPTL3-related diseases and conditions, such as dyslipidemia, hypobetalipoproteinemia, familial hypercholesterolemia, hypertriglyceridemia, familial combined hyperlipidemia, familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome, by permanently reducing the levels of ANGPTL3 protein, ApoB protein, and lipids such as total cholesterol, triglycerides, LDL, HDL and / or other non-HDL in the blood.
[0082] The ANGPTL3 gene encodes the ANGPTL3 protein, which is a member of a secretory protein family that plays a role in angiogenesis. The ANGPTL3 protein, which is primarily expressed in the liver, contains a unique signal peptide sequence, an N-terminal coiled coil domain (predicted to form a dimer or trimer coiled coil structure), and a C-terminal globular fibrinogen homology domain. The N-terminal coiled coil region affects plasma triglyceride levels by reversibly inhibiting the catalytic activity of lipoprotein lipase. The fibrinogen-like domain binds to the integrin αvβ3 receptor and affects angiogenesis. The short linker region between the N-terminal and C-terminal domains serves as a furin cleavage site. After secretion, ANGPTL3 targets adipose tissue and muscle, activating lipolysis in the former, increasing the release of free fatty acids and glycerol from adipocytes, and inhibiting lipoprotein lipase in the latter, increasing triglyceride-rich lipoproteins.
[0083] ANGPTL3 acts as a dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and has been recognized as a potent regulator of plasma triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Based on experimental evidence, individuals with loss-of-function mutations in the ANGPTL3 gene have been observed to be affected by familial combined hypolipidemia and are characterized by very low levels of apolipoprotein B, apolipoprotein A1, and their associated lipoproteins (e.g., very low-density lipoprotein, LDL, and HDL) compared to individuals without the mutation. These subjects are protected from cardiovascular events, making ANGPTL3 an important pharmacological target for reducing cardiovascular risk.
[0084] The ANGPTL3 gene (also known as ANL3, ANG-5, FHBL2, and ANGPT5) has a cytogenetic location of lp31.3, and genomic coordinates at positions 62,597,520-62,606,313 on the forward strand of chromosome 1. The nucleotide sequence of ANGPTL3 can be found on the NCBI website, and the NCBI reference sequence is: NC_000001.11. USP1 is a gene upstream of ANGPTL3 on the forward strand, and ATG4C is a gene downstream of ANGPTL3 on the forward strand. DOCK7 is a gene located on the reverse strand opposite ANGPTL3. The NCBI gene ID of ANGPTL3 is 27329, the Uniprot ID is Q9Y5C1, and the Ensembl gene ID is ENSG00000132855. ANGPTL3 has 2 SNPs, 9 introns, and 12 exons. Additional information about the ANGPTL3 gene, including exons, introns, and start / stop sites of exons, and information about transcripts of the ANGPTL3 gene are described in detail in WO2018154387, the contents of which are incorporated herein by reference.
[0085] Gene Editing Provided herein include methods, compositions and kits for editing the ANGPTL3 gene to reduce the expression level of the ANGPTL3 protein (e.g., the plasma concentration of the ANGPTL3 protein), the level of the ApoB protein (e.g., the plasma concentration of the ApoB protein) and the lipid level (e.g., or triglycerides, LDL, HDL and non-HDL, etc.) in a subject. Gene editing (including genome editing) is a type of genetic engineering in which one or more nucleotides / one or more nucleic acids are inserted, deleted and / or substituted in a DNA sequence (such as in the genome of a target cell). Targeted gene editing enables insertion, deletion and / or substitution at a preselected site in the genome of a target cell (e.g., in a targeted gene or a targeted DNA sequence). When the sequence of an endogenous gene is edited, for example, by deletion, insertion or substitution of one or more nucleotides / one or more nucleic acids, the endogenous gene containing the affected sequence can be knocked out or knocked down due to the sequence change. Therefore, targeted editing can be used to disrupt endogenous gene expression. "Targeted integration" refers to a process involving the insertion of one or more exogenous sequences, with or without the deletion of endogenous sequences at the insertion site. Targeted integration can result from targeted gene editing when a donor template containing exogenous sequences is present.
[0086] Targeted editing can be achieved by nuclease-independent methods or by nuclease-dependent methods. In nuclease-independent targeted editing methods, homologous recombination is guided by homologous sequences flanking the exogenous polynucleotide to introduce endogenous sequences through the enzymatic machinery of the host cell. The exogenous polynucleotide can introduce deletions, insertions, or substitutions of nucleotides in the endogenous sequence.
[0087] Alternatively, the nuclease-dependent method can specifically introduce double-strand breaks (DSBs) by specific rare cutting nucleases (e.g., endonucleases) to achieve targeted editing with higher frequency. Such nuclease-dependent targeted editing also utilizes DNA repair mechanisms, such as non-homologous end joining (NHEJ) that occurs in response to DSB. DNA repair by NHEJ generally results in random insertion or deletion (insertion / deletion (indel)) of a small amount of endogenous nucleotides. Compared with the repair mediated by NHEJ, repair can also occur by homology-directed repair (HDR). When there is a donor template containing an exogenous genetic material flanked by a pair of homology arms, the exogenous genetic material can be introduced into the genome by HDR, which results in targeted integration of the exogenous genetic material.
[0088] Available endonucleases capable of introducing specific and targeted DSBs include, but are not limited to, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and RNA-guided CRISPR-Cas9 nucleases (CRISPR / Cas9; clustered regularly interspaced short palindromic repeats-related 9). Additionally, the DICE (Dual Integrase Cassette Exchange) system utilizing phiC31 and Bxb1 integrases can also be used for targeted integration.
[0089] ZFN is a targeted nuclease comprising a nuclease fused to a zinc finger DNA binding domain (ZFBD), which is a polypeptide domain that binds DNA in a sequence-specific manner through one or more zinc fingers. A zinc finger is a domain of about 30 amino acids within a zinc finger binding domain whose structure is stabilized by the coordination of zinc ions. Examples of zinc fingers include, but are not limited to, C2H2 zinc fingers, C3H zinc fingers, and C4 zinc fingers. A designed zinc finger domain is a domain that does not exist in nature, and the design / composition of the designed zinc finger domain is primarily generated by reasonable criteria, such as applying substitution rules and computerized algorithms to process information in a database storing information on existing ZFP designs and binding data. See, e.g., U.S. Pat. Nos. 6,140,081; 6,453,242; and 6,534,261; WO 98 / 53058; WO 98 / 53059; WO 98 / 53060; WO 02 / 016536 and WO 03 / 016496, the contents of which are incorporated by reference in their entirety. The selected zinc finger domain is a domain not found in nature, and the generation of the selected zinc finger domain is mainly generated by empirical processes, such as phage display, interaction traps or hybrid selection. ZFNs are described in more detail in U.S. Pat. Nos. 7,888,121 and 7,972,854. The most recognized example of a ZFN is a fusion of a FokI nuclease with a zinc finger DNA binding domain.
[0090] TALEN is a targeted nuclease comprising a nuclease fused to a TAL effector DNA binding domain. A "transcription activator-like effector DNA binding domain", "TAL effector DNA binding domain" or "TALE DNA binding domain" is a polypeptide domain of a TAL effector protein that is responsible for binding of the TAL effector protein to DNA. TAL effector proteins are secreted by plant pathogens of the genus Xanthomonas during infection. These proteins enter the nucleus of plant cells, bind effector-specific DNA sequences via their DNA binding domains, and activate gene transcription at these sequences via their transactivation domains. TAL effector DNA binding domain specificity depends on the effector-variable number of imperfect 34 amino acid repeats, which contain polymorphisms at select repeat positions called repeat variable diresidues (RVDs). TALEN is described in more detail in US2011 / 0145940. The most recognized example of TALEN in the art is a fusion polypeptide of the FokI nuclease and a TAL effector DNA binding domain.
[0091] Additional examples of targeted nucleases suitable for use as provided herein include, but are not limited to, Bxb1, phiC31, R4, PhiBT1, and Wβ / SPBc / TP901-1, whether used alone or in combination. Other non-limiting examples of targeted nucleases include naturally occurring and recombinant nucleases, such as CRISPR / Cas9, restriction endonucleases, mega-nucleases, homing endonucleases, and the like.
[0092] CRISPR-Cas gene editing system and RNA-guided nucleases In some embodiments, the vectors, compositions, methods and kits described herein can be used in gene editing systems, such as CRISPR-Cas gene editing systems, to genetically edit the ANGPTL3 gene. For example, the CRISPR-Cas9 system is a naturally occurring defense mechanism in prokaryotes that has been repurposed as a DNA targeting platform for RNA guidance for gene editing. The CRISPR-Cas9 system relies on the DNA nuclease Cas9 and two non-coding RNAs-crisprRNA (crRNA) and trans-activating RNA (tracrRNA) to target DNA cleavage. CrRNA drives the sequence recognition and specificity of the CRISPR-Cas9 complex by Watson-Crick base pairing with a 20 nucleotide (nt) sequence in the target DNA. If the target sequence is followed by a specific short DNA motif (having the sequence NGG) called a protospacer adjacent motif (PAM), the CRISPR-Cas9 complex only binds to a DNA sequence containing a sequence matching the first 20 nt of crRNA and single guide RNA (sgRNA). TracrRNA hybridizes with the 3' end of crRNA to form an RNA duplex structure, which is bound by the Cas9 endonuclease to form a catalytically active CRISPR-Cas9 complex, which can then cleave the target DNA. After the CRISPR-Cas9 complex binds to DNA at the target site, the two independent nuclease domains in the Cas9 enzyme each cleave one of the DNA chains upstream of the PAM site, leaving a double-strand break (DSB), where the two chains of DNA terminate in base pairs (flat ends). After the CRISPR-Cas9 complex binds to DNA at a specific target site and forms a site-specific DSB, the next key step is the repair of DSB. Cells use two major DNA repair pathways to repair DSB: non-homologous end joining (NHEJ) and homology-directed repair (HDR). In some embodiments, the CRISPR-Cas9 gene editing system comprises an RNA-guided nuclease and one or more guide RNAs targeting one or more target genes.
[0093] As described herein, RNA-guided endonucleases can be naturally occurring or non-naturally occurring. Non-limiting examples of RNA-guided endonucleases include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cpf1 endonucleases and functional derivatives thereof. In some cases, the RNA-guided endonuclease is a Cas9 endonuclease. The Cas9 endonuclease can be from, for example, Streptococcus pyogenes (SpyCas9), Staphylococcus lugdunensis (SluCas9) or Staphylococcus aureus (SaCas9). In some embodiments, the RNA-guided endonuclease is a variant of Cas9, including but not limited to small Cas9, dead Cas9 (dCas9) and Cas9 nickase. In some embodiments, the Cas nuclease can include RuvC or RuvC-like nuclease domains (e.g., Cpf1) and / or HNH or HNH-like nuclease domains (e.g., Cas9). In some embodiments, the Cas9 endonuclease is Streptococcus pyogenes Cas9, Staphylococcus aureus Cas9, Neisseria meningitidis Cas9, Streptococcus thermophilus Cas9, Streptococcus thermophilus 3 Cas9, Treponema denticola Cas9, or a variant thereof.
[0094] The RNA-guided endonuclease can be a small RNA-guided endonuclease. The small RNA-guided endonuclease can be engineered from a portion of an RNA-guided endonuclease derived from any RNA-guided endonuclease described herein and known in the art. The small RNA-guided endonuclease can be, for example, a small Cas endonuclease. In some cases, the length of the small RNA-guided nuclease is shorter than about 1,100 amino acids.
[0095] The RNA-guided endonuclease can be a mutant RNA-guided endonuclease. For example, the RNA-guided endonuclease can be a mutant of a naturally occurring RNA-guided endonuclease. The mutated RNA-guided endonuclease can also be a mutated RNA-guided endonuclease with a changed activity compared to a naturally occurring RNA-guided endonuclease, such as a changed endonuclease activity (e.g., a changed or eliminated DNA endonuclease activity, while the binding affinity to DNA is not substantially weakened). Such modifications can allow sequence-specific DNA targeting of the mutant RNA-guided endonuclease for the following purposes: transcriptional regulation (e.g., activation or repression); epigenetic modification or chromatin modification by methylation, demethylation, acetylation or deacetylation, or any other modification of DNA binding and / or DNA-modifying proteins known in the art. In some embodiments, the mutant RNA-guided endonuclease does not have DNA endonuclease activity.
[0096] The RNA-guided endonuclease can be a nickase that cleaves the complementary strand of the target DNA but has a reduced ability to cleave the non-complementary strand of the target DNA, or a nickase that cleaves the non-complementary strand of the target DNA but has a reduced ability to cleave the complementary strand of the target DNA. In some embodiments, the RNA-guided endonuclease has a reduced ability to cleave both the complementary and non-complementary strands of the target DNA.
[0097] In some embodiments, a nucleic acid encoding an endonuclease guided by RNA is administered to a subject. In some embodiments, the nucleic acid can be produced by an in vitro transcription reaction. In some embodiments, the production of in vitro transcribed RNA includes incubating a linear DNA template with an RNA polymerase and a nucleotide mixture under conditions that allow (run-off) RNA in vitro transcription. The nucleotide mixture can be part of an in vitro transcription mixture (IVT-mix). In some embodiments, the RNA polymerase is a T7 RNA polymerase.
[0098] The nucleotide mixture for RNA in vitro transcription can additionally contain the modified nucleotide defined as follows.In some embodiments, the nucleotide mixture (for example, the ratio of each nucleotide in the mixture) (NTP mixture of optimization) for RNA in vitro transcription reaction can be optimized for a given RNA sequence.Such method is described in, for example, WO2015 / 188933.In some embodiments, the RNA obtained by using the method for the NTP mixture of optimization is characterized by the immunostimulatory properties of reduction.
[0099] In some embodiments, the nucleotide mixture is composed of (chemically) unmodified ribonucleoside triphosphates (NTPs) GTP, ATP, CTP, and UTP. In some embodiments, in vitro transcription can include the presence of at least one cap analog, such as cap 1 (cap1) trinucleotide cap analog, m7G (5') ppp (5') (2'OMeA) pG or m7G (5') ppp (5') (2'OMeG) pG, m7G (5') ppp (5') (2'OMeA) pG or rn7 (3'OMeG) (5') ppp (5') (2'OMeA) pG. In some embodiments, the 5'-cap structure is formed via enzymatic capping using a capping enzyme (e.g., vaccinia virus capping enzyme and / or cap-dependent 2'-O-methyltransferase) to produce cap 0 or cap 1 or cap 2 structures. The methods and means disclosed in WO2016 / 193226 can also be used to add a 5'-cap structure (cap 0 or cap 1) using a fixed capping enzyme and / or a cap-dependent 2'-O-methyltransferase. In some embodiments, a portion or all of at least one (ribose) nucleoside triphosphate is replaced by a modified nucleoside triphosphate. In some embodiments, the modified nucleoside triphosphate includes pseudouridine (ψ), N1-methylpseudouridine (m1 ψ), 5-methylcytosine, or 5-methoxyuridine. In some embodiments, the uracil nucleotides in the nucleotide mixture are replaced (partially or completely) by pseudouridine (ψ) and / or N1-methylpseudouridine (m1 ψ) to obtain modified RNA. In some embodiments, the chemically modified nucleotide is pseudouridine (ψ). In some embodiments, the chemically modified nucleotide is N1-methylpseudouridine (M1 ψ). In some embodiments, the nucleotide mixture comprises at least one modified nucleotide and / or at least one nucleotide analog or nucleotide derivative for incorporation into RNA. For example, the nucleotide of modification as defined herein can include nucleotide analogs / modifications, such as backbone modifications, sugar modifications or base modifications. The backbone modification can include modifications in which the phosphoric acid of the nucleotide backbone is chemically modified. Sugar modifications can include chemical modifications of the sugar of the nucleotide. In addition, base modifications can include chemical modifications of the base moiety of the nucleotide. In this context, nucleotide analogs or modifications can include nucleotide analogs suitable for transcription and / or translation. In some embodiments, the nucleotide mixture comprises at least one modified nucleotide and / or at least one nucleotide analog selected from the nucleotides of the backbone modification, sugar-modified nucleotides and / or base-modified nucleotides or any combination thereof.
[0100] Modified nucleosides and nucleotides that can be included in nucleotide mixtures and incorporated into RNA can be modified in the sugar moiety. For example, the 2' hydroxyl group (OH) can be modified or replaced by many different "oxy" or "deoxy" substituents. Examples of "oxy"-2' hydroxyl group modifications include, but are not limited to, alkoxy or aryloxy (-OR, such as R = H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar); polyethylene glycol (PEG), -O(CH2CH 20 )nCH2CH2OR; a "locked" nucleic acid (LNA) in which the 2' hydroxyl group is connected to the 4' carbon of the same ribose, for example, by a methylene bridge; and an amino group (-O-amino, wherein the amino group can be alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino or diheteroarylamino, ethylenediamine, polyamino) or aminoalkoxy. "Deoxy" modifications include hydrogen, amino (e.g., NH2, alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino or amino acid); or the amino group can be connected to the sugar through a linker, wherein the linker contains one or more of the atoms C, N and O. The glycosyl group can also contain one or more carbons with a stereochemical configuration relative to the corresponding carbon in the ribose. Thus, the modified RNA molecule can include nucleotides containing, for example, arabinose as a sugar.
[0101] The phosphate backbone can be further modified in the nucleosides and nucleotides of modification, which can be included in the nucleotide mixture and incorporated in the RNA of the in vitro transcription of modification. The phosphate group of the main chain can be modified by replacing one or more oxygen atoms with different substituents. In addition, the nucleosides and nucleotides of modification can include the phosphoric acid with the modified phosphoric acid as described herein to completely replace the unmodified phosphate moiety. The example of the phosphate group of modification includes but is not limited to phosphorothioate, selenophosphate (phosphoroselenates), boranophosphates (borano phosphates), boranophosphate esters (boranophosphate esters), hydrogen phosphonate, phosphoramidate, alkyl or aryl phosphonate and phosphotriester. Two non-connected oxygens of dithiophosphate are replaced by sulfur. Phosphate joints can also be modified by replacing connected oxygen with nitrogen (phosphoramidate of bridge joint), sulfur (phosphorothioate of bridge joint) and carbon (methylene-phosphonate of bridge joint).
[0102] Nucleotides as described herein can be modified in the nucleobase portion. Examples of nucleobases present in RNA include, but are not limited to, adenine, guanine, cytosine, and uracil. For example, nucleosides and nucleotides described herein can be chemically modified on the major groove surface. In some embodiments, the major groove chemical modification includes an amino group, a thiol group, an alkyl group, or a halogen group.
[0103] In some embodiments, nucleotide analogs / modifications include 2-amino-6-chloropurine riboside-5'-triphosphate, 2-aminopurine-nucleoside-5'-triphosphate; 2-aminoadenosine-5'-triphosphate, 2'-amino-2'-deoxycytidine-triphosphate, 2-thiocytidine-5'-triphosphate, 2-thiouridine-5'-triphosphate, 2'-fluorothymidine-5'-triphosphate, 2'-O-methyl-inosine-5'-triphosphate, 4 -thiouridine-5'-triphosphate, 5-aminoallylcytidine-5'-triphosphate, 5-aminoallyluridine-5'-triphosphate, 5-bromocytidine-5'-triphosphate, 5-bromouridine-5'-triphosphate, 5-bromo-2'-deoxycytidine-5'-triphosphate, 5-bromo-2'-deoxyuridine-5'-triphosphate, 5-iodocytidine-5'-triphosphate, 5-iodo-2'-deoxycytidine-5'-triphosphate, 5-iodouridine-5'- triphosphate, 5-iodo-2'-deoxyuridine-5'-triphosphate, 5-methylcytidine-5'-triphosphate, 5-methyluridine-5'-triphosphate, 5-propynyl-2'-deoxycytidine-5'-triphosphate, 5-propynyl-2'-deoxyuridine-5'-triphosphate, 6-azacytidine-5'-triphosphate, 6-azauridine-5'-triphosphate, 6-chloropurine riboside-5'-triphosphate, 7-deazaadenosine-5'-triphosphate, 7-deazaguanosine-5'-triphosphate, 8-azaadenosine-5'-triphosphate, 8-azidoadenosine-5'-triphosphate, benzimidazole-riboside-5'-triphosphate, N1-methyladenosine-5'-triphosphate, N1-methylguanosine-5'-triphosphate, N6-methyladenosine-5'-triphosphate, O6-methylguanosine-5'-triphosphate, pseudouridine-5'-triphosphate, puromycin-5'-triphosphate, xanthosine-5'-triphosphate. The base modified nucleotides may include 5-methylcytidine-5'-triphosphate, 7-deazaguanosine-5'-triphosphate, 5-bromocytidine-5'-triphosphate and pseudouridine-5'-triphosphate, pyridine-4-ketone ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurine methyl uridine, 1-taurine methyl-pseudouridine, 5-taurine methyl-2-thio-uridine, 1-taurine methyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thiodihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, 5-aza-cytidine,pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy- 5-methyl-cytidine, 4-methoxy-pseudoisocytidine and 4-methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylamino Formyl adenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine and 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl -6-thio-guanosine and N2,N2-dimethyl-6-thio-guanosine, 5'-O-(1-phosphorothioate)-adenosine, 5'-O-(1-phosphorothioate)-cytidine, 5'-O-(1-phosphorothioate)-guanosine, 5'-O-(1-phosphorothioate)-uridine, 5'-O-(1-phosphorothioate)-pseudouridine, 6-aza-cytidine, 2-thio-cytidine, α-thio-cytidine, pseudo-iso-cytidine, 5-aminoallyl-uridine, 5-iodo-uridine, N1-methyl-pseudouridine, 5,6-dihydrouridine, α-thio-uridine, 4-thio-uridine, 6-aza-uridine, 5-hydroxy-uridine, deoxy-thymidine, 5-methyl-uridine, pyrrolo-cytidine, inosine, α-thio-guanosine,6-methyl-guanosine, 5-methyl-cytidine, 8-oxo-guanosine, 7-deaza-guanosine, N1-methyl-adenosine, 2-amino-6-chloro-purine, N6-methyl-2-amino-purine, pseudo-iso-cytidine, 6-chloro-purine, N6-methyl-adenosine, α-thio-adenosine, 8-azido-adenosine or 7-deaza-adenosine.
[0104] At least one modified nucleotide and / or at least one nucleotide analog may include 1-methyladenosine, 2-methyladenosine, N6-methyladenosine, 2'-O-methyladenosine, 2-methylthio-N6-methyladenosine, N6-isopentenyladenosine, 2-methylthio-N6-isopentenyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6-methyl-N6-threonylcarbamoyladenosine, N6-hydroxynorvalylcarbamoyladenosine, 2-methylthio-N6-hydroxynorvalylcarbamoyladenosine, inosine, 3-methylcytidine, 2-O-methylcytidine, 2-thiocytidine, N4-acetylcytidine, lysine, 1-methylguanosine, 7-methylguanosine, 2'-O-methylguanosine, braided glycoside, epoxy braided glycoside, 7-cyano-7-deazaguanosine, 7-aminomethyl-7-deazaguanosine, pseudouridine, dihydrouridine, 5-methyluridine, 2'-O-methyluridine, 2-thiouridine, 4-thiouridine, 5-methyl-2-thiouridine, 3-(3-amino-3-carboxypropyl)uridine, 5'-hydroxyuridine, 5-methoxyuridine, uridine 5-oxyacetic acid, uridine 5-oxyacetic acid methyl ester, 5-aminomethyl-2-thiouridine, 5-methylaminomethyluridine, 5-methylaminomethyl-2-thiouridine, 5-methylaminomethyl-2-selenouridine, 5-carboxymethylaminomethyluridine, 5-carboxymethylaminomethyl-2'-O-methyluridine, 5-carboxymethylaminomethyl-2-thiouridine, 5-(isopentenylaminomethyl)uridine, 5-(isopentenylaminomethyl)-2-thiouridine or 5-(isopentenylaminomethyl)-2'-O-methyluridine.
[0105] In some embodiments, the chemical modification includes pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thiol-1-methyl-1-deaza-pseudouridine, 2-thiol-1-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thiol-1-methyl-pseudouridine, 4-thiol-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, or 2'-O-methyluridine.
[0106] In some embodiments, 100% of uracil in the coding sequence as defined herein can have chemical modification. In some embodiments, the chemical modification is in the 5'-position of uracil. In some embodiments, 100% of uracil in the coding sequence (cds) of RNA can have chemical modification, such as chemical modification in the 5' position of uracil. In other embodiments, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of uracil nucleotides in cds have chemical modification, such as chemical modification in the 5-position of the uracil nucleotides. Such modification can reduce the stimulation to the innate immune system (after the RNA comprising such modified nucleotides is used in vivo).
[0107] The term "cds" or "coding sequence" or "coding region" as used herein will be recognized and understood by those of ordinary skill in the art, and may, for example, refer to a sequence of several nucleotide triplets that can be translated into a peptide or protein. The cds of the RNA may contain at least one modified nucleotide, wherein the at least one modified nucleotide may be selected from pseudouridine (ψ), N1-methyl pseudouridine (M1 ψ), 5-methylcytosine and 5-methoxyuridine.
[0108] As used herein, the term "modified nucleotides" or "chemically modified nucleotides" may refer to all potential natural and non-natural chemical modifications of the building blocks of RNA (ie, ribonucleotides A, G, C, and U).
[0109] In various embodiments, the nucleotide mixture in the in vitro transcription reaction comprises a cap analog. Thus, in some embodiments, the cap analog is cap 0, cap 1, cap 2, a modified cap 0 or a modified cap 1 analog or a cap 1 analog as described below.
[0110] As used herein, the term "cap analog" or "5'-cap structure" may refer to the 5' structure of an RNA, in particular a guanine nucleotide located at the 5' end of an RNA (e.g., mRNA). In some embodiments, the 5'-cap structure is attached to the RNA via a 5'-5'-triphosphate bond. In some embodiments, a "5'-cap structure" or "cap analog" is not considered a "modified nucleotide" or "chemically modified nucleotide". Potentially suitable 5'-cap structures include cap 0 (methylation of the first nucleobase, such as m7GpppN), cap 1 (additional methylation of the ribose of the adjacent nucleotide to m7GpppN), cap 2 (additional methylation of the ribose of the second nucleotide downstream of m7GpppN), cap 3 (additional methylation of the ribose of the third nucleotide downstream of m7GpppN), cap 4 (additional methylation of the ribose of the fourth nucleotide downstream of m7GpppN), ARCA (antisense reverse cap analog), modARCA (e.g., phosphorothioate modARCA), inosine, N1-methyl-guanosine, 2'-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine and 2-azido-guanosine.
[0111] The 5'-cap (cap 0 or cap 1) structure can be formed using a capping enzyme in chemical RNA synthesis, or using a cap analog in RNA in vitro transcription (co-transcriptional capping). As used herein, the term "cap analog" may refer to a non-polymerizable dinucleotide or trinucleotide having a cap functional group, because when incorporated at the 5' end of the RNA, the cap analog promotes translation or localization of the RNA and / or prevents degradation of the RNA. Non-polymerizable means that the cap analog will only be incorporated at the 5' end because it does not have a 5' triphosphate and therefore cannot be extended in the 3' direction by a template-dependent polymerase (e.g., a DNA-dependent RNA polymerase). Examples of cap analogs include m7GpppG, m7GpppA, m7GpppC; unmethylated cap analogs (e.g., GpppG); dimethylated cap analogs (e.g., m2,7GpppG), trimethylated cap analogs (e.g., m2,2,7GpppG), dimethylated symmetric cap analogs (e.g., m7Gpppm7G) or antisense reverse cap analogs (e.g., ARCA; m7,2'OmeGpppG, m7,2'dGpppG, m7,3'OmeGpppG, m7,3'dGpppG and tetraphosphate derivatives thereof). Additional cap analogs have been described previously, e.g., in WO2008 / 016473, WO2008 / 157688, WO2009 / 149253, WO2011 / 015347 and WO2013 / 059475. Further suitable cap analogs in this context are described, for example, in WO2017 / 066793, WO2017 / 066781, WO2017 / 066791, WO2017 / 066789, WO2017 / 053297, WO2017 / 066782, WO2018 / 075827 and WO2017 / 066797, the disclosures relating to cap analogs being incorporated herein by reference.
[0112] In some embodiments, the cap 1 structure is generated using a trinucleotide cap analog as disclosed in WO2017 / 053297, WO2017 / 066793, WO2017 / 066781, WO2017 / 066791, WO2017 / 066789, WO2017 / 066782, WO2018 / 075827, and WO2017 / 066797. For example, any cap analog that can be derived from the structure disclosed in claims 1-5 of WO2017 / 053297 can be suitably used to co-transcriptionally generate the cap 1 structure. In some embodiments, any cap analog that can be derived from the structure described in WO2018 / 075827 can be suitably used to co-transcriptionally generate the cap 1 structure. In some embodiments, the cap 1 analog is a cap 1 trinucleotide cap analog. In some embodiments, the cap 1 structure of the in vitro transcribed RNA is formed using co-transcriptional capping using the trinucleotide cap analog m7G(5')ppp(5')(2'OMeA)pG or m7G(5')ppp(5')(2'OMeG)pG. In some embodiments, the cap 1 analog is m7G(5')ppp(5')(2'OMeA)pG.
[0113] In some embodiments, RNA (e.g., mRNA) comprises a 5'-cap structure, such as a cap 1 structure. In some embodiments, the 5' cap structure can improve the stability and / or expression of mRNA. The cap 1 structure comprising mRNA (generated by, for example, in vitro transcription) has several advantageous features, including increased translation efficiency and reduced stimulation of the innate immune system. In some embodiments, the in vitro transcribed RNA comprises at least one coding sequence encoding at least one peptide or protein. In some embodiments, the protein is an RNA-guided endonuclease. In some embodiments, the RNA-guided endonuclease is Cas9 or a derivative thereof.
[0114] The present disclosure provides an optimized mRNA ("SpCas9mRNA") encoding a Streptococcus pyogenes Cas9 endonuclease, and optionally includes chemically modified nucleotides, which provide effective genome editing of a target cell population when administered with one or more gRNAs. In some embodiments, the present disclosure provides an mRNA comprising (i) a 5' untranslated region (UTR); (ii) an open reading frame (ORF) comprising a nucleotide sequence encoding a site-directed endonuclease; and (iii) a 3' untranslated region (UTR). In some embodiments, the site-directed endonuclease is a Cas nuclease. In some embodiments, the Cas nuclease is a Cas9 polypeptide. In some embodiments, the Cas9 polypeptide is a Cas9 (SpCas9) polypeptide derived from Streptococcus pyogenes. In some embodiments, the ORF also comprises one or more nucleotide sequences encoding a nuclear localization signal, such as the nucleotide sequences described herein. In some embodiments, the ORF comprises a nucleotide sequence encoding a site-directed endonuclease (such as a SpCas9 polypeptide) and at least one NLS, which is a nucleoplasmic protein and / or an SV40 NLS. In some embodiments, the ORF comprises a nucleotide sequence encoding an N-terminal and / or C-terminal NLS operably linked to a site-directed endonuclease (such as a SpCas9 polypeptide). In some embodiments, the ORF comprises a nucleotide sequence encoding an N-terminal SV40 NLS operably linked to a site-directed endonuclease (such as a SpCas9 polypeptide) and a C-terminal nucleoplasmic protein NLS operably linked to a site-directed endonuclease (such as a SpCas9 polypeptide).
[0115] In some embodiments, the present disclosure provides an mRNA comprising a nucleotide sequence that is at least 85% or more (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) identical to the nucleotide sequence of SEQ ID NO: 17. In some embodiments, the present disclosure provides an mRNA comprising a nucleotide sequence that is 100% identical to the nucleotide sequence of SEQ ID NO: 17. In some embodiments, the mRNA comprises a codon-optimized sequence containing a nucleotide sequence that is at least 85% or more (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) identical to the nucleotide sequence of SEQ ID NO: 17.
[0116] In some embodiments, the present disclosure provides an mRNA comprising a nucleotide sequence that is at least 85% or more (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) identical to the nucleotide sequence of SEQ ID NO: 16. In some embodiments, the present disclosure provides an mRNA comprising a nucleotide sequence that is 100% identical to the nucleotide sequence of SEQ ID NO: 16.
[0117] In some embodiments, mRNA can include at least one chemically modified nucleoside and / or nucleotide.In some embodiments, the chemically modified nucleoside is selected from pseudouridine, N1-methyl pseudouridine and 5-methoxyuridine.In some embodiments, the chemically modified nucleoside is N1-methyl pseudouridine (e.g., 1-methyl pseudouridine).In some embodiments, at least about 80% or more (e.g., about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) of uridine in mRNA is modified or replaced by N1-methyl pseudouridine.In some embodiments, 100% of uridine (e.g., uracil) in mRNA is modified or replaced by N1-methyl pseudouridine. In some embodiments, the present disclosure provides an mRNA comprising a nucleotide sequence that is at least 85% or more (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) identical to the nucleotide sequence of SEQ ID NO: 16, wherein 100% of the uridine or uracil in the mRNA is modified or substituted with N1-methylpseudouridine. In some embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55 5, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500, 600, 700, 800 or more) is N1-methylpseudouridine.
[0118] In some embodiments, the present disclosure provides an mRNA comprising a nucleotide sequence that is at least 85% or more (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) identical to the nucleotide sequence of SEQ ID NO: 18. In some embodiments, the present disclosure provides an mRNA comprising a nucleotide sequence that has one, two, three, four, or five mismatches to the nucleotide sequence of SEQ ID NO: 18. In some embodiments, the present disclosure provides an mRNA comprising a nucleotide sequence that is 100% identical to the nucleotide sequence of SEQ ID NO: 18.
[0119] In some embodiments, the present disclosure provides an mRNA comprising a nucleotide sequence that is at least 85% or more (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) identical to the nucleotide sequence of SEQ ID NO: 19. In some embodiments, the present disclosure provides an mRNA comprising a nucleotide sequence that has one, two, three, four, or five mismatches to the nucleotide sequence of SEQ ID NO: 19. In some embodiments, the present disclosure provides an mRNA comprising a nucleotide sequence that is 100% identical to the nucleotide sequence of SEQ ID NO: 19.
[0120] In some embodiments, the present disclosure provides an mRNA comprising a nucleotide sequence 100% identical to the nucleotide sequence of SEQ ID NO: 16, wherein 100% of the uridine (e.g., uracil) in the mRNA is modified or replaced by N1-methyl pseudouridine. In some embodiments, the present disclosure provides an mRNA comprising or consisting of the following: the nucleotide sequence of SEQ ID NO: 18. In some embodiments, the present disclosure provides an mRNA comprising or consisting of the following: the nucleotide sequence of SEQ ID NO: 19. In some embodiments, the mRNA may also include a 5' cap, such as the 5' cap described herein. In some embodiments, the 5' cap is a cap-0, cap-1, or cap-2 structure. SEQ ID NO: 17 is the sequence of a non-limiting exemplary parent Cas9 mRNA. SEQ ID NOs: 18 and 19 are codon-optimized sequences derived from parent Cas9 mRNAs, and some u are N1-methyl pseudouridines in SEQ ID NOs: 18 and 19.
[0121] Guide RNA (gRNA) In some embodiments, the CRISPR / Cas-mediated gene editing system for genetically editing the ANGPTL3 gene comprises a genome targeting nucleic acid (e.g., a guide RNA) that can direct the activity of an RNA-guided endonuclease to a specific target sequence within the ANGPTL3 gene. The guide RNA comprises at least a spacer sequence and a CRISPR repeat sequence that hybridizes to a target nucleic acid sequence of interest. The gRNA can be a single-molecule guide RNA (sgRNA) or a double-molecule guide RNA. The RNA-guided endonuclease can be, for example, a Cas endonuclease, including a Cas9 endonuclease. The Cas9 endonuclease can be, for example, a SpyCas9, SaCas9, or SluCas9 endonuclease. In some embodiments, the RNA-guided endonuclease is a Cas9 variant. In some embodiments, the RNA-guided endonuclease is a small RNA-guided endonuclease. In some embodiments, the RNA-guided endonuclease is a small Cas endonuclease.
[0122] In some embodiments, gRNA comprises 5' to 3': crRNA and tracrRNA, wherein crRNA and tracrRNA hybridize to form a duplex. In some embodiments, crRNA comprises a spacer sequence and a crRNA repeat sequence capable of targeting a target sequence in a target nucleic acid (e.g., a genomic DNA molecule). In some embodiments, tracrRNA comprises a tracrRNA antisense repeat sequence and a 3'tracrRNA sequence. In some embodiments, the 3' end of the crRNA repeat sequence is connected to the 5' end of the tracrRNA antisense repeat sequence, for example, through a tetraloop, wherein the crRNA repeat sequence and the tracrRNA antisense repeat sequence hybridize to form sgRNA. In some embodiments, sgRNA comprises 5' to 3': a spacer sequence, a crRNA repeat sequence, a tetraloop, a tracrRNA antisense repeat sequence, and a 3'tracrRNA sequence. In some embodiments, sgRNA comprises a 5' spacer extension sequence. In some embodiments, sgRNA comprises a 3' tracrRNA extension sequence. 3' tracrRNA may comprise or consist of one or more stem loops, such as one, two, three or more stem loops.
[0123] In some embodiments, the invariant sequence of the sgRNA comprises a nucleotide sequence of GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 1), or a nucleotide sequence having up to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide deletions, insertions, or substitutions relative to SEQ ID NO: 1. In some embodiments, the sgRNA is used with a SpyCas9 endonuclease.
[0124] The guide RNA disclosed herein can target any sequence of interest via the spacer sequence in the crRNA. The spacer sequence in the gRNA is a sequence (e.g., a 20 nucleotide sequence) that defines a target sequence (e.g., a DNA target sequence, such as a genomic target sequence) of a target gene of interest (e.g., an ANGPTL3 gene). In some embodiments, the range of the spacer sequence is 15 to 30 nucleotides. For example, the length of the spacer sequence can be below, can be about below, can be at least below, or can be at most below: 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50 or a number or range of nucleotides between any two of these values. In some embodiments, the spacer sequence contains 20 nucleotides. In some embodiments, the gRNA is capable of hybridizing with the forward strand of the target dsDNA. In some embodiments, the gRNA is capable of hybridizing with the reverse strand of the target dsDNA.
[0125] The terms "target nucleic acid," "target site," and "target sequence" may be used interchangeably throughout the text and may refer to any nucleic acid sequence that can be targeted by a gRNA sequence described herein. In some embodiments, the "target sequence" is in a target gene adjacent to a PAM sequence and is a sequence to be modified by an RNA-guided nuclease (e.g., Cas9). The "target sequence" is on a so-called PAM-strand in a "target nucleic acid," which is a double-stranded molecule containing a PAM-strand and a complementary non-PAM strand. Those skilled in the art recognize that the gRNA spacer sequence hybridizes with a complementary sequence located in the non-PAM strand of a target nucleic acid of interest. Thus, the gRNA spacer sequence is the RNA equivalent of the target sequence. The spacer of the gRNA interacts with the target nucleic acid of interest in a sequence-specific manner via hybridization (i.e., base pairing). Thus, the nucleotide sequence of the spacer varies depending on the target sequence of the target nucleic acid of interest. In some embodiments, the target sequence of the ANGPTL3 gene is within exon 1, 2, 3, 4, 5, 6, or 7 of the ANGPTL3 gene. In some embodiments, the target sequence of the ANGPTL3 gene is within exon 1 of the ANGPTL3 gene. In some embodiments, the spacer region of the gRNA complementarily binds to the target sequence located at chr1: 62597719-62597738 (-) (without PAM) or chr1: 62597716-62597738 (-) (with PAM).
[0126] In the CRISPR / Cas system used herein, the spacer sequence is designed to hybridize with a region of the target nucleic acid located 5' of the PAM that can be recognized by the Cas9 enzyme used in the system. The spacer can completely match the target sequence or can have a mismatch. Each Cas9 enzyme has a specific PAM sequence that it recognizes in the target DNA. For example, Streptococcus pyogenes Cas9 recognizes a PAM containing the sequence 5'-NRG-3' in the target nucleic acid, where R contains A or G, where N is any nucleotide, and N is adjacent to the 3' of the target nucleic acid sequence targeted by the spacer sequence.
[0127] In some embodiments, the target nucleic acid sequence is 20 nucleotides in length. In some embodiments, the target nucleic acid is less than 20 nucleotides in length. In some embodiments, the target nucleic acid is more than 20 nucleotides in length. In some embodiments, the target nucleic acid is at least: 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30 or more nucleotides in length. In some embodiments, the target nucleic acid is at most: 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30 or more nucleotides in length. In some embodiments, the target nucleic acid sequence has 20 bases immediately adjacent to the first nucleotide 5' of the PAM. For example, in the case of a 5'-NNNNNNNNNNNNNNNNNNNNNN NRG -3' sequence, the target nucleic acid can be a sequence corresponding to N, wherein N can be any nucleotide, and the underlined NRG sequence (R is G or A) is the Streptococcus pyogenes PAM. In some embodiments, the PAM sequence used as a sequence recognized by SpCas9 in the compositions and methods of the present disclosure is NGG, wherein N can be A, T, C or G.
[0128] In some embodiments, the percent complementarity between the spacer sequence and the target nucleic acid is about less than, at least less than, at least about less than, at most less than, or at most about less than: 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100%. In some embodiments, the spacer sequence of the guide RNA and the target nucleic acid in the target gene are 100% complementary. In some embodiments, the percent complementarity between the spacer sequence and the target nucleic acid is 100% over the six consecutive 5' nucleotides of the target sequence of the complementary strand of the target nucleic acid. In some embodiments, the percent complementarity between the spacer sequence and the target nucleic acid is at least 60% over about 20 consecutive nucleotides. In other embodiments, the spacer sequence of the guide RNA and the target sequence in the target gene can contain up to 10 mismatches, such as up to 9, up to 8, up to 7, up to 6, up to 5, up to 4, up to 3, up to 2, or up to 1 mismatch.
[0129] In some embodiments, the gRNA comprises a spacer sequence selected from SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26 listed in Table 1. In some embodiments, the gRNA comprises a spacer sequence capable of hybridizing to a sequence selected from SEQ ID NOs: 3-9 listed in Table 1 or to a sequence complementary to a sequence selected from SEQ ID NOs: 3-9.
[0130] Table 1: Exemplary spacer sequences
[0131] In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26, or a variant thereof having about less than, at least less than, at least about less than 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology to any of the spacers of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26. In some embodiments, the gRNA is an sgRNA. In some embodiments, the gRNA comprises a spacer sequence from any one of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26, or a variant thereof having no more than 3 mismatches compared to any one of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26.
[0132] In some embodiments, two gRNAs comprising a spacer complementary to a target sequence of an ANGPLT3 gene are provided to a cell. In some embodiments, the gRNA is any two gRNAs comprising a spacer selected from the group consisting of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26, or a variant thereof having at least 85% homology with the spacer of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26, or a variant having no more than 3 mismatches compared to any one of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26.
[0133] In some embodiments, the gRNA comprises a spacer sequence of SEQ ID NO: 4 or SEQ ID NO: 21, or a variant thereof having about less than, at least less than, at least about less than 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology to the spacer of SEQ ID NO: 4 or SEQ ID NO: 21. In some embodiments, the gRNA comprises a spacer sequence of SEQ ID NO: 4 or SEQ ID NO: 21, or a variant thereof having no more than 3 mismatches compared to SEQ ID NO: 4 or SEQ ID NO: 21. In some embodiments, the gRNA comprises a spacer sequence of SEQ ID NO: 4 or SEQ ID NO: 21.
[0134] In some embodiments, the gRNA comprises a spacer sequence of SEQ ID NO: 3 or SEQ ID NO: 20, or a variant thereof having about less than, at least less than, or at least about less than 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology to the spacer of SEQ ID NO: 3 or SEQ ID NO: 20. In some embodiments, the gRNA comprises a spacer sequence of SEQ ID NO: 3 or SEQ ID NO: 20, or a variant thereof having no more than 3 mismatches compared to SEQ ID NO: 3 or SEQ ID NO: 20. In some embodiments, the gRNA comprises a spacer sequence of SEQ ID NO: 3 or SEQ ID NO: 20. In some embodiments, the gRNA is a sgRNA.
[0135] In some embodiments, the gRNA comprises a first gRNA comprising a spacer sequence of SEQ ID NO: 3 or SEQ ID NO: 20 (or a variant having about 85% homology, at least 85% homology, or at least about 85% homology to SEQ ID NO: 3 or SEQ ID NO: 20) and a second gRNA comprising a spacer sequence of SEQ ID NO: 4 or SEQ ID NO: 21 (or a variant having about 85% homology, at least 85% homology, or at least about 85% homology to SEQ ID NO: 4 or SEQ ID NO: 21). The gRNA may also comprise one or more gRNAs having a spacer sequence of any one of SEQ ID NOs: 5-8 and SEQ ID NOs: 22-25, or a variant having about 85% homology, at least 85% homology, or at least about 85% homology to any one of SEQ ID NOs: 5-8 and SEQ ID NOs: 22-25.
[0136] In some embodiments, gRNA is a chemically modified gRNA. Various types of RNA modifications can be introduced into gRNA to enhance stability, reduce the possibility or degree of innate immune response and / or enhance other properties described in the art. The gRNA described herein may include one or more modifications, including internucleoside bonds, purine or pyrimidine bases or sugars. In some embodiments, modifications are introduced at the ends of gRNA using chemical synthesis or polymerase. Modified nucleic acids and examples of their synthesis are disclosed in WO2013 / 052523. The synthesis of modified polynucleotides is also described in Verma and Eckstein, Annual Review of Biochemistry, Vol. 76, 99-134 (1998).
[0137] In some embodiments, the chemically modified gRNA comprises thiophosphorylated 2'-O-methyl nucleotides at the 3' end and 5' end of the gRNA. In some embodiments, the chemically modified gRNA comprises thiophosphorylated 2'-O-methyl nucleotides at the 3' end of the gRNA. In some embodiments, the chemically modified gRNA comprises thiophosphorylated 2'-O-methyl nucleotides at the 5' end of the gRNA. In some embodiments, the chemically modified gRNA comprises three or four thiophosphorylated 2'-O-methyl nucleotides at the 3' end of the gRNA and / or comprises three or four thiophosphorylated 2'-O-methyl nucleotides at the 5' end. In some embodiments, comprising SEQ ID NO: 3-9 and SEQ ID NO: Any one of the gRNAs in any one of 20-26 can be chemically modified to have four thiophosphorylated 2'-O-methyl nucleotides at the 3' end of the gRNA and / or have three thiophosphorylated 2'-O-methyl nucleotides at the 5' end.
[0138] The number and position of phosphorothioate bonds can vary. In some embodiments, the bond can be between the first and second, second and third, third and fourth positions, fourth and fifth, fifth and sixth, sixth and seventh, seventh and eighth, eighth and ninth, ninth and tenth or other positions at the 5' end of the gRNA. In some embodiments, the bond can be between the first and second, second and third, third and fourth positions, fourth and fifth, fifth and sixth, sixth and seventh, seventh and eighth, eighth and ninth, ninth and tenth or other positions at the 3' end of the gRNA.
[0139] In some embodiments, nucleotide analogs / modifications may include 2-amino-6-chloropurine riboside-5'-triphosphate, 2-aminopurine-riboside-5'-triphosphate; 2-aminoadenosine-5'-triphosphate, 2'-amino-2'-deoxycytidine-triphosphate, 2-thiocytidine-5'-triphosphate, 2-thiouridine-5'-triphosphate, 2'-fluorothymidine-5'-triphosphate, 2'-O-methyl-inosine-5'-triphosphate , 4-thiouridine-5'-triphosphate, 5-aminoallylcytidine-5'-triphosphate, 5-aminoallyluridine-5'-triphosphate, 5-bromocytidine-5'-triphosphate, 5-bromouridine-5'-triphosphate, 5-bromo-2'-deoxycytidine-5'-triphosphate, 5-bromo-2'-deoxyuridine-5'-triphosphate, 5-iodocytidine-5'-triphosphate, 5-iodo-2'-deoxycytidine-5'-triphosphate, 5-iodo-uridine-5 '-triphosphate, 5-iodo-2'-deoxyuridine-5'-triphosphate, 5-methylcytidine-5'-triphosphate, 5-methyluridine-5'-triphosphate, 5-propynyl-2'-deoxycytidine-5'-triphosphate, 5-propynyl-2'-deoxyuridine-5'-triphosphate, 6-azacytidine-5'-triphosphate, 6-azauridine-5'-triphosphate, 6-chloropurine riboside-5'-triphosphate, 7-deazaadenosine-5'-triphosphate , 7-deazaguanosine-5'-triphosphate, 8-azaadenosine-5'-triphosphate, 8-azidoadenosine-5'-triphosphate, benzimidazole-riboside-5'-triphosphate, N1-methyladenosine-5'-triphosphate, N1-methylguanosine-5'-triphosphate, N6-methyladenosine-5'-triphosphate, O6-methylguanosine-5'-triphosphate, pseudouridine-5'-triphosphate, puromycin-5'-triphosphate or xanthosine-5'-triphosphate. The base modified nucleotides may include 5-methylcytidine-5'-triphosphate, 7-deazaguanosine-5'-triphosphate, 5-bromocytidine-5'-triphosphate and pseudouridine-5'-triphosphate, pyridine-4-ketone ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurine methyl uridine, 1-taurine methyl-pseudouridine, 5-taurine methyl-2-thio-uridine, 1-taurine methyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thiodihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine and 4-methoxy-2-thio-pseudouridine, 5-aza-cytidine,pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5 -methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyl adenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine and 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wyosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine and N2,N2-dimethyl-6-thio- Guanosine, 5'-O-(1-phosphorothioate)-adenosine, 5'-O-(1-phosphorothioate)-cytidine, 5'-O-(1-phosphorothioate)-guanosine, 5'-O-(1-phosphorothioate)-uridine, 5'-O-(1-phosphorothioate)-pseudouridine, 6-aza-cytidine, 2-thio-cytidine, α-thio-cytidine, pseudo-iso-cytidine, 5-aminoallyl-uridine, 5-iodo-uridine, N1-methyl-pseudouridine, 5,6-dihydrouridine, α-thio-uridine, 4-thio-uridine, 6-aza-uridine, 5-hydroxy-uridine, deoxy-thymidine, 5-methyl-uridine, pyrrolo-cytidine, inosine, α-thio-guanosine, 6-methyl-guanosine, 5-methyl-cytidine, 8-oxo-guanosine,7-deaza-guanosine, N1-methyl-adenosine, 2-amino-6-chloro-purine, N6-methyl-2-amino-purine, pseudo-iso-cytidine, 6-chloro-purine, N6-methyl-adenosine, α-thio-adenosine, 8-azido-adenosine or 7-deaza-adenosine.
[0140] At least one modified nucleotide and / or at least one nucleotide analog may include 1-methyladenosine, 2-methyladenosine, N6-methyladenosine, 2'-O-methyladenosine, 2-methylthio-N6-methyladenosine, N6-isopentenyladenosine, 2-methylthio-N6-isopentenyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6-methyl-N6-threonylcarbamoyladenosine, N6-hydroxynorvalylcarbamoyladenosine, 2-methylthio-N6-hydroxynorvalylcarbamoyladenosine, inosine, 3-methylcytidine, 2-O-methylcytidine, 2-thiocytidine, N4-acetylcytidine, lysine, 1-methylguanosine, 7-methylguanosine, 2'-O-methylguanosine, braided glycoside, epoxy braided glycoside, 7-cyano-7-deazaguanosine, 7-aminomethyl-7-deazaguanosine, pseudouridine, dihydrouridine, 5-methyluridine, 2'-O-methyluridine, 2-thiouridine, 4-thiouridine, 5-methyl-2-thiouridine, 3-(3-amino-3-carboxypropyl)uridine, 5'-hydroxyuridine, 5-methoxyuridine, uridine 5-oxyacetic acid, uridine 5-oxyacetic acid methyl ester, 5-aminomethyl-2-thiouridine, 5-methylaminomethyluridine, 5-methylaminomethyl-2-thiouridine, 5-methylaminomethyl-2-selenouridine, 5-carboxymethylaminomethyluridine, 5-carboxymethylaminomethyl-2'-O-methyluridine, 5-carboxymethylaminomethyl-2-thiouridine, 5-(isopentenylaminomethyl)uridine, 5-(isopentenylaminomethyl)-2-thiouridine or 5-(isopentenylaminomethyl)-2'-O-methyluridine.
[0141] In some embodiments, the chemical modification includes pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thiol-1-methyl-1-deaza-pseudouridine, 2-thiol-1-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thiol-1-methyl-pseudouridine, 4-thiol-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, or 2'-O-methyluridine. In some embodiments, the modification comprises 2'-O-methyluridine (2'OMe-rU), 2-O-methylcytidine (2'OMe-rC), 2'-O-methyladenosine (2'OMe-rA), or 2'-O-methylguanosine (2'OMe-rG).
[0142] The gRNA can contain any number of modified nucleic acids. In some embodiments, the percentage of modified nucleic acids in the gRNA molecule can be the following, can be at least the following, can be about the following, or can be at least about the following: 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31% of the gRNA sequence , 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74% or 75%.
[0143] For example, SEQ ID NO: 20 can be chemically modified to: * a * a * GAC CAU GUC CCA ACU GA" (SEQ ID NO: 12) (convert T to U), wherein u = 2'OMe-rU; a = 2'OMe-rA; * = thiolated phosphate.
[0144] In some embodiments, the gRNA comprises the sequence of SEQ ID NO: 10, and the RNA sequence can be modified to: 5'-her * your * your * GAC CAU GUC CCA NOTHING G UUU UAG Agc uag aaa uag cAA GUU AAAAUA AGG CUA GUC CGU UAU Caa cuu gaa aaa gug gca ccg agu cgg ugc u * u * u * u-3' (SEQ ID No: 13), where u = 2'OMe-rU; a = 2'OMe-rA; c = 2'OMe-rC; g = 2'OMe-rG; * = thiolated phosphate. The underlined sequence corresponds to the spacer region.
[0145] In another example, the gRNA spacer sequence of SEQ ID NO: 9 can be chemically modified to: * u * a * CUA AAG GAA CAA CAA AA" (SEQ ID NO:14) (converting T to U), wherein u = 2'OMe-rU; a = 2'OMe-rA; * = thiolated phosphate.
[0146] In some embodiments, the gRNA comprises the sequence of SEQ ID NO: 11 and can be chemically modified to: 5'- u * u * a * CUA AAG GAA CAA CAA AA G UUU UAG Agc uag aaa uag cAA GUU AAAAUA AGG CUA GUC CGU UAU CAa cuu gaa aaa gug gca ccg agu cgg ugc u * u * u * u-3' (SEQ ID NO: 15), where u = 2'OMe-rU; a = 2'OMe-rA; c = 2'OMe-rC; g = 2'OMe-rG; * = thiolated phosphate. The underlined sequence corresponds to the spacer region.
[0147] In some embodiments, more than one guide RNA can be used with the CRISPR / Cas nuclease system. Each guide RNA can contain different targeting sequences so that the CRISPR / Cas system cleaves more than one target nucleic acid. In some embodiments, one or more guide RNAs can have the same or different properties within the Cas9 RNP complex, such as activity or stability. When more than one guide RNA is used, each guide RNA can be encoded on the same or different vectors.
[0148] In some embodiments, the gRNA described herein can be produced by in vitro transcription (IVT), synthesis and / or chemical synthesis methods or a combination thereof. One or more of enzymatic IVT, solid phase, liquid phase, combinatorial synthesis methods, small area synthesis, and ligation methods can be utilized. In some embodiments, gRNA is prepared using IVT enzymatic synthesis methods. Methods for preparing polynucleotides by IVT are known in the art and are described in WO2013 / 151666. Polynucleotide constructs and vectors can be used to transcribe the gRNA described herein in vitro.
[0149] How to edit ANGPTL3 Provided herein is a method of using genome editing to edit ANGPTL3 by functionally knocking out or reducing the expression of the ANGPTL3 gene in the genome of a cell. The method can be used to treat a subject, such as a patient suffering from an ANGPTL3-related disease or condition.
[0150] Provided herein include a method for treating an ANGPTL3-related disease or disorder in a subject in need thereof, such as a primate subject. In some embodiments, the method comprises administering to a primate subject more than one nanoparticle complexed with (a) a guide RNA (gRNA) or a nucleic acid encoding a gRNA targeting an ANGPTL3 gene and (b) a nucleic acid encoding an RNA-guided endonuclease, thereby ameliorating an ANGPTL3-related disease or disorder in a primate subject. More than one nanoparticle may be administered to a subject two or more times, such as twice, for treatment. Two administrations of the nanoparticle to a subject may be separated by a suitable period of time. In some embodiments, a suitable period of time is or is about one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, three months, four months, five months, six months, one year, two years, three years, or longer. In some embodiments, two of the two or more administrations are separated by about two weeks to about two months, such as about three weeks. In some embodiments, each of the two or more administrations is separated by about two weeks to about two months, such as about three weeks. The appropriate time period between two administrations can be the same or different than the appropriate time period between two other administrations. In some embodiments, more than one nanoparticle is administered to a subject at a dose of about 0.01-5 mg / kg, e.g., 0.05-2 mg / kg, 0.5-3 mg / kg, or 0.1-1 mg / kg per administration. In some embodiments, an ANGPTL3 gRNA or a nucleic acid encoding an ANGPTL3 gRNA is administered to a subject at a dose of or about 0.01-5 mg / kg, e.g., 0.1-1 mg / kg gRNA per administration. In some embodiments, a nucleic acid encoding an RNA-guided endonuclease is administered to a subject at a dose of or about 0.1-5 mg / kg, e.g., 0.5-3 mg / kg or 0.3-2 mg / kg per administration. The dose can be the same or different for each administration to a subject.
[0151] In some embodiments, the gRNA targets within or near a coding sequence in an ANGPTL3 gene. In some embodiments, the gRNA targets a sequence within one of the 12 exons of the ANGPTL3 gene. In some embodiments, the gRNA targets a sequence within exon 1 of the ANGPTL3 gene. In some embodiments, the gRNA targets a sequence within exon 1 of the ANGPTL3 gene. The gRNA may comprise a spacer sequence complementary to a target sequence within exon 1 of the ANGPTL3 gene. In some embodiments, one or more spacers are complementary to a sequence within or near exon 1 of the ANGPTL3 gene (e.g., within any of the following distances from exon 1: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more bases). In some embodiments, the spacer region of the gRNA is complementary to the target sequence located at chr1: 62597719-62597738 (-) (without PAM) or chr1: 62597716-62597738 (-) (with PAM). The complementarity between the spacer region of the gRNA and the target sequence in the ANGPTL3 gene can be complete or incomplete. In some embodiments, the complementarity can be at least 70%, 80%, 90%, 100%, or a number or range between any two of these values. In some embodiments, the complementarity is complete, i.e., 100%.
[0152] In some embodiments, the gRNA comprises a spacer sequence selected from SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26, or a variant thereof having about less than, at least less than, at least about less than 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology with any of the spacers of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26. In some embodiments, the gRNA comprises a spacer sequence selected from SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26, or a variant thereof having no more than 3 mismatches compared to any of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26. In some embodiments, the gRNA comprises a spacer sequence selected from SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26. In some embodiments, the gRNA comprises or consists of a spacer sequence of SEQ ID NO: 12.
[0153] In some embodiments, the gRNA used in the methods herein may include two or more gRNAs, each of which includes a spacer region complementary to the target sequence of the ANGPLT3 gene (e.g., any one of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26, or a variant thereof having at least 85% homology with any one of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26, or a variant having no more than 3 mismatches compared to any one of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26).
[0154] In some embodiments, the guide sequence comprises the spacer sequence of SEQ ID NO: 4 or SEQ ID NO: 21, or a variant thereof having about less than, at least less than, at least about less than 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology to the spacer of SEQ ID NO: 4 or SEQ ID NO: 21. In some embodiments, the guide sequence comprises the spacer sequence of SEQ ID NO: 4 or SEQ ID NO: 21.
[0155] In some embodiments, the guide sequence comprises a spacer sequence of SEQ ID NO: 3, SEQ ID NO: 20, or a variant thereof having about less than, at least less than, at least about less than 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology to the spacer of SEQ ID NO: 3 or SEQ ID NO: 20. In some embodiments, the guide sequence comprises a spacer sequence of SEQ ID NO: 3 or SEQ ID NO: 20. In some embodiments, the guide sequence comprises or consists of a spacer sequence of SEQ ID NO: 12. In some embodiments, the guide sequence comprises a sequence of SEQ ID NO: 10, or a variant thereof having about less than, at least less than, at least about less than 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% homology to the sequence of SEQ ID NO: 10. In some embodiments, the guide sequence comprises a sequence of SEQ ID NO: 10. In some embodiments, the guide sequence comprises or consists of the sequence of SEQ ID NO: 13.
[0156] The gRNA used herein can enhance on-target activity while significantly reducing potential off-target effects (i.e., cleavage of genomic DNA at undesired locations other than the ANGPTL3 gene). In some embodiments, off-target binding is reduced by about less than, at least less than, or at least about less than: 80%, 85%, 90%, 95%, 98%, 99%, or 100%.
[0157] In some embodiments, the DNA endonuclease is a Cas endonuclease described herein or known in the art. The Cas endonuclease can be naturally occurring or non-naturally occurring (e.g., recombinant or with mutations). In some embodiments, the DNA endonuclease is selected from the group consisting of: Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, or Cpf1 endonuclease or a functional derivative thereof. In some embodiments, the DNA endonuclease is a Cas9 endonuclease or a variant thereof. In some embodiments, the Cas9 endonuclease is from Streptococcus pyogenes (SpyCas9). In some embodiments, the Cas9 endonuclease is from Staphylococcus lugdunensis (SluCas9).
[0158] In some embodiments, genetic modification of the ANGPTL3 gene results in a significant decrease in plasma ANGPTL3 protein, plasma ApoB protein, and / or lipid levels, such as triglyceride levels, in a subject (e.g., a mammal, NHP, human subject). In some embodiments, plasma ANGPTL3 protein levels are decreased by 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, , 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values. In some embodiments, the methods described herein may reduce plasma ANGPTL3 protein levels by about less than, at least less than, or at least about less than 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values.
[0159] In some embodiments, genetic modification of the ANGPTL3 gene results in a significant reduction in lipid levels (e.g., total cholesterol, triglycerides, HDL, LDL, and other non-HDL lipids) in a subject (e.g., a mammal, NHP, a human subject). In some embodiments, the gene editing methods described herein can reduce non-HDL lipid levels (e.g., LDL, VLDL, and / or triglycerides) by 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110 6%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values. In some embodiments, plasma triglyceride levels are reduced by about less than, at least less than, or at least about less than 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values.
[0160] In some embodiments, genetic modification of the ANGPTL3 gene results in a significant decrease in plasma ApoB protein levels in a subject (e.g., a mammal, NHP, human subject). In some embodiments, plasma ApoB protein levels are decreased by 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values. In some embodiments, the methods described herein can reduce plasma ApoB protein levels by about less than, at least less than, or at least about less than 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values.
[0161] In some embodiments, the plasma ANGPTL3 protein, ApoB protein, and / or non-HDL lipid levels (e.g., triglycerides) in a genetically modified subject (e.g., a mammal, NHP, human subject) is about less than, less than, or less than about 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 119 %, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%.
[0162] In some embodiments, the concentration of ANGPTL3 protein, the level of one or more of non-high-density lipoprotein (non-HDL) lipids, and / or the concentration of ApoB protein in a subject (e.g., a mammal, NHP, human subject) is reduced by at least 20%, at least 40%, or at least 70% three weeks, four weeks, five weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, or more after administration. In some embodiments, the concentration of ANGPTL3 protein, the level of one or more of non-high-density lipoprotein (non-HDL) lipids, and / or the concentration of ApoB protein is reduced by at least 20%, at least 40%, or at least 70% three weeks, four weeks, five weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, or more after a single administration.
[0163] In some embodiments, the qualifications and endpoints of the methods disclosed herein (e.g., at 6 months) include: the subject is non-HDL-C> 160 mg / dL, triglycerides> 300 mg / dL and / or ApoB> 100 mg / dL before treatment, and the results of the method are determined by measuring the change from baseline of non-HDL-C (total cholesterol-HDL), the change from baseline of triglycerides and / or the change from baseline of ApoB. Non-HDL levels are 30 mg / dL higher than LDL, non-HDL = LDL, VLDL, IDL and Lp (a). In some embodiments, the subject has a triglyceride level greater than 300 mg / dL, a non-high-density lipoprotein (HDL) level greater than 160 mg / dL, a low-density lipoprotein cholesterol (LDL-C) level greater than 100 mg / dL, an ApoB level greater than 100 mg / dL, or a combination thereof. The method may include measuring blood levels of one or more of ANGPTL3, ApoB, triglycerides, very low density lipoprotein (VLDL), low density lipoprotein (LDL), LDL-C, HDL, and non-HDL lipids in the subject before, during, and / or after administration.
[0164] In some embodiments, the subject is refractory to one or more (or all) available SOC treatment lines (including ezetimibe and / or PCSK9 inhibitors) at least 12 weeks prior to screening. In some embodiments, HoFH subjects who have received Evinacumab but have not reached treatment-related target lipid targets and meet non-HDL eligibility criteria can be treated. The subject may be in previous PCSK9 inhibitor treatment. In some embodiments, the subject has not been treated with a PCSK9 inhibitor.
[0165] Pharmaceutical compositions and therapeutic applications The content provided herein also includes pharmaceutical compositions for implementing the methods disclosed herein. The composition can include one or more gRNAs, RNA-guided endonucleases, or nucleotide sequences encoding RNA-guided endonucleases described herein. In some embodiments, the composition can also include a polynucleotide to be inserted into the ANGPTL3 gene (e.g., a donor template) to achieve the desired genetic modification method disclosed herein.
[0166] In some embodiments, one or more gRNAs each comprise a spacer region complementary to a genomic sequence within or near any exon of an ANGPTL3 gene (e.g., within any of the following distances from any exon of an ANGPTL3 gene: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more bases). In some embodiments, the gRNA targets a sequence within exon 1 of an ANGPTL3 gene. The gRNA may comprise a spacer region sequence complementary to a target sequence within exon 1 of an ANGPTL3 gene. In some embodiments, the gRNA comprises a spacer region sequence of any one of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26 or a variant thereof having at least 85% homology to a spacer region sequence of any one of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26. In some embodiments, the gRNA comprises a spacer of SEQ ID NO: 3 or SEQ ID NO: 20, or a variant thereof having at least 85% homology to a spacer having a sequence of SEQ ID NO: 3 or SEQ ID NO: 20. In some embodiments, the gRNA comprises a spacer of SEQ ID NO: 4, SEQ ID NO: 21, or a variant thereof having at least 85% homology to a spacer having a sequence of SEQ ID NO: 4 or SEQ ID NO: 21. In some embodiments, the gRNA comprises a spacer comprising or consisting of a sequence of SEQ ID NO: 12. In some embodiments, the gRNA comprises a sequence of SEQ ID NO: 10, or a variant thereof having at least 85% homology to a sequence of SEQ ID NO: 10. In some embodiments, the gRNA comprises or consists of a sequence of SEQ ID NO: 13.
[0167] In some embodiments, the RNA-guided endonuclease is Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csy1, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cpf1 endonucleases or functional derivatives thereof. In some embodiments, the DNA endonuclease is Cas9. In some embodiments, the Cas9 endonuclease is from Streptococcus pyogenes (SpyCas9). In some embodiments, the Cas9 endonuclease is from Staphylococcus lugdunensis (SluCas9). In some embodiments, the DNA sequence transcribed into the nucleic acid encoding the DNA endonuclease is codon optimized. In some embodiments, the nucleic acid (e.g., mRNA) encoding the DNA endonuclease includes a 5' cap structure and a 3' poly-A tail. In some embodiments, the nucleic acid encoding the DNA endonuclease is connected to the gRNA via a covalent bond.
[0168] In some embodiments, one or more of the nucleic acid sequences and / or polypeptides can be delivered to cells in vitro or in vivo via a viral or non-viral based delivery system, including adenoviral vectors, adeno-associated viral (AAV) vectors, retroviral vectors, lentiviral vectors, herpes virus vectors, liposomes, lipid nanoparticles, poxviruses, naked DNA administration, plasmids, cosmids, phages, encapsulated cell technology, etc.
[0169] In some embodiments, the compounds of the compositions disclosed herein (e.g., ANGPTL3 gRNA or nucleic acids encoding ANGPTL3 gRNA and nucleic acids encoding RNA-guided endonucleases) can be formulated in liposomes or lipid nanoparticles. In some embodiments, the compounds of the compositions are formulated in lipid nanoparticles (LNPs). LNPs are non-viral delivery systems that safely and effectively deliver nucleic acids to target organs (e.g., liver). The term "lipid nanoparticle" refers to nanoscale particles composed of lipids having a size measured in nanometers (e.g., 1-5,000 nm). In some embodiments, the lipids contained in the lipid nanoparticles include cationic lipids and / or ionizable lipids. Any suitable cationic lipids and / or ionizable lipids known in the art can be used to formulate LNPs for delivering gRNA and Cas endonucleases to cells. Exemplary cationic lipids include one or more positively charged amine groups. In some embodiments, the cationic lipids are ionizable so that they can exist in a positively charged or neutral form depending on the pH. In some embodiments, the cationic lipid of lipid nanoparticle is included in the protonable tertiary amine head group that shows positive charge at low pH.Lipid nanoparticle can also include one or more neutral lipids (for example, distearoylphosphatidylcholine (DSPC) as auxiliary lipid, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) etc.), charged lipid, steroid and polymer conjugated lipid.In some embodiments, LNP can include cholesterol.In some embodiments, LNP can include polyethylene glycol (PEG) lipid.
[0170] Lipid nanoparticles can include composition lipids of different concentrations.In some embodiments, the molar percentage of ionizable lipids in the total lipid of lipid nanoparticles is about below, at least below, at least about below, at most below or at most about below: 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or any two of these values between the number or scope.In some embodiments, the molar percentage of ionizable lipids in lipid nanoparticles is in the range of about 40%-70% (for example, about 60%).In some embodiments, lipid nanoparticles can also include auxiliary lipids (for example DSPC), sterol lipids (for example cholesterol) and PEG lipids or phospholipid PEG conjugates.In some embodiments, the molar percentage of auxiliary lipids in lipid nanoparticles is about 5% to 20% (for example, about 10.5%), the molar percentage of sterol lipids is about 10% to 40% (for example, about 21%), and the molar percentage of PEG lipids is about 0.5% to 10% (for example, about 8.5%).
[0171] LNP uptake in hepatocytes can be mediated by apolipoprotein E-low-density lipoprotein receptor (ApoE-LDLR) or N-acetyl-D-galactosamine / asialoglycoprotein receptor pathway (GalNAc-ASGPR) (Sato et al., 2020, Journal of Controlled Release, 322, 217-226.). In some embodiments, the LNP described herein for delivering gRNA and Cas endonuclease to cells can be formulated to follow the ApoE-LDLR uptake pathway. In some embodiments, the LNP described herein for delivering gRNA and Cas endonuclease to cells can be formulated to follow the GalNAc-ASGPR uptake pathway. In some embodiments, the LNP formulations described herein can be used to treat subjects with diseases or disorders manifested as heterozygous (HeFH) or homozygous (HoFH) lost by low-density lipoprotein receptor (LDLR).
[0172] In some embodiments, lipid nanoparticles include N-acetylgalactosamine (GalNAc), an amino sugar derivative of galactose. In some embodiments, GalNAc is present in LNPs at a molar percentage of about 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5% or 6.0% with about 2.5% molar percentage. In some embodiments, GalNAc is present in LNPs at a molar percentage of about 2.5%.
[0173] In some embodiments, the concentration of the nanoparticles in the compositions disclosed herein is about 58.2 mg / mL (e.g., total lipid), and the nanoparticles are complexed with a total of about 2 mg / mL of (a) ANGPTL3 gRNA and (b) Cas9 mRNA nucleic acid. In some embodiments, the concentration of more than one nanoparticle is about 58.2 mg / mL, and the nanoparticles are complexed with (a) about 1.5 mg / mL ANGPTL3 gRNA and (b) about 0.5 mg / mL Cas9 mRNA.
[0174] In different embodiments, the relative amounts of total RNA ((a) ANGPTL3 gRNA or nucleic acid encoding a gRNA targeting an ANGPTL3 gene, and (b) nucleic acid encoding an RNA-guided endonuclease) and total lipid in the nanoparticle can vary. For example, the nanoparticle can have a weight ratio of total lipid to total RNA of about 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, or 30:1. In some embodiments, the nanoparticle can have a weight ratio of total lipid to total RNA of about 30:1. In some embodiments, the nanoparticles can have a total lipid and total RNA at a molar ratio of about 30: 1, 31: 1, 32: 1, 33: 1, 34: 1, 35: 1, 36: 1, 37: 1, 38: 1, 39: 1, 40: 1, 41: 1, 42: 1, 43: 1, 44: 1, 45: 1, 46: 1, 47: 1, 48: 1, 49: 1, or 50: 1. In some embodiments, the nanoparticles can have a total lipid and total RNA at a molar ratio of about 40: 1.
[0175] In some embodiments, the concentration of nanoparticles (e.g., total lipid) in a composition disclosed herein is about less than, at least less than, at least about less than, at most less than, or at most about less than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 93, 94, 95, 96, 97, 98, 99, 100 mg / mL, or a number or range between any two of these values. In some embodiments, the RNA in the nanoparticle is formulated at a concentration of about less than, at least less than, at least about less than, at most less than, or at most about less than 50, 75, 100, 200, 400, 600, 800, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 μg / ml, or a number or range between any two of these values.
[0176] The amounts in the nanoparticles (e.g., the relative amounts of (a) ANGPTL3 gRNA or nucleic acid encoding a gRNA targeting an ANGPTL3 gene and (b) nucleic acid encoding an RNA-guided endonuclease (e.g., mRNA encoding a Cas protein (e.g., Cas9 mRNA)) can vary. For example, the nanoparticles can have a 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, or 5:1 ratio (by weight) of nucleic acid encoding an RNA-guided endonuclease (e.g., SpCas9 mRNA) and ANGPTL3 gRNA. In some embodiments, the nanoparticles can have a 3:1 ratio (by weight) of nucleic acid encoding an RNA-guided endonuclease and ANGPTL3 gRNA.
[0177] In some embodiments, more than one nanoparticle is administered to a subject at a dose of about 0.01-5 mg / kg (determined by total nucleic acid (eg, the sum of ANGPTL3 gRNA and Cas9 mRNA)) per administration. For example, a single dose or each dose of more than one nanoparticle administered to a subject can be at 0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 0.7 mg / kg, 0.8 mg / kg, 0.9 mg / kg, 1 mg / kg, 1.1 mg / kg, 1.2 mg / kg, 1.3 mg / kg, 1.4 mg / kg, 1.5 mg / kg, 1.6 mg / kg, 1.7 mg / kg, 1.8 mg / kg, 1.9 mg / kg, 2 mg / kg, 2.1 mg / kg, 2.2 mg / kg, 2.3 mg / kg, 2.4 mg / kg, 2.5 mg / kg, 2.6 mg / kg, 2.7 mg / kg, 2.8 mg / kg, 2.9 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 In some embodiments, the subject is administered with nanoparticles containing at least one nanoparticle of ...
[0178] The present disclosure includes compositions. In some embodiments, the composition comprises more than one nanoparticle complexed with (a) a guide RNA (gRNA) targeting an ANGPTL3 gene (ANGPTL3 gRNA) and (b) an mRNA encoding a Cas9 endonuclease, wherein the gRNA comprises a spacer sequence of SEQ ID NO: 3, SEQ ID NO: 20, or SEQ ID NO: 12. In some embodiments, the gRNA comprises a sequence of SEQ ID NO: 10 or SEQ ID NO: 13. The Cas9 endonuclease can be a Streptococcus pyogenes Cas9 endonuclease. In some embodiments, the concentration of the more than one nanoparticle is about 58.2 mg / mL and is complexed with a total of about 2 mg / mL of (a) ANGPTL3 gRNA and (b) Cas9 mRNA nucleic acid. In some embodiments, the concentration of the more than one nanoparticle is about 58.2 mg / mL and is complexed with (a) about 1.5 mg / mL of ANGPTL3 gRNA and (b) about 0.5 mg / mL of Cas9 mRNA.
[0179] Non-limiting examples of dose escalation of the compositions disclosed herein (e.g., lipid nanoparticles complexed with ANGPTL3 gRNA or a nucleic acid encoding an ANGPTL3 gRNA and a nucleic acid encoding an RNA-guided endonuclease) are provided in Table 2. The dose is determined by the total amount of ANGPTL3 gRNA and Cas9 mRNA complexed with the nanoparticle.
[0180] Table 2: ANGPTL3 dose escalation Dosage (mg / kg) Patient weight (kg) Single dose (mg) Number of patients 0.1 80 8 3 0.3 80 24 3 0.6 80 48 3 1 80 80 3 In some embodiments, the lipid nanoparticles may have an average diameter of about 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 150 nm, or a number or range between any two of these values. In some embodiments, the lipid nanoparticle size is about 50 to about 100 nm in diameter, or about 70 to about 90 nm in diameter, or about 55 to about 95 nm in diameter.
[0181] In some embodiments, the compound of the composition described herein is encapsulated in the lipid portion of the lipid nanoparticle or in the aqueous space encapsulated by some or all of the lipid portion of the lipid nanoparticle. Encapsulation can be complete encapsulation, partial encapsulation or both. In some embodiments, nucleic acids and / or polypeptides are completely or substantially encapsulated (e.g., greater than 90% of RNA) in lipid nanoparticles.
[0182] In some embodiments, one or more compounds described herein are associated with liposomes or lipid nanoparticles via covalent or non-covalent bonds. In some embodiments, any compound in the composition may be contained in a liposome or lipid nanoparticle, either alone or together.
[0183] The composition described above may also have one or more additional reagents, wherein such additional reagents are selected from a buffer, a buffer for introducing a polypeptide or polynucleotide into a cell, a washing buffer, a control reagent, a control vector, a control RNA polynucleotide, a reagent for producing a polypeptide from DNA in vitro, an adapter for sequencing, etc. The buffer may be a stabilization buffer, a reconstitution buffer, a dilution buffer, etc. In some embodiments, the composition may also include one or more components that can be used to promote or enhance the target binding or cleavage of the endonuclease to the DNA or improve the specificity of the targeting.
[0184] In some embodiments, any component of the composition is formulated with a pharmaceutically acceptable excipient such as a carrier, solvent, stabilizer, adjuvant, diluent, etc., depending on the specific mode of administration and dosage form. In some embodiments, the guide RNA composition is generally formulated to achieve a physiologically compatible pH, and ranges from about pH 3 to about pH 11, about pH 3 to about pH 7, depending on the formulation and route of administration. In some embodiments, the pH is adjusted to a range of about pH 5.0 to about pH 8.
[0185] Suitable excipients can include, for example, carrier molecules including large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acid, polyglycolic acid, polyamino acids, amino acid copolymers, and inactive viral particles. Other exemplary excipients include antioxidants (such as, but not limited to, ascorbic acid), chelating agents (such as, but not limited to, EDTA), carbohydrates (such as, but not limited to, dextrins, hydroxyalkyl cellulose, and hydroxyalkyl methyl cellulose), stearic acid, liquids (such as, but not limited to, oils, water, saline, glycerol, and ethanol), wetting agents or emulsifiers, pH buffer substances, and the like.
[0186] Physiologically tolerable carriers are well known in the art. Exemplary liquid carriers are sterile aqueous solutions that do not contain any substance except the active ingredient and water, or contain buffers such as sodium phosphate, saline or both at physiological pH, such as phosphate buffered saline. Aqueous carriers can contain more than one buffer salt, as well as salts (such as sodium chloride and potassium chloride), dextrose, polyethylene glycol and other solutes. Liquid compositions can also contain a liquid phase in addition to water and a liquid phase without water. Examples of such additional liquid phases are glycerol, vegetable oils such as cottonseed oil and water-oil emulsions. The amount of active compound used in a cell composition that is effective in treating a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques.
[0187] As used herein, the term "stable" or "stability" can refer to the ability of a compound described herein (e.g., an RNA-guided endonuclease or a nucleic acid encoding an RNA-guided endonuclease and / or a gRNA) to maintain therapeutic efficacy (e.g., all or a substantial portion of its intended biological activity and / or physicochemical integrity) over an extended period of time. The stability of one or more of the compounds described herein (e.g., RNA-guided endonucleases or nucleic acids encoding RNA-guided endonucleases and / or gRNAs and nanoparticles) can be 2 weeks, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 3 weeks, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 2 years, 3 years, or more than 3 years. The storage temperature can vary. For example, the storage temperature can be below, can be about below, can be at least below, or can be at least about below: -80°C, -65°C, -20°C, 5°C, or a number or range between any two of these values. In some embodiments, the storage temperature is less than or equal to -65°C.
[0188] The stability of the compounds herein can be evaluated by measuring their relative potency (e.g., relative to a reference). In some embodiments, the editing of target cells (e.g., Hep3B hepatocytes) by, for example, CTX310 with different targets: effector ratios can be determined. The percentage of editing can be calculated relative to a negative control (i.e., without CTX310) product. In some embodiments, the concentration of CTX310 is plotted relative to the editing percentage determined by NGS or sanger sequencing using a 4-parameter logistic fit to generate an efficacy curve. The relative potency of the sample is calculated relative to a reference standard.
[0189] In some embodiments, the compound described herein of the composition (e.g., RNA-guided endonucleases or nucleic acids encoding RNA-guided endonucleases and / or gRNA) can be delivered via transfection, such as calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, electronuclear transport, chemical transduction, electrotransduction, Lipofectamine-mediated transfection, Effectene-mediated transfection, lipid nanoparticle (LNP)-mediated transfection, or any combination thereof. In some embodiments, lipid nanoparticles are used to introduce the composition into cells via lipid-mediated transfection.
[0190] The compositions described herein can be administered to a subject in need thereof to treat an ANGPTL3-related condition. Thus, the present disclosure also provides a gene therapy method for treating an ANGPTL3-related condition in a subject by editing the subject's ANGPTL3 gene. In some embodiments, the gene therapy method functionally knocks out the ANGPTL3 gene in the genome of a relevant cell type in a patient (e.g., liver). The ANGPTL3 gene of a relevant cell in a subject (e.g., liver) is edited using the materials and methods described herein, which use an RNA-guided endonuclease (such as Cas9) to permanently delete, insert, edit, correct or replace a target sequence from the genome or insert an exogenous sequence, thereby functionally knocking out the ANGPTL3 gene. This can provide a permanent cure for an ANGPTL3-related condition by permanently reducing the levels of ANGPTL3 protein, ApoB protein, and lipids such as triglycerides, LDL, VLDL, total cholesterol, HDL, non-HDL, and / or other adipose phospholipids in the blood. As used herein, the term "associated" with respect to two items (e.g., ANGPTL3 and a disease / condition) refers to a relationship between the two items such that the occurrence of one item (e.g., ANGPTL3 protein levels) is accompanied by the occurrence of the other item (e.g., a disease or condition), including but not limited to cause-effect relationships and sign / symptom-disease relationships.
[0191] As described herein, in some embodiments, nanoparticles (e.g., LNPs containing ionizable lipids) complexed with (a) guide RNA (gRNA) or nucleic acid encoding a gRNA targeting an ANGPTL3 gene and (b) nucleic acid encoding an RNA-guided endonuclease (e.g., Cas9 mRNA) are administered to a subject in need via IV infusion. Administration may be, for example, a single dose or two or more doses. The nanoparticles may, for example, be rapidly distributed to, for example, the subject's liver, and the nanoparticles may enter the subject's hepatocytes (e.g., via endocytosis). In some embodiments, ionizable lipid destruction of the endosome may destroy the nanoparticles, thereby releasing nucleic acid encoding an RNA-guided endonuclease (e.g., Cas9 mRNA) from the nanoparticles. RNA-guided endonucleases (e.g., Cas9) may be synthesized and endonuclease-gRNA RNP complexes may be formed to achieve gene editing. In some embodiments, endogenous DNA repair by non-homologous end joining (NHEJ) results in the introduction of an indel into the ANGPTL3 gene, resulting in a frameshift mutation that prevents the production of a functional ANGPTL3 protein. As shown herein, using the methods, compositions, systems and kits described herein, robust on-target editing of the ANGPTL3 gene can be achieved without off-target editing.
[0192] In some embodiments, a method of treating an ANGPTL3-associated disease or disorder comprises administering to a subject in need thereof (e.g., a primate subject) more than one nanoparticle complexed with (a) a guide RNA (gRNA) or a nucleic acid encoding a gRNA targeting an ANGPTL3 gene and (b) a nucleic acid encoding an RNA-guided endonuclease, thereby ameliorating the ANGPTL3-associated disease or disorder in the primate subject.
[0193] ANGPTL3-related diseases and disorders include, but are not limited to, arteriosclerosis, atherosclerosis, cardiovascular disease, coronary heart disease, diabetes, diabetes mellitus, non-insulin-dependent diabetes, fatty liver, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, hypobetalipoproteinemia, inflammation, insulin resistance, metabolic diseases, obesity, oral malignancies, lipid metabolism disorders, lip and oral cavity carcinoma, dyslipidemia, metabolic syndrome X, hypotriglyceridemia, Opitz trigonocephaly syndrome, ischemic stroke, hypertriglyceridemia, familial hypobetalipoproteinemia 2, familial hypobetalipoproteinemia, and ischemic cerebrovascular accident. Editing the ANGPTL3 gene using any of the methods described herein can be used to treat, prevent, and / or alleviate the symptoms of the diseases and disorders described herein.
[0194] In some embodiments, the methods and compositions described herein are used to treat dyslipidemia, hypobetalipoproteinemia, familial hypercholesterolemia (including homozygous familial hypercholesterolemia (HoFH) and heterozygous familial hypercholesterolemia (HeFH)), hypertriglyceridemia, familial combined hyperlipidemia, familial chylomicronemia syndrome, multifactorial chylomicronemia syndrome, familial combined hyperlipidemia (FCHL), metabolic syndrome (MetS), non-alcoholic fatty liver disease (NAFLD), elevated lipoprotein (a), and total cholesterol by permanently reducing the levels of ANGPTL3 protein and lipids in the blood, such as total cholesterol, triglycerides, LDL, HDL, and / or other non-HDL. In some embodiments, the methods disclosed herein include genetic screening of the patient. For example, for HoFH and / or HeFH, genetic screening can be performed for one or more of LDLr, APOB, and PCSK9. For FCS and / or MCS, genetic screening can be performed for one or more of LPL, Apo CII, Apo V, LMF-1, and GP1HBP1. In some embodiments, the subject receiving the ANGPTL3 gene editing treatment described herein has been genetically screened before receiving treatment, such as genetic screening for one or more of LDLr, APOB, and PCSK9 (e.g., for the treatment of HoFH and / or HeFH), or genetic screening for one or more of LPL, ApoCII, Apo V, LMF-1, and GP1HBP1 genotypes (e.g., for the treatment of FCS and / or MCS). In some embodiments, the subject does not carry an LPL mutation, a GP1HBP1 mutation, or a combination thereof. The subject may have a monogenic, allogenic, or polygenic background.
[0195] In some embodiments, the methods, compositions and kits described herein can be used to treat dyslipidemia. Dyslipidemia is a genetic disease characterized by elevated lipid levels in the blood, leading to the development of arterial blockage (atherosclerosis). These lipids include plasma cholesterol, triglycerides or high-density lipoproteins. Dyslipidemia increases the risk of heart attack, stroke or other circulatory problems. Current management includes lifestyle changes, such as exercise and dietary adjustments, and the use of lipid-lowering drugs, such as statins. Non-statin lipid-lowering drugs include bile acid sequestrants, cholesterol absorption inhibitors, homozygous familial hypercholesterolemia drugs, fibrates, niacin, omega-3 fatty acids and / or combination products. Treatment options usually depend on specific lipid abnormalities, although different lipid abnormalities usually coexist. Treatment of children is more challenging because dietary changes may be difficult to implement and lipid-lowering therapy has not yet been proven to be effective.
[0196] In some embodiments, methods described herein, compositions and kits can be used to treat hypobetalipoproteinemia. Hypobetalipoproteinemia is a hereditary disease (autosomal recessive), affecting people between 1 / 1000 and 1 / 3000 worldwide. Common symptoms of hypobetalipoproteinemia include plasma levels of LDL cholesterol or apolipoprotein B below the 5th percentile, which impairs the body's ability to absorb and transport fat, and can lead to abnormal accumulation of fat in retinal degeneration, neuropathy, coagulopathy or liver (called hepatic steatosis). In severely affected patients, hepatic steatosis may progress to chronic liver disease (cirrhosis). Current treatment of hypobetalipoproteinemia includes strict restriction of long-chain fatty acids to 15 grams per day to improve fat absorption. In infants suffering from hypobetalipoproteinemia, short-term supplementation of medium-chain triglycerides may be effective, but the dosage must be closely monitored to avoid hepatotoxicity. Another option for treating hypobetalipoproteinemia is to administer high doses of vitamin E to prevent neurological complications. Alternatively, if an elevated prothrombin time suggests vitamin K deficiency, supplementation with vitamin A (10,000-25,000 IU / day) may be effective.
[0197] In some embodiments, the methods, compositions, and kits described herein can be used to treat familial hypercholesterolemia. Familial hypercholesterolemia ("FH") is an inherited disorder of low-density lipoprotein cholesterol characterized by elevated cholesterol levels at birth and a high risk of premature coronary heart disease. Mutations in any of three genes (LDLR, APOB, and PCSK9) are known to cause autosomal dominant FH.
[0198] In some embodiments, the methods, compositions and kits described herein can be used to treat hypertriglyceridemia. Hypertriglyceridemia is defined as an abnormal concentration of triglycerides in the blood. Hypertriglyceridemia can be primary or secondary in nature. Primary hypertriglyceridemia is the result of various genetic defects that cause triglyceride metabolism disorders. Secondary causes are acquired causes, such as high-fat diets, obesity, diabetes, hypothyroidism, and certain drugs.
[0199] In some embodiments, the target tissue for the compositions and methods described herein is liver tissue. In some embodiments, the target cell for the compositions and methods described herein is a hepatocyte.
[0200] In some embodiments, the pharmaceutical composition can be administered by aerosol delivery, nasal delivery, vaginal delivery, rectal delivery, buccal delivery, ocular delivery, topical delivery, surface delivery, intracisternal delivery, intraperitoneal delivery, oral delivery, intramuscular injection, intravenous injection, subcutaneous injection, intranodal injection, intratumoral injection, intraperitoneal injection and / or intradermal injection or any combination thereof. Administration can be local or systemic. Systemic administration includes enteral and parenteral administration. In some embodiments, more than one administration can be used to achieve the desired gene expression level within a time period of various intervals (e.g., daily, weekly, monthly or annually).
[0201] The pharmaceutical composition can be administered to a subject in need thereof in a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" means the amount of the pharmaceutical composition that will elicit the desired therapeutic effect and / or biological or medical response of a tissue, system, animal or human. Administration can result in a desired decrease in ANGPTL3 gene expression, such as a desired decrease in the levels of ANGPTL3 protein and lipids such as triglycerides, cholesterol and / or adipose phospholipids in the blood.
[0202] In some embodiments, other treatment is applied to the subject. Other treatment can include the use of corticosteroids, anti-H1 antihistamines, anti-H2 antihistamines or any combination thereof. In some embodiments, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week or longer time before applying more than one nanoparticle to the subject and applying other treatment to the subject. In some embodiments, before applying more than one nanoparticle, at most 2 hours, other treatment is applied to the subject. In some embodiments, other treatment and more than one nanoparticle are applied simultaneously.
[0203] In some embodiments, the additional treatment includes one or more of the following: hepatoprotective drugs (silymarin, polyene phosphatidylcholine, bicyclol, glycyrrhizic acid preparations, N-acetylated L-cysteine (NAC) and glutathione (GSH)); anticholestatic drugs (ursodeoxycholic acid, S-adenosylmethionine, cholestyramine); immunosuppressants (glucocorticoids) and / or antihistamines. In some embodiments, antihistamines include acrivastine, azelastine, emadastine, epinastine, brompheniramine, carbinoxamine, cetirizine, chlorpheniramine, clamastine, cyproheptadine, desloratadine, diphenhydramine, naphazoline, fexofenadine, hydroxyzine, ketotifen, levociterizine, loratadine, olopatadine, and / or pharmaceutically acceptable salts thereof. In some embodiments, corticosteroids include corticosteroids such as hydrocortisone, hydroxyl-triamcinolone, alpha-methyldexamethasone, dexamethasone phosphate, beclomethasone dipropionate, clobetasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluocinolone acetonide, fluocinonide, flucortine butylesters, fluocortolone, fluprednidene acetate, fluocinolone acetonide, fluocinonide, flucortine butylesters, fluocortolone, fluprednidene acetate, fluocinolone acetonide, fluocinonide, fluocinonide, fluocinolone butylesters, fluocortolone, fluprednidene acetate, fluocinolone acetonide, fluocinolone acetonide, fluocinon ... acetate,fluprednylidene acetate), flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, flurandrenolone, fludrocortisone, diflurosone diacetate, fluradrenolone acetonide, medrysone, amcinafel, amcinafide, betamethasone and the balance of its esters esters), chloroprednisone, chloroprednisone acetate, clocortolone, clescinolone, diclosone, difluprednate, flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone cyclopentyl propionate, hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, triamcinolone, or any combination thereof. In some embodiments, the corticosteroid is dexamethasone. In some embodiments, the antihistamine comprises diphenhydramine, cetirizine, famotidine, or any combination thereof. ,
[0204] Other treatments (e.g., corticosteroids and / or antihistamines) can be administered orally, intramuscularly, intravenously, subcutaneously, or any combination thereof. In some embodiments, the administration routes of corticosteroids and antihistamines are different. In some embodiments, the administration routes of corticosteroids and antihistamines are identical. In some embodiments, corticosteroids are administered intravenously with a dosage of, about, at least, or at most: 10 mg. In some embodiments, corticosteroids are administered with a dosage of 10 mg or less (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0.5 mg or any two of these values, or a range). In some embodiments, the corticosteroid is administered at a dose of, about, at least, or at most, 5 to about 60 mg (e.g., about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 mg, or a number or range between any two of these values). In some embodiments, a 10 mg dose of dexamethasone is administered intravenously to a subject.
[0205] In some embodiments, the antihistamine is administered at a dose of about 10 mg, about 20 mg, or about 50 mg (e.g., about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 mg, or a number or range between any two of these values). In some embodiments, at least one of an H1-antihistamine and an H2-antihistamine is administered to a subject. In some embodiments, the H1-antihistamine is diphenhydramine. In some embodiments, diphenhydramine is administered intravenously at a dose of about 50 mg. In some embodiments, the H1-antihistamine is cetirizine, and cetirizine is orally administered at a dose of about 10 mg. In some embodiments, the H2-antihistamine is famotidine. In some embodiments, famotidine is orally or intravenously administered at a dose of about 20 mg.
[0206] In some embodiments, a subject in need of treatment has high levels of ANGPTL3 protein (e.g., plasma ANGPTL3 protein). Subjects with high levels of ANGPTL3 can include, for example, subjects with ANGPTL3 levels greater than 90% of the human population. In some embodiments, the subject has symptoms of an ANGPTL3-related disease or condition. In some embodiments, the subject does not have symptoms of an ANGPTL3-related disease or condition. In some embodiments, the subject is at risk of developing an ANGPTL3-related disease or condition. In some embodiments, the subject is suspected of having or developing an ANGPTL3-related disease or condition.
[0207] In some embodiments, the subject has an abnormal level of ApoB protein (e.g., plasma ApoB protein). In some embodiments, the subject has a plasma ApoB level greater than 100 mg / dL (such as greater than about any one of 100 mg / dL, 110 mg / dL, 120 mg / dL, 130 mg / dL, 140 mg / dL, 150 mg / dL, 160 mg / dL, 180 mg / dL, 200 mg / dL, 250 mg / dL, 300 mg / dL, 350 mg / dL, 400 mg / dL, 500 mg / dL, 750 mg / dL, 1000 mg / dL or greater).
[0208] In some embodiments, the subject has abnormal levels of lipids (e.g., total cholesterol, HDL, triglycerides, LDL, VLDL and other non-HDL). Diagnostic tests, such as blood and urine laboratory tests, can be performed to measure lipid levels. In some embodiments, the subject has a total cholesterol level greater than 200 mg / dL (such as greater than about any of the following: 225 mg / dL, 250 mg / dL, 300 mg / dL, 350 mg / dL, 400 mg / dL, 500 mg / dL, 750 mg / dL, 1000 mg / dL or greater). In some embodiments, the subject has a plasma triglyceride level of greater than about 150 mg / dL (e.g., greater than about any of 160 mg / dL, 180 mg / dL, 200 mg / dL, 250 mg / dL, 300 mg / dL, 350 mg / dL, 400 mg / dL, 500 mg / dL, 750 mg / dL, 1000 mg / dL, or greater). In some embodiments, the subject has a plasma HDL level of greater than about 60 mg / dL (such as greater than about 65 mg / dL, 70 mg / dL, 80 mg / dL, 90 mg / dL, 100 mg / dL, 150 mg / dL, or greater). In some embodiments, the subject has a plasma VLDL level of greater than about 30 mg / dL (such as greater than about 35 mg / dL, 40 mg / dL, 50 mg / dL, 60 mg / dL, 70 mg / dL, 80 mg / dL, 90 mg / dL, 100 mg / dL or greater). In some embodiments, the subject has a plasma LDL level of greater than about 50 mg / dL (such as greater than about 60 mg / dL, 70 mg / dL, 75 mg / dL, 80 mg / dL, 90 mg / dL, 100 mg / dL, 130 mg / dL, 150 mg / dL, 200 mg / dL or greater). In some embodiments, the subject has a plasma LDL-C level greater than 100 mg / dL (such as greater than about any of 100 mg / dL, 110 mg / dL, 120 mg / dL, 130 mg / dL, 140 mg / dL, 150 mg / dL, 160 mg / dL, 180 mg / dL, 200 mg / dL, 250 mg / dL, 300 mg / dL, 350 mg / dL, 400 mg / dL, 500 mg / dL, 750 mg / dL, 1000 mg / dL, or greater).In some embodiments, the subject has a plasma Lp(a) level of greater than about 50 mg / dL (such as greater than about 60 mg / dL, 70 mg / dL, 80 mg / dL, 90 mg / dL, 100 mg / dL, 125 mg / dL, 150 mg / dL or greater). In some embodiments, the level of lipids (e.g., triglycerides and LDL) is the blood level of lipids. In some embodiments, the level of lipids (e.g., triglycerides and LDL) is the plasma level of lipids.
[0209] In some embodiments, the subject has one or more genetic markers (e.g., deletions, insertions, and / or mutations) in an endogenous ANGPTL3 gene or its regulatory sequence, such that the activity (including expression level or function) of the ANGPTL3 protein is significantly increased compared to a normal healthy subject. In some embodiments, the subject has one or more genetic mutations in a gene directly or indirectly related to lipid or lipoprotein metabolism (e.g., familial hypercholesterolemia). In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.
[0210] In some embodiments, there is a subject in need of clinical atherosclerotic cardiovascular disease (ASCVD). Clinical ASCVD is defined as a patient diagnosed with coronary heart disease, cardiovascular disease, stroke or peripheral arterial disease. In some embodiments, the subject suffering from ASCVD has elevated triglyceride and / or LDL cholesterol levels. In some embodiments, the subject suffering from ASCVD with elevated triglyceride and / or LDL cholesterol levels also suffers from type 2 diabetes, chronic kidney disease and / or hepatic steatosis (e.g., nonalcoholic fatty liver disease).
[0211] In some embodiments, a subject in need thereof has a blood glucose level (e.g., hemoglobin A1C, which measures the percentage of red blood cells with sugar-coated hemoglobin) of about less than, at least less than, at least about less than, at most less than, or at most about less than 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10.0%, 10.5%, 11%, or a number or range between any two of these values. In some embodiments, a subject in need has an estimated average glucose level of about, at least, at least, at most, or at most about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350 mg / dL, or a number or range between any two of these values. In some embodiments, a subject in need has a normal blood glucose level. In some embodiments, a subject in need has prediabetes or diabetes. In some embodiments, a subject in need has a hemoglobin A1C in the range of about 5.7% to about 6.4%. In some embodiments, a subject in need has a hemoglobin A1C of about 6.5% or greater.
[0212] In some embodiments, the subject in need has a body mass index (BMI) of about 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, or a number or range between any two of these values. In some embodiments, the subject in need has a healthy weight with a BMI in the range of about 18.5 to about 24.9. In some embodiments, the subject in need is overweight, with a BMI in the range of about 25 to about 29.9. In some embodiments, the subject in need is obese, with a BMI of about 30 or greater.
[0213] In some embodiments, the subject in need has an estimated glomerular filtration rate of about or less, at least or less, at least about or less, at most or less than about: 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120 or a number or range between any two of these values. In some embodiments, the subject in need has an estimated glomerular filtration rate (i.e., mild renal function loss) within the range of 60-90. In some embodiments, the subject in need has a mild to moderate, moderate to severe or severe renal function loss. For example, the subject in need has an estimated glomerular filtration rate lower than 60, such as in the range of 45-59, 30-44, 15-29 or less than 15.
[0214] In some embodiments, the subject in need suffers from fatty liver disease or hepatic steatosis, including alcoholic liver disease and non-alcoholic fatty liver disease. In some embodiments, the subject in need has liver fat relative to liver weight about below, at least below, or at least about below: 5%, 6%, 7%, 8%, 9% or 10%. The subject can be diagnosed as suffering from fatty liver disease by elevated liver enzyme levels, ultrasound, magnetic resonance imaging (MRI), computed tomography (CT scan) or liver biopsy.
[0215] In some embodiments, after implementation of the method, the plasma ANGPTL3 protein level in the subject is reduced by about less than, at least less than, or at least about less than: 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or a number or range between any two of these values. In some embodiments, after implementation of the method, the plasma ANGPTL3 protein level in the subject is reduced by about less than, at least less than, or at least about less than: 75%, 80%, 90%, 95%, 98%, 99% or greater.
[0216] In some embodiments, after implementing the method, the plasma ApoB protein level in the subject is reduced by about less than, at least less than, or at least about less than: 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or a number or range between any two of these values. In some embodiments, after implementing the method, the plasma ApoB protein level in the subject is reduced by about less than, at least less than, or at least about less than: 75%, 80%, 90%, 95%, 98%, 99% or greater.
[0217] In some embodiments, the compositions and methods herein described herein can result in a reduction in triglycerides and other cholesterol levels in non-HDL, which have been indicated as risk factors for cardiovascular disease.
[0218] In some embodiments, the plasma triglyceride level in the subject after implementation of the method is reduced to about 150 mg / dL or less (e.g., about less than, at most less than, or at most about less than: 145 mg / dL, 140 mg / dL, 130 mg / dL, 120 mg / dL, 110 mg / dL, 100 mg / dL, 90 mg / dL, 80 mg / dL, 70 mg / dL, 60 mg / dL, 50 mg / dL, 40 mg / dL, 30 mg / dL, 20 mg / dL or less). In some embodiments, the plasma triglyceride level in the subject after implementation of the method is reduced to about 40 mg / dL or less. In some embodiments, the plasma triglyceride level in the subject after implementation of the method is reduced to about 30 mg / dL or less. In some embodiments, the plasma triglyceride level in the subject after implementation of the method is reduced to about 20 mg / dL or less.
[0219] In some embodiments, after implementing the method, the plasma triglyceride level in the subject is reduced by about less than, at least less than, or at least about less than: 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or a number or range between any two of these values. In some embodiments, after implementing the method, the plasma triglyceride level in the subject is reduced by about less than, at least less than, or at least about less than: 75%, 80%, 90%, 95%, 98%, 99% or greater.
[0220] In some embodiments, after implementing the method, the plasma LDL level in the subject is reduced to about below, at most below, or at most about below: 130 mg / dL, 100 mg / dL, 70 mg / dL, 50 mg / dL, or a number between any two of these values. In some embodiments, after implementing the method, the plasma LDL-C level in the subject is reduced to about below, at most below, or at most about below: 90 mg / dL, 80 mg / dL, 70 mg / dL, 60 mg / dL, 50 mg / dL, or a number between any two of these values. In some embodiments, after implementing the method, the plasma VLDL level in the subject is reduced to about below, at most below, or at most about below, at most below, or at most about below: 30 mg / dL, 25 mg / dL, 20 mg / dL, 10 mg / dL, or a number between any two of these values. In some embodiments, after practicing the method, the total cholesterol level in the subject is reduced to below, at most below, or at most about below: 200 mg / dL, 175 mg / dL, 150 mg / dL, 100 mg / dL, 75 mg / dL, or a number between any two of these values.
[0221] In some embodiments, after implementing the method, the plasma LDL level in the subject is reduced by about less than, at least less than, or at least about less than: 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or any two of these values. In some embodiments, after implementing the method, the plasma LDL-C level in the subject is reduced by about less than, at least less than, or at least about less than: 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or any two of these values. In some embodiments, after implementing the method, the plasma VLDL level in the subject is reduced by about less than, at least less than, or at least about less than: 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or any two of these values. In some embodiments, after implementing the method, the total cholesterol level in the subject is reduced by about less than, at least less than, or at least about less than: 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or any two of these values. The number or range between two.
[0222] In some embodiments, clinical studies are used to determine the safety and efficacy of the pharmaceutical formulations and compositions described herein. The inclusion / exclusion criteria for the studies may vary (see also Example 5 below). In some embodiments, the inclusion criteria may include one or more of the following:
[0223] 1. Subjects are human subjects between the ages of 18 and 70, with a maximum body weight of no more than 100 kg.
[0224] 2. The subjects are able to provide written informed consent.
[0225] 3. Subjects were diagnosed with clinical atherosclerotic cardiovascular disease (ASCVD) and had high TG levels greater than 200 mg / dl and / or high LDL levels greater than 100 mg / dl. The study population included patients with a history of coronary heart disease, cardiovascular disease, stroke, or peripheral arterial disease.
[0226] 4. Subjects receiving statin therapy should receive the maximum tolerated dose of statin. If considered statin-intolerant, patients should be intolerant to all doses of two different statin preparations.
[0227] - Based on the investigator's judgment, refractory to other current standard of care (SOC) treatment lines (including ezetimibe, PCSK9 inhibitors, etc.).
[0228] - Subjects receiving statins or ezetimibe should be on stable doses for >30 days prior to screening with no planned medication or dose increases during study participation.
[0229] 5. Subjects of childbearing potential (post-menarche, with an intact uterus and at least 1 ovary, and less than 1 year post-menopause) and biological male subjects must agree to use one or more acceptable methods of contraception for at least 6 months from consent until after drug infusion (e.g., CTX310 infusion).
[0230] 6. The subject is willing and able to comply with scheduled visits, treatment plans, laboratory tests, contraceptive instructions, and other study procedures.
[0231] 7. The subject is willing to participate in additional long-term follow-up studies after completing this study.
[0232] Exclusion criteria may include one or more of the following criteria. In some embodiments, in order to be eligible for entry into a clinical study, a subject must not meet any of the exclusion criteria listed below.
[0233] 1. The subject has a history of obvious coagulation disorder.
[0234] 2. The subject has a history of any disease or any clinical condition that the investigator believes may confound the study results or impose additional risks on the subject's administration of the study drug. This may include, but is not limited to: a history of allergies to related drugs; a history of central nervous system disease; a history or presence of clinically significant pathology; or a history of psychiatric illness, or a history of familial cancer syndrome.
[0235] 3. The subject suffers from any previous or current malignancy or myeloproliferative disorder or significant immunodeficiency disorder.
[0236] 4. The subjects are patients diagnosed with homozygous familial hypercholesterolemia.
[0237] 5. Subjects have the following complete blood count (CBC): normal white blood cells (WBC) less than 2,500 cells / mcL, hemoglobin (Hb) less than 11 g / dL (male) and 10 g / dL (female), platelet count less than 100,000 / mcL.
[0238] 6. Subjects had advanced liver disease, defined as: (a) aspartate aminotransferase (AST), alanine aminotransferase (ALT) greater than 3× upper limit of normal (ULN), or direct bilirubin value greater than 2× ULN, or (b) baseline prothrombin time (international normalized ratio [INR]) greater than 1.5× ULN, or (c) history of cirrhosis.
[0239] 7. The subject's left ventricular ejection fraction (LVEF) is less than 40% by echocardiography.
[0240] 8. Subjects have uncontrolled hypertension, uncontrolled arrhythmia, or New York Heart Association (NYHA) class II, III, and IV heart failure (HF).
[0241] 9. The subject has had an acute coronary syndrome event within 24 weeks from Day 1.
[0242] 10. Subject has had a central nervous system (CNS) stroke within 24 weeks from Day 1.
[0243] 11. Subjects with a baseline estimated glomerular filtration rate less than 60 mL / min / 1.73 m 2 .
[0244] 12. The subject has been previously treated with gene therapy / editing products.
[0245] 13. Subjects have positive serology for human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2), hepatitis B virus (HBV) (hepatitis B core antibody [HBcAb] or nucleic acid test [NAT]), or hepatitis C virus (HCV) (NAT).
[0246] 14. The subject is currently using or has used any hepatocyte-targeted siRNA or antisense oligonucleotide molecule within 365 days from Day 1.
[0247] 15. Subject is currently using or has used any monoclonal Ab therapy within 90 days from Day 1.
[0248] 16. The subject has participated in another clinical study of an investigational drug / product within 30 days of screening or less than 5 half-lives of the study agent (whichever is longer) from screening.
[0249] 17. The subject has had an investigator assessment that the subject will not comply with the study procedures outlined in the protocol.
[0250] 18. The subject is a pregnant or breastfeeding woman.
[0251] 19. The subject suffers from non-alcoholic steatohepatitis (NASH).
[0252] The methods, systems, kits and compositions disclosed herein can be used to treat subjects with one or more of the following: clinical atherosclerotic cardiovascular disease (ASCVD), homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH), familial chylomicronemia syndrome (FCS), multifactorial chylomicronemia syndrome (MCS), familial mixed hyperlipidemia (FCH or FCHL), metabolic syndrome (MetS), type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). HoFH and FCS are rare diseases. In some embodiments, the method effectively reduces LDL and thereby treats familial hypercholesterolemia (FH). In some embodiments, the subject is a subject with ASCVD and elevated triglyceride (TG) levels and / or high low-density lipoprotein cholesterol (LDL-C) levels, including such subjects that are refractory to currently available treatments (e.g., one or more non-responders to ivisumab, Inclisiran, ezetimibe and statins).
[0253] The content provided herein also includes a kit for implementing the methods described herein. The kit may include a nucleic acid targeting the genome (e.g., a gRNA targeting the ANGPTL3 gene) and an RNA-guided endonuclease (e.g., Cas9) or a nucleic acid encoding an RNA-guided endonuclease. In any of the above kits, the kit may also include a polynucleotide to be inserted to achieve the desired genetic modification (e.g., a donor template). The components of the kit may be in separate containers, or combined in a single container.
[0254] Any of the kits described above may also include one or more additional reagents selected from the following: a buffer, a buffer for introducing a polypeptide or polynucleotide into a cell, a wash buffer, a control reagent, a control vector, a control RNA polynucleotide, a reagent for producing a polypeptide from DNA in vitro, an adapter for sequencing, etc. The buffer may be a stabilization buffer, a reconstitution buffer, a dilution buffer, etc. The kit may also include one or more components that can be used to promote or enhance the target binding or cleavage of the endonuclease to the DNA or improve the specificity of the targeting.
[0255] In some embodiments, the test kit may also include instructions for use of the components of the test kit to implement the method described herein. The instructions for use of the implementation method are usually recorded on a suitable recording medium. For example, instructions for use can be printed on a substrate, such as paper or plastic, etc. Instructions for use can be present in the test kit as a packaging insert, in the label of the container of the test kit or its components (that is, associated with packaging or sub-packaging), etc. Instructions for use can exist as an electronic storage data file present in a suitable computer-readable storage medium (such as CD-ROM, floppy disk, flash drive, etc.). In some cases, there are no actual instructions for use in the test kit, but the means for obtaining instructions for use from a remote resource (for example, via the Internet) can be provided. The example of this embodiment is a test kit including a website, and instructions for use can be viewed at the website and / or instructions for use can be downloaded from the website. Like instructions for use, this means for obtaining instructions for use can be recorded on a suitable substrate.
[0256] Example Some aspects of the embodiments discussed above are disclosed in further detail in the following examples, which are not intended to limit the scope of the present disclosure in any way.
[0257] Example 1 Evaluation of ANGPTL3 gene editing efficiency in non-human primates (NHPs) This example evaluates ANGPTL3 gene editing efficiency in non-human primates (NHPs) (eg, cynomolgus monkeys) by measuring ANGPTL3 protein levels and triglyceride levels before and after treatment.
[0258] Many CRISPR-Cas9 / gRNA combinations have been evaluated, and a lead formulation that produces highly efficient deletions in the ANGPTL3 gene with substantially low off-target effects was tested in vivo in NHPs. Lipid nanoparticles encapsulating gRNA molecules of SEQ ID NO: 4 (e.g., SEQ ID NO: 21) and Cas9 mRNA were injected into NHPs, and within the first day after administration and according to Figure 1The study design shown in the figure was used to collect plasma samples every hour.
[0259] As shown in Table 3, according to Figure 1 According to the study design of FIG. 3 , five groups of animals (2 animals / group) were treated with 1 dose or 2 doses (see also the last column of Table 3 ). For example, NHPs of Group 1 (Table 3 ) were treated with a first dose (e.g., 2 mg / kg) on Day 1 and a second dose (e.g., 2 mg / kg) on Day 22. Plasma samples were collected on Days 4, 8, 15, 22, 29, and 36. NHPs of Group II (Table 3 ) were treated with only the first dose on Day 1. Plasma samples were collected on Days 4, 8, 15, and 22. The concentration of ANGPTL3 protein in the collected plasma was detected using a sandwich enzyme-linked immunosorbent assay (ELISA) for ANGPTL3 protein, and the lipid profile of the samples was analyzed using the EasyRA assay.
[0260] Table 3: Non-limiting exemplary NHP study design
[0261] Figure 2 is a graph showing the percent change from baseline in plasma ANGPTL3 protein in Group 1 NHP and Group 3 NHP. The results show that NHP plasma ANGPTL3 levels were significantly reduced using Cas9 mRNA and gRNA targeting the ANGPTL3 gene. Generally, about 70%-90% reduction from baseline was observed in NHP. For example, in Group 1, 73% and 90% reductions in ANGPTL3 protein from baseline were observed.
[0262] Figure 3A is a graph showing plasma triglyceride levels of NHPs in Group 1 before and after treatment. Figure 3B is a graph showing the percent change from baseline in plasma triglyceride levels of NHPs in Group 1. Figure 4A is a graph showing plasma triglyceride levels of NHPs in Group 3 before and after treatment. Figure 4B is a graph showing the percent change from baseline in plasma triglyceride levels of NHPs in Group 3. Figure 5A-Figure 5B It shows that the first group ( Figure 5A ) and Group 3 ( Figure 5B ) are two graphs showing the maximum percent change in plasma triglyceride levels of NHPs. Figure 5C-5D It shows that the first group ( Figure 5C ) and Group 3 ( Figure 5D) Two graphs showing the percent change from baseline in plasma triglyceride levels on Day 36. On Day 36, a 50% and 76% reduction in triglyceride levels from baseline was observed in Group 1, and an approximately 31% reduction was observed in Group 3.
[0263] The results showed that both ANGPTL3 protein and plasma triglyceride levels were significantly reduced using Cas9 mRNA and gRNA targeting the ANGPTL3 gene.
[0264] Example 2 Evaluation of ANGPTL3 gene editing efficiency in liver and other organ tissues In this example, ANGPTL3 gene editing efficiency (e.g., indel editing percentage) was measured in liver and other organ tissues, including spleen, brain, heart, kidney, lung, and testis.
[0265] Biopsies of NHP organs were performed, cells were isolated from the biopsy material, chromosomal DNA was extracted from these cells, and the frequency of on-target cleavage was measured by determining the indel frequency using TIDES analysis.
[0266] Figure 6A-6D It is a graph showing the ANGPTL3 gene editing efficiency in different organ tissues. The results show that the ANGPTL3 gene editing efficiency is significantly higher in the liver than in other organ tissues. In the hepatocytes of the 4 tested NHPs, the insertion / deletion frequency ranged from 30% to 65%, while the insertion / deletion frequency in other organ cells was significantly lower (e.g., between 0% and 10%). Figure 7 is a graph showing the percentage of ANGPTL3 gene editing in hepatocytes of Group I NHP and Group III NHP.
[0267] Liver function tests were also performed before and after treatment to provide information about the liver status of the NHPs. Figure 8A-8E Alanine aminotransferase (ALT) ( Fig. 8A )、Aspartate aminotransferase (AST) ( Figure 8B )、alkaline phosphatase (ALP) ( Figure 8C )、Albumin (ALB) Fig.8D ) and bilirubin (TBIL) ( Fig. 8E ) Figure 3. No liver functional impairment or damage was detected after ANGPTL3 gene editing.
[0268] Example 3 Toxicity studies of ANGPTL3 gRNA formulations In this example, toxicity studies were performed in NHPs. Lipid nanoparticles encapsulating the gRNA molecule of SEQ ID NO: 3 (ANGPTL3_T10, e.g., SEQ ID NO: 20) and Cas9 mRNA were formulated into an ANGPTL3 gRNA formulation, referred to as "CTX310". The CTX310 formulation was administered as a single dose to three groups of NHPs (e.g., cynomolgus monkeys) via a 60-minute IV infusion on day 1 at dose levels of 0.5 mg / kg, 1.5 mg / kg, and 3.0 mg / kg, respectively. Each group of NHPs included four female and four male cynomolgus monkeys. According to Fig. 9 Plasma samples were collected according to the study design shown in . An interim necropsy was performed on day 37 and a terminal necropsy was performed on day 103.
[0269] Data obtained from the CTX310 preliminary toxicity study are shown together with data from the ANGPTL3 NHP study conducted in Example 1.
[0270] Table 4: Results of preliminary toxicity studies of CTX310
[0271] The tissue distribution of gene editing in CTX310-treated cynomolgus monkeys was also determined (see e.g. Figures 10A-10D ). Cynomolgus monkeys were IV infused with three different doses of CTX310: 0.5 mg / kg ( Fig. 10A )、1.5 mg / kg ( Fig. 10B ) and 3.0mg / kg ( Fig. 10C ). Four monkeys from each treatment group were sacrificed on day 37, and different tissues were collected and the editing frequency in the autopsy samples was measured using next generation sequencing. The data for the 0.5, 1.5 and 3 mg / kg treatment cohorts on day 37 are shown in Fig. 10A , Fig. 10B and Fig. 10C Data are presented as mean ± SD. Fig. 10D The gene editing efficiency data for each dosing cohort up to 3 months after administration are shown. The results show that the ANGPTL3 gene editing efficiency is significantly higher in the liver than in other organ tissues. The editing efficiency at 1 month (Table 10A) and 3 months (Table 10B) is also shown below.
[0272] Table 10A: Tissues and cell types used for off-target evaluation - 1 month cohort
[0273] Table 10B: Tissues and cell types used for off-target assessment - 3-month cohort
[0274] Fig.11Table 5 below shows the percentage of ANGPTL3 gene editing in hepatocytes of cynomolgus monkeys treated with 0.5, 1.5 and 3 mg / kg CTX310. Efficient editing in the liver was achieved. Fig.11 Dose-dependent hepatic editing of up to 70% in NHPs was shown.
[0275] Table 5: Percentage of ANGPTL3 gene editing in liver 0.5 mg / kg 1.5 mg / kg 3 mg / kg 31 66 73 51 49 69 26 72 71 57 73 72 Table 6 and Fig. 12A The plasma levels of ANGPTL3 protein in cynomolgus monkeys treated with three different doses of CTX310 (0.5, 1.5 and 3.0 mg / kg) compared to the control group are shown. Table 7 and Fig. 12B The percent change from baseline in plasma levels of ANGPTL3 protein in CTX310-treated cynomolgus monkeys is shown. Baseline is the average of ANGPTL3 protein levels 13 days (Day -13) and 10 days (Day -10) before treatment and Day 1 (pre-dose).
[0276] Table 6: ANGPTL3 plasma protein levels (ng / mL)
[0277] Table 7: Percent Change from Baseline in ANGPTL3 Plasma Protein Levels Day 8 Day 15 Day 29 Day 37 Comparison 40 -9 5 7 0.5 mg / kg -34 -46 -52 -56 1.5 mg / kg -79 -88 -87 -84 3 mg / kg -85 -90 -92 -89 Fig. 12A and Fig. 12B Both showed a dose-dependent decrease in plasma ANGPTL3 protein following CTX310 administration. An approximately 56% decrease in ANGPTL3 protein from baseline was observed in cynomolgus monkeys treated with 0.5 mg / kg CTX310, and an approximately 84%-89% decrease from baseline was observed in cynomolgus monkeys treated with 1.5 mg / kg and 3 mg / kg CTX310 (see, e.g. Fig. 12B ). Fig. 12C is a graph showing the percent change from baseline in plasma ANGPTL3 protein in cynomolgus monkeys on Day 37 following CTX310 treatment. Fig.12D is a graph showing the percent change in serum ANGPTL3 protein, which shows about 90% reduction in serum ANGPTL3 protein. Fig.12E is a graph showing the percent change from baseline in cynomolgus monkey plasma ANGPTL3 protein at approximately 3 months following CTX310 treatment.
[0278] Figure 13A-13C is a graph showing the percent change in plasma triglyceride levels normalized to baseline in cynomolgus monkeys following treatment with three different doses of CTX310: 0.5 mg / kg ( Fig.13A )、1.5 mg / kg ( Fig. 13B ) and 3.0 mg / kg ( Fig. 13C ). The baseline is the average of the triglyceride levels of the 10 days before treatment (day -10) and the triglyceride levels of day 1 (before dosing). Table 8 and Fig.13D Shown are the percent changes from baseline in plasma triglyceride levels in cynomolgus monkeys following CTX310 treatment on Day 37. On Day 37, a greater than 50% reduction in triglyceride levels from baseline was observed in NHPs treated with the 1.5 mg / kg and 3 mg / kg CTX310 formulations. Fig.13E is a graph showing the percent change from baseline in serum triglyceride levels one month following CTX310 treatment, the graph showing a >50% reduction in serum triglycerides at one month. Figure 13F-13H Depicted are plasma triglyceride levels in mg / dL in cynomolgus monkeys following treatment with three different doses of CTX310: 0.5 mg / kg ( Fig.13F )、1.5 mg / kg ( Figure 13G ) and 3.0 mg / kg ( Fig.13H ). Fig.13I is a graph showing the percent change from baseline in triglyceride levels three months after CTX310 treatment.
[0279] Table 8: Percent Change from Baseline in Triglycerides Group %Change Comparison -0.2 0.5 mg / kg -26.1 1.5 mg / kg -57.7 3 mg / kg -51.5 Fig.14A is a graph showing the correlation between triglyceride reduction in liver and the percentage of ANGPTL3 gene editing. Fig. 14B is a graph showing the correlation between the reduction of ANGPTL3 protein in the liver and the percentage of ANGPTL3 gene editing. The results showed that the efficiency of ANGPTL3 gene editing in the liver was positively correlated with the reduction of triglyceride levels and ANGPTL3 protein levels.
[0280] Liver function tests were also performed before and after treatment to provide information about the liver status of the NHP. The data indicated that CTX310 caused a dose-dependent transient increase in ALT, AST, ALP, and bilirubin. No liver functional impairment or damage was detected after administration (e.g., 14 days after administration). Figure 20A-Figure 21B ). Figure 20A-20B The data shown in are from non-Good Laboratory Practice (non-GLP) toxicology studies (see below), and Figure 21A-21B These are data from GLP toxicology studies.
[0281] A non-GLP dose range discovery toxicity study was performed on CTX310. This study includes data on safety pharmacology. A 3-month dose range discovery study was conducted to evaluate the toxicity of a single dose of CTX310 in cynomolgus monkeys (non-GLP, Table 11). The endpoints of this study included clinical observations, clinical pathology (hematology, serum chemistry, and coagulation), snapshot ECG, and histology.
[0282] Table 11: Dose range finding study design
[0283] There were no unplanned deaths in this study. No abnormal clinical signs or weight changes related to CTX310 were observed. Figure 20A-20B As shown in Figure 2, in animals treated with 1.5 or 3.0 mg / kg CTX310, transient increases in liver enzymes (alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase) were observed in a dose-dependent manner. These increases peaked on the 3rd day, partially subsided on the 8th day, and returned to baseline levels by the 15th day. Bilirubin levels were elevated only in the 3.0 mg / kg group and completely subsided by the 15th day. The TG levels of 2 animals in the 3.0 mg / kg group increased sharply on the 3rd day, but quickly subsided by the 8th day. In all animals treated with CTX310, both TG levels and total cholesterol levels were reduced in a dose-dependent manner. There were no CTX310-related changes in any hematological or coagulation parameters.
[0284] ECG traces were recorded once on day -6 during the acclimation period, then once on day 28, and captured once on day 79. All ECGs evaluated in this study were considered normal qualitatively and quantitatively. No rhythm or waveform morphology abnormalities were found at any dose level based on comparison of the averages of one on day -6 during the acclimation period and one on days 28 and 79 after dosing with control values. No relevant effects of CTX310 on heart rate were observed at any dose level.
[0285] During mid-term and final autopsy, tissues were collected, weighed, and histopathology was evaluated. Throughout the 12-week study, no abnormal findings of overall pathology or organ weight were observed. In both the control group and the treatment group, there was a single abnormal histopathological finding of minimal mixed inflammatory cell infiltration, although the frequency was higher in the 3 mg / kg group (1 / 4 animal in the vehicle group, 4 / 4 animal in the 3 mg / kg group). This finding was unrelated to degeneration or necrosis, and was therefore considered to be harmless. During 1 month and 3 month autopsy, the incidence and severity of this finding were similar. The study of LNP persistence after analysis was found to remove most LNPs from circulation within 1 week of use.
[0286] Example 4 Effect of LDL receptor on the uptake of lipid nanoparticles Traditional LNP uptake in hepatocytes is mediated by apolipoprotein E-low-density lipoprotein receptor (ApoE-LDLR) or N-acetyl-D-galactosamine / asialoglycoprotein receptor pathway (GalNAc-ASGPR). The ApoE-LDLR pathway requires the presence of LDLR on target hepatocytes, while the GalNAc-ASGPR pathway requires the presence of GalNAc on the LNPs administered. These pathways are particularly interesting for the treatment based on LNPs of familial hypercholesterolemia, because the patient with this genetic disorder is usually shown as heterozygous (HeFH) or homozygous (HoFH) for the loss of LDLR. In the absence of LDLR on hepatocytes, treatment based on LNPs may be impossible in these patients. Alternatively, GalNAc can be incorporated into LNPs to force uptake via the GalNAc-ASGPR pathway in LDLR defective patients.
[0287] In this example, different LNPs containing gRNA targeting the mouse ANGPTL3 gene were administered to mice to determine whether the delivery of the LNP to the liver was dependent on the LDL receptor. Two LNPs (RIV-000005 and RIV-000006) were formulated following the GalNAc-ASGPR uptake pathway, one without GalNAc (RIV-000005) and the other with 2.5% GalNAc (RIV-000006). A third LNP (RIV-000004) was formulated with ALN-369 / DSPC / cholesterol / DMPE-PEG. RIV-000004 is known to follow the ApoE-LDLR uptake pathway and is expected to be ineffective in homozygous LDLR loss mice. All three LNPs contain the same gRNA and SpCas9 RNA targeting the mouse ANGPTL3 gene described herein. In this example, formulations RIV-000004, RIV-000005, and RIV-000006 were evaluated for editing efficiency in the liver, plasma ANGPTL3 protein levels, and plasma lipid levels.
[0288] A total of 71 female mice, 4-5 weeks old, weighing between 20-25 g, were used in these studies. 21 C57BL / 6J or wild-type mice (stock number 000664), 25 B6.129S7-Ldlr tm1Her / J or LDLR KO mice (LDLR- / -) (Stock No. 002207) and 25 LDLR heterozygous (LDLR+ / -) mice were obtained from The Jackson Laboratory (BarHarbor, ME). LDLR heterozygous mice were custom ordered from The Jackson Laboratory (Bar Harbor, ME) and were generated by crossing C57BL / 6J or wild-type strains with LDLR KO mice.
[0289] The in vivo experimental design is summarized in Table 9.
[0290] Table 9: Summary of study details.
[0291]
[0292] In Study 1 (see Table 9 for study design), wild-type and LDLR-deficient mice were administered 2 mg / kg of RIV-000005 or RIV-000006. Mice were sacrificed 96 hours after administration. Liver and plasma were collected immediately after sacrifice to determine editing efficiency, circulating mANGPTL3 levels, and triglycerides.
[0293] Figure 15A-Figure 15C Figure 2 shows wild-type (WT) and LDLR treated with two exemplary lipid nanoparticles (RIV-000005 and RIV-000006) with gRNA targeting the mouse ANGPTL3 gene. - / - Gene editing efficiency in liver of mice (Hom) Fig.15A ), Angptl3 protein level ( Fig. 15B ) and triglyceride levels ( Fig. 15C ). Editing efficiency in the liver was determined by TIDE 96 hours after administration ( Fig.15A Circulating mANGPTL3 protein levels in collected plasma samples were determined by ELISA ( Fig. 15B Plasma triglycerides in collected plasma were determined by EasyRA ( Fig. 15C ).
[0294] Comparable editing efficiency was observed between wild-type and LDLR-deficient mice dosed with RIV-000005 or RIV-000006 ( Fig.15A Consistent with the editing efficiency, both circulating mANGPTL3 protein and plasma triglycerides were reduced in LNP-administered mice compared with untreated controls ( Figure 15B-Figure 15C ).
[0295] Similar to Study 1, in Study 2, wild-type and LDLR-deficient mice were administered 1 mg / kg of RIV-000005 or RIV-000006. Additional groups of WT and LDLR-deficient mice were administered RIV-000004 LNPs. Mice were sacrificed 96 hours after dosing. Liver and plasma were collected immediately after sacrifice to determine editing efficiency, circulating mANGPTL3 levels, triglycerides, and LDL.
[0296] Figure 16A-16C Figure 3 shows wild-type (WT) and LDLR treated with three exemplary lipid nanoparticles (RIV-000004, RIV-000005, and RIV-000006) with gRNA targeting the mouse ANGPTL3 gene. - / - Gene editing efficiency in liver of mice (Hom) Fig.16A ), ANGPTL3 protein level ( Fig. 16B ) and triglyceride levels ( Fig. 16C ). Editing efficiency in the liver was determined by TIDE 96 hours after dosing. Circulating mANGPTL3 protein levels in collected plasma samples were determined by ELISA. Plasma triglycerides in collected plasma were determined by EasyRA. No differences in editing efficiency were detected in wild-type and LDLR-deficient mice treated with RIV-000005 and RIV-000006 ( Fig.16A ). However, no editing was observed in LDLR homozygous mice dosed with RIV-000004, indicating that this LNP cannot be taken up in the absence of LDLR. The reduction in circulating mANGPTL3 and plasma triglycerides is consistent with the editing data ( Figure 16B-Figure 16C ).
[0297] Plasma LDL levels of Study 2 animals were also determined and are shown in Fig.16D Middle. LDL levels were determined using EasyRA. The red dashed line indicates the EasyRA detection limit of 6 mg / dL for LDL.
[0298] Figure 16E-16H Depicted are editing efficiencies in LDLR homozygous mice after 1 month of treatment with the indicated treatments ( Fig.16E ), ANGPTL3 level ( Fig.16F ), triglyceride levels ( Figure 16G ) and LDL levels ( Fig.16H )data.
[0299] Wild-type mice naturally have low levels of LDL, and LDL measurements for wild-type mice were below the limit of detection (data not shown). Heterozygous loss of LDLR raises plasma LDL high enough to be detected, but levels are too low to determine differences between treatment groups. Homozygous loss of LDLR results in a sharp increase in plasma LDL levels. Homozygous mice treated with RIV-000005 had plasma levels reduced to below the limit of detection. Two of the three mice treated with RIV-000006 had plasma LDL levels reduced to below the limit of detection, but one mouse had LDL levels consistent with untreated homozygous mice. Note that mice with high LDL levels exhibit liver editing efficiencies similar to those of mice with reduced LDL levels. Consistent with the editing data, homozygous mice treated with RIV-000004 showed no reduction in plasma LDL ( Fig.16D ).
[0300] In summary, in both studies, wild-type mice and LDLR-deficient mice treated with the LNP formulations described herein showed comparable mANGPTL3 editing in the liver and reductions in circulating mouse ANGPTL3 protein and plasma triglyceride levels, regardless of the presence of GalNAc. These data indicate that LNPs formulated following the GalNAc-ASGPR uptake pathway are effective in both heterozygous and homozygous LDLR-deficient settings and do not require the addition of GalNAc, whereas LNPs formulated following the ApoE-LDLR uptake pathway are ineffective in mice with homozygous LDLR loss.
[0301] Example 5 Exemplary inclusion and exclusion criteria in clinical studies This example describes non-limiting exemplary criteria for inclusion and exclusion of patients in clinical trials to determine the safety and efficacy of the pharmaceutical formulations described herein.
[0302] Inclusion criteria may include one or more of the following criteria. In some embodiments, a subject must meet all of the following criteria to be considered eligible to participate in a clinical study.
[0303] 1. Age ≥18 years and ≤75 years; 2. Able to provide written informed consent; 3. Subjects diagnosed with persistent dyslipidemia, as defined by: documented history of high TG levels >300 mg / dL and / or high LDL-C levels >100 mg / dL (>70 mg / dL for ASCVD) and / or non-HDL levels >160 mg / dL and / or ApoB levels >100 mg / dL; 4. Subjects receiving statin therapy must have received a stable dose for >30 days prior to screening and must have been refractory to the standard of care treatment line available through routine clinical care for at least 26 weeks prior to screening, which standard of care treatment line includes ezetimibe and / or bempedoic acid and / or PCSK9 (alirocumab or evolocumab) and / or ANGPTL3 (ivisuzumab) monoclonal antibody; 5. Subjects with homozygous hypercholesterolemia receiving PCSK9-targeted interfering RNA therapy (inclisiran) must be refractory for at least 365 days of exposure prior to screening; 6. Subjects receiving available standard of care treatment lines including statins, ezetimibe and / or bepedic acid and / or PCSK9 and / or ANGPTL3 inhibitors must be on a stable dose for >30 days prior to screening and have no planned medication or dose increases during participation in the study; 7. Subjects of childbearing potential (post-menarche, with an intact uterus and at least 1 ovary, and less than 1 year postmenopausal) and biological male subjects must agree to use one or more acceptable contraceptive methods as defined in the protocol from consent to at least 1 year after CTX310 infusion; 8. Willing and able to comply with scheduled visits, treatment plans, laboratory tests, contraceptive guidelines and other study procedures; and 9. Willing to participate in a long-term follow-up study for up to 15 years after completion of this study.
[0304] To be eligible for study entry, subjects must not meet any of the exclusion criteria listed below: 1. FCS patients with confirmed biallelic LPL or GP1HBP1 mutations; 2. Complete blood count (CBC): normal white blood cells (WBC) <2,500 cells / mcL, hemoglobin (Hb) <11 g / dL for males and hemoglobin (Hb) <10 g / dL for females; platelet count <100,000 / mcL; 3. Evidence of liver disease, defined as: aspartate aminotransferase, alanine aminotransferase >2 × upper limit of normal (ULN), or total bilirubin value >2 × ULN, or: baseline prothrombin time (international normalized ratio) >1.5 × ULN, or fibrosis score ≥2 (NAFLD activity score); 4. Currently using (except inclisiran) or using any hepatocyte-targeted small interfering RNA or antisense oligonucleotide molecule within 365 days from Day 1; 5. Currently using (except evolocumab, alirocumab or ivizumab) or using any monoclonal antibody treatment within 90 days from Day 1; 6. Participating in another clinical study of the investigational drug / product within 30 days after screening or within less than 5 half-lives of the investigational agent (whichever is longer from screening), 7. Left ventricular ejection fraction of the heart by echocardiogram <50%; 8. Uncontrolled hypertension or uncontrolled arrhythmia; 9. Acute coronary syndrome event within 24 weeks before Day 1, 8. CNS stroke within 24 weeks before Day 1; 10. Acute pancreatitis within 12 weeks before Day 1; 11. Baseline estimated glomerular filtration rate <60 mL / min / 1.73 m 2; 12. Diagnosis of nephrotic syndrome or albuminuria, > 2+ on urine test strip; 13. Inadequate diabetes control, with glycated hemoglobin (HbA1C) > 10%; 14. History of alcohol or drug abuse and non-compliance with abstinence during the study duration; 15. History of significant coagulopathy; 16. Uncontrolled or untreated thyroid disease; 17. Patients receiving selective serotonin reuptake inhibitor drugs or receiving chronic systemic corticosteroid therapy; 18. Previous treatment with gene therapy / editing products; 19. Current use of niacin-based supplements or nutritional products that may affect lipid levels at a dose / amount that was unstable for > 30 days prior to the screening visit; 20. Human immunodeficiency virus-1 1. Positive serology for HIV-1 or HIV-2, hepatitis B virus (hepatitis B core antibody or nucleic acid test [NAT]), or hepatitis C virus (NAT); 21. History of any illness or any clinical condition that the investigator believes may confound the study results or pose an additional risk to the subject of the study drug. This may include, but is not limited to: history of allergies to related drugs, history of central nervous system (CNS) disease, history or presence of clinically significant pathology or history of psychiatric illness or family history of cancer syndrome; 22. Any previous or current malignancy or myeloproliferative disorder or significant immunodeficiency disorder; 23. Pregnant or lactating women; 24. Investigator assessment that the subject will not comply with the study procedures outlined in the protocol.
[0305] Example 6 Phase 1 Study Design A non-limiting exemplary design for a Phase 1 safety and tolerability clinical study of one or more of the ANGPTL3 gene editing nanoparticles described herein (e.g., CTX310) and a determination of how to proceed to a Phase 2 clinical study based on the results of the Phase 1 study is shown in Fig.17 and Fig.18 In. Fig.17 and Fig.18Indications 1-4 and Cohorts 1-4 being pursued in Phase 2 include, but are not limited to: clinical atherosclerotic cardiovascular disease (ASCVD), homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH), familial chylomicronemia syndrome (FCS), multifactorial chylomicronemia syndrome (MCS), familial combined hyperlipidemia (FCH or FCHL), and metabolic syndrome (MetS), others (type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD)). HoFH and FCS are rare diseases. Subjects aged 18 to 75 years (inclusive) with dyslipidemia with persistently high levels of TG and / or non-HDL-C [including LDL, VLDL, IDL, and Lp(a)] and / or ApoB levels above the thresholds recommended by the ACC and AHA guidelines (refractory population) despite maximum tolerated doses of available lipid-lowering therapy, diet, and lifestyle improvements. Common HeFH mutants may include LDLR, ApoB, PCSK9, and LDLRAP1.
[0306] In some embodiments, the objectives include the following: evaluation of the safety of LNP formulated CRISPR-guide RNA-Cas9 nuclease for in vivo editing of ANGPTL3 in the liver, a dose finding safety study to establish an optimal biological dose (OBD) or maximum tolerated dose (MTD) for a Phase 2 study, and evaluation of activity by evaluating the percent reduction in ANGPTL3 levels and the percent reduction in lipids. Exemplary study objectives and endpoints are described below in Table 13. A non-limiting study schematic is shown in Fig.23 middle.
[0307] Table 13: Study objectives and endpoints
[0308] like Fig.23 As shown in , oral steroids and / or antihistamines can be provided to the subjects. Oral steroids and antihistamines are standard treatments for LNP formulated drugs Tx (Onpatro, NTLA-2001 and Verve 101) to control inflammatory response (IR) and LFT. For follow-up, adverse events (AEs), adverse events of special concern (AESIs) and effects on lipid parameters are monitored for each subject within 12 months after infusion. For long-term follow-up, subjects can be transferred to (rolled over) a separate follow-up study for up to 15 years.
[0309] In some cases, a Phase 1 safety and tolerability study of CTX310 was conducted in patients with clinical atherosclerotic cardiovascular disease (ASCVD) and with elevated triglyceride (TG) levels and / or high levels of low-density lipoprotein cholesterol (LDL-C) who were refractory to available treatments ( Fig.17 ). Clinical ASCVD is defined as patients diagnosed with coronary heart disease, cardiovascular disease, stroke, or peripheral arterial disease. For example, a patient may have TG ≥ 200 mg / dL, LDL-C ≥ 100 mg / dL, or both. The patient may be between 18 and 70 years old. In some cases, a Phase 1 safety and tolerability study of CTX310 is conducted in patients with refractory dyslipidemia with elevated triglyceride levels and / or elevated ApoB levels and / or elevated non-HDL levels ( Fig.18 ). For example, in some cases, the patient has or is required to have: non-HDL-C ≥ 160 mg / dL, TG ≥ 300 mg / dL, ApoB ≥ 100 mg / dL, or a combination thereof.
[0310] According to the Canadian Cardiology Society, the American Heart Association, and the European Society of Cardiology guidelines, ApoB and non-HDL are better markers for calculating CVD risk than LDL-C. The following cutoff values shown in Table 14 below are recommended for inclusion. Cutoff values include: TG levels >300 mg / dL and / or LDL-C >100 mg / dL (or ASCVD >70 mg / dL) and / or non-HDL levels >160 mg / dL and / or ApoB levels >100 mg / dL.
[0311] Table 14: ApoB and non-HDL-C threshold selection
[0312] Normal TG levels are <150 mg / dL (1.7 mml / L). Borderline high levels are 150-199, 200-500 are high levels, and 500 is very high. For HoFH, TG levels are >300, and for HeFH, TG levels can be >130.
[0313] In some cases, the patient has failed one or more prior treatments with statins, ezetimibe, and / or PCSK9 inhibitors. In some cases, the patient has received one or more prior treatments with statins, ezetimibe, and / or PCSK9 inhibitors for at least 12 weeks prior to screening. In some cases, the patient has refractory dyslipidemia. In some cases, the subject receiving statins has been receiving the maximum tolerated dose of statins, or if considered intolerant to statins, the subject is intolerant to all doses of two different statin formulations. Refractory: Subjects who have not achieved the recommended target lipid levels despite lifestyle changes, dietary interventions, and all available and obtainable medications.
[0314] Subjects receiving statins must have been on a stable dose for >30 days prior to screening and must have been refractory to standard of care lines of treatment available through routine clinical care, including statins, ezetimibe and / or bepedic acid and / or monoclonal antibodies to PCSK9 (alirocumab or evolocumab) and / or ANGPTL3 (ivisucumab), for at least 26 weeks prior to screening.
[0315] Subjects with homozygous hypercholesterolemia receiving PCSK9-targeted interfering RNA therapy (inclisiran) must have been refractory to the therapy for at least 365 days of treatment prior to screening.
[0316] In this study, a single dose escalation of 3+3 was performed. The proposed dose levels are shown in Table 2. Based on preliminary preclinical toxicity, 3 mg / kg was determined as the no observed adverse effect level (NOAEL). When the expected NOAEL in the GLP study is 3 mg / kg, 1 / 3 of this dose plus a 1 / 10 safety factor = 0.1 mg / kg starting dose. When the NOAEL determined in the GLP study is 1 mg / kg, 1 / 3 after allometric scaling is ~3×safety factor = 0.1 mg / kg starting dose.
[0317] For safety monitoring and toxicity management, a 30-day dose-limiting toxicity (DLT) acute toxicity monitoring period for escalation to the next dose level (DL) was used. This ensured that LFTs had returned to baseline levels before continuing treatment to the next patient / DL. Eligibility criteria Subjects were excluded based on strict liver function criteria. ALT / AST >2 × upper limit of normal (ULN) at screening, or total bilirubin value >2 × ULN, or baseline prothrombin time (international normalized ratio) >1.5 × ULN, or fibrosis score ≥2 (NAFLD activity score). LFTs and coagulation were monitored at each evaluation time point, e.g., Day 1, Day 2, Day 3, Day 4; Week 1, Week 2, Week 3; Day 30; and Months 2, 3, 6, 9, and 12. Prophylactic steroids and antihistamines prior to infusion were used to mitigate potential infusion-related reactions and elevations in LFTs.
[0318] One or more endpoints of a Phase 1 study may be a 6-month endpoint (or a 3-month, 4-month, 5-month, 7-month, 8-month, 9-month, 10-month, 11-month, or 12-month endpoint), such as an endpoint of an LDL-C level of no more than 70 mg / dL. In some cases, the endpoint of the LDL-C level is no more than 80 mg / dL, 75 mg / dL, 65 mg / dL, 60 mg / dL, 55 mg / dL, or 50 mg / dL. In some embodiments, the endpoint of non-HDL is about less than, at least less than, or at least about less than the LDL level: 20 mg / dL, 25 mg / dL, 30 mg / dL, 35 mg / dL, or 40 mg / dL. In some cases, the patient receives a liver biopsy three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, or more after treatment.
[0319] An exemplary Phase 2 patient population based on dose escalation results (e.g., 6 months after treatment) is shown in Fig.19 middle.
[0320] Example 7 Genome Editing Characterization Computational and experimental methods were used to evaluate the potential of CTX310 to introduce unexpected genomic changes (Table 12). Genomic sites with the potential for off-target editing induced by CTX310 sgRNA were nominated using homology-dependent and whole-genome homology-independent methods. Hybrid capture was followed by deep sequencing to evaluate the insertion / deletion formation at these candidate sites in PHH (expected cell type for editing) and cell types representing spleen and adrenal tissue (tissues for which significant on-target editing was observed in vivo in NHP studies indicating accidental exposure to CTX310 editing components). Importantly, the hybrid capture sequencing experiment included measurements of on-target editing and also evaluated the reduction of ANGPTL3 protein in the sample. Off-target evaluation used pharmacologically relevant in vitro editing conditions. Off-target sites with statistically confirmed editing were determined and presented together with a discussion of the potential functional disruption of proximal genomic elements and an overall evaluation of safety risks.
[0321] Chromosomal rearrangements associated with CTX310 editing were characterized using 2 complementary assays: ddPCR for quantification of homologous translocations and long read sequencing for characterization of large insertions and deletions. Each assay was performed on 3 PHH donor batches treated with pharmacologically relevant CTX310 concentrations. An overview of the planned genomic studies is shown in Table 12 below.
[0322] Table 12: Overview of genomic research
[0323] Planned in vitro editing conditions can be chosen to match in vivo conditions in monkeys, with on-target editing calibration ( Figure 22A-22B ). The matched in vivo conditions were 3× allometric scaling of the highest recommended CTX310 dose level of 1 mg / kg in humans, yielding a 3 mg / kg dose in monkeys. Logistic curves were fit to the in vivo editing rates (3 CTX310 doses in monkeys) and in vitro editing rates (CTX310 dose titration in 4 PHH donors). EC90 was calculated from all curves, keeping the highest value from the PHH donor. The scaling factor c can be calculated from the in vivo data to scale the EC90 to the desired conditions: c = (3 mg / kg) / EC90 = 2.7. The scaling factor c can be applied to the in vitro EC90 to yield a final in vitro CTX310 concentration of EC90 × c (0.43 ng / μL).
[0324] Tissues with the highest risk for off-target editing were evaluated. Unintended tissues spleen and adrenal glands had elevated exposure to CTX310 (see Figures 10A-10Dand Tables 10A-10B). Off-target editing was evaluated in PHH, spleen primary cells, and adrenal primary cells. For spleen and adrenal cells, it is expected that the planned editing will achieve on-target editing that exceeds the average rate observed in monkeys at a dose of 3 mg / kg. Tissues with low average on-target editing have a low risk of off-target editing.
[0325] To identify genomic sites of potential off-target editing, both homology-dependent and -independent approaches were used. For homology-dependent site nominations, the human genome was searched for sites similar to the sgRNA target sequence. This included homology distances of up to 4 mismatches and NGGs and 7 atypical PAMs. For homology-independent site nominations, the Digenome-seq cell-free assay was used to identify sites of cleavage with high sensitivity. The lack of chromatin means that the sites are not specific to any cell type. DNA from 3 unique donors was used.
[0326] To evaluate off-target editing, in vitro editing was evaluated. For in vitro editing, primary human hepatocytes (PHH) and cell types from spleen and adrenal tissue were used. For PHH, 4 donors and 3 technical replicates for each donor, as well as donor-matched untreated controls. Tissue-type-specific editing was performed with CTX310 LNP conditions matching expected in vivo conditions. For NGS evaluation, hybrid capture was performed, followed by deep sequencing at the nominated off-target sites. If editing in any donor was ≥ 0.2% higher than the untreated control, and the t-test between treatment and untreatment was significant, off-target editing was confirmed.
[0327] Structural variants and chromosomal rearrangement characteristics were also evaluated. Structural variants and chromosomal rearrangements may occur due to on-target editing. For in vitro editing, PHH cells were edited with CTX310 at a concentration of EC90 × c, where c is the condition derived for off-target evaluation. To evaluate chromosomal rearrangements, the ratio of quantitative homologous translocations (2 species) was determined using ddPCR. For structural variants at the on-target site, PacBio sequencing of the ~10 kb amplicon at the target site was used to characterize large insertions and deletions by semi-quantitatively measuring the ratio.
[0328] Example 8 Persistence Research Studies evaluating the persistence of ANGPTL3 protein knockdown in plasma (ELISA) and evaluating ANGPTL3 disruption in liver tissue (>1 year) are described in this Example. In some embodiments, results up to 2 months after a single administration of CTX310 (e.g., LNPs comprising a Cas9 sequence and a gRNA for targeting ANGPTL3) are described herein. In some embodiments, pre-treatment with steroids and / or antihistamines is administered. Table 15 below shows a summary of the persistence studies described herein.
[0329] Table 15: Summary of persistence studies
[0330] Dosing and endpoints for the persistence study are shown in Table 16. In some embodiments, pretreatment with dexamethasone, diphenhydramine, and famotidine is administered. In some embodiments, 1 mg / kg dexamethasone, 0.5 mg / kg famotidine, and 5 mg / kg diphenhydramine are administered one day prior to LNP administration and then again 30-60 min prior to LNP administration.
[0331] Table 16: Persistence Study Overview - Dosing
[0332] Purpose In some embodiments, the primary objective of the studies described herein is to determine the durability of ANGPTL3 knockdown and the efficacy of modulating lipid levels.
[0333] In some embodiments, LFT (e.g., AST) is observed to increase for about 1 week after administration of CTX310, however, after 1 week, the levels return to baseline. In some embodiments, administration of CTX310 results in at least a 40% reduction in total cholesterol levels, triglyceride levels, and HDL levels at 1 to 5 weeks after administration.
[0334] like Figure 24-Figure 27 As shown in Figure 3, ANGPTL3 levels were reduced after CTX310 administration. This effect was specific, as administration of controls targeting different proteins involved in lipidemia did not have any effect on ANGPTL3 levels. Pretreatment with antihistamines and steroids had no effect on the activity of CTX310. The 2 mg / kg dose resulted in an approximately 90% reduction in plasma ANGPTL3 protein levels. A group of NHPs administered controls targeting LNPs was used as a comparison.
[0335] Example 9 Exemplary Phase I Trial Protocol An exemplary clinical trial protocol for testing the efficacy and safety of the compositions and methods disclosed herein for treating subjects with, for example, refractory dyslipidemia is provided in the prophetic examples (see Fig.28 ).
[0336] CTX310 is an LNP formulation of CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats - CRISPR-associated protein 9) components for in vivo editing of the target gene ANGPTL3. In some embodiments, the investigational drug product comprises a capped and polyadenylated spacer Cas9 mRNA containing N1-methylpseudouridine and a 100-nucleotide-long single guide RNA targeting the gene of interest. CTX310 is designed to utilize CRISPR-Cas9 to disrupt exon 1 of human ANGPTL3 in the liver, resulting in a reduction in ANGPTL3 protein levels.
[0337] principle Cardiovascular disease (CVD) remains the leading cause of death worldwide, and the management of dyslipidemia remains the cornerstone of CVD prevention. As reported by the American Heart Association (AHA) in 2021, from 2015 to 2018, 38% of adults (93.9 million) in the United States had total cholesterol levels ≥200 mg / dL, and between 2013 and 2016, 29% of adults were reported to have elevated low-density lipoprotein cholesterol levels (LDL-C; ≥130 mg / dL). Dyslipidemia involving elevated levels of LDL-C (hypercholesterolemia), triglycerides (TG; hypertriglyceridemia [HTG]), or both, leads to CVD and associated risks, including type 2 diabetes, chronic kidney disease, and nonalcoholic fatty liver disease. Additional clinical consequences are associated with rare dyslipidemia, such as severe increases in TG that increase the risk of pancreatitis.
[0338] Recent recommendations from the Canadian, Australian, European, and American heart associations emphasize the role of elevated levels of non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (ApoB) rather than LDL-C and TG in assessing CVD risk. Non-HDL cholesterol (i.e., total cholesterol - HDL-C) is the sum of LDL, intermediate-density lipoprotein (IDL), very low-density lipoprotein (VLDL), and lipoprotein (a) (Lp(a)) cholesterol. ApoB, the major structural protein in VLDL, IDL, LDL-C, and Lp(a), is a highly atherogenic lipoprotein that, due to its retention, over time, contributes to plaque accumulation in the artery wall. Although there is generally a good correlation between LDL-C and ApoB when calculating CVD risk, in approximately 20% of cases, there is a discordance between these two parameters. Therefore, in non-fasting samples and in individuals with low LDL-C concentrations, non-HDL-C (indirectly) and ApoB (directly) provide more accurate assessments of the total concentration of atherogenic particles, particularly at higher TG concentrations. The 2021 Canadian Cardiovascular Society guidelines use non-HDL-C or ApoB as the preferred parameter for assessing risk. The implementation of therapeutic target values for ApoB and non-HDL-C has been modified from the previous form of these guidelines to accurately represent all recommended thresholds in the same percentile equivalent as LDL-C (as listed in Table 17 below) and to inform the inclusion of non-HDL-C and ApoB in this study.
[0339] Table 17: ApoB and non-HDL-C threshold selection
[0340] Patients with dyslipidemia are usually treated with lipid-lowering therapies, which may include statins, ezetimibe, and proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitors, monoclonal antibodies, and RNA inhibitors and ANGPTL3 monoclonal antibodies (where indicated and available). Despite the use of all available treatments, only 45% of patients achieve target lipid levels recommended by the AHA and American College of Cardiology (ACC) guidelines, particularly those at very high risk for cardiovascular events.
[0341] The methods disclosed herein include gene editing therapy using CRISPR-Cas9 to specifically target and destroy ANGPTL3, which encodes a regulator of lipoprotein metabolism expressed in the liver and has become a therapeutic target for patients with mixed dyslipidemia. ANGPTL3 has been shown to inhibit lipoprotein lipase (LPL) activity and endothelial lipase (EL), which is the main enzyme involved in the hydrolysis of TG-rich lipoproteins. Endothelial lipase (EL) hydrolyzes HDL phospholipids and thus increases the levels of TG and other lipids. It has been shown that reduced ANGPTL3 levels exhibit higher LPL activity and thus reduced TG levels. ANGPTL3 inhibition can also lead to effective clearance of VLDL particles via EL activation in an LDL receptor (LDLR)-independent mechanism, resulting in a reduction in LDL-C, non-HDL-C and ApoB levels.
[0342] ANGPTL3 has been identified as a gene mutated in familial combined hypolipidemia, characterized by low fasting plasma TG levels and low LDL-C and HDL-C levels. Large-scale genetic studies in humans have shown that loss-of-function variants of ANGPTL3 have low levels of TG and LDL-C and reduce the risk of atherosclerotic cardiovascular disease (ASCVD). In addition, clinical studies targeting ANGPTL3 by reduction or inactivation through antisense oligonucleotide or monoclonal antibody treatment have shown efficacy in significantly reducing plasma LDL-C and TG levels in subjects with various forms of dyslipidemia.
[0343] In addition to clearing and lowering VLDL and LDL (non-HDL) cholesterol and TG, ANGPTL3 inhibition significantly reduced ApoB levels, which has been shown to proportionally reduce CVD risk. Taken together, these studies indicate that ANGPTL3 is an effective therapeutic target for lowering plasma non-HDL-C, ApoB, and TG levels in patients with dyslipidemia who are unable to achieve minimally acceptable lipid target levels with currently available treatments and who remain at high risk for CVD.
[0344] In non-human primate (NHP) studies, a single dose of CTX310 resulted in a significant and sustained reduction in TG levels in a dose-dependent manner, and in a mouse LDLR knockout model, a mouse surrogate of CTX310 resulted in a significant reduction in LDL-C. Together, these rationale and preclinical data support the use of CTX310 as a one-time treatment to reduce atherogenic lipid levels.
[0345] Mode of administration In some embodiments, the subject receives a single intravenous (IV) infusion.
[0346] Study Group The study population consists of subjects aged 18 to 70 years (inclusive) with dyslipidemia, despite the maximum tolerated dose of available lipid-lowering therapy, diet and lifestyle improvements, but with persistently high levels of TG and / or non-HDL-C (including LDL, VLDL, IDL and Lp(a)) and / or ApoB levels above the thresholds recommended by the ACC and AHA guidelines (refractory population). In some embodiments, the Phase 1 study described herein includes subjects with the following monogenic or polygenic refractory dyslipidemia (with or without ASCVD), dyslipidemia covering HTG and / or hypercholesterolemia syndromes: familial chylomicronemia syndrome (FCS), multifactorial chylomicronemia syndrome, homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, and other HTG / hypercholesterolemia syndromes of unknown etiology.
[0347] Due to the high prevalence of polygenic hypercholesterolemia and HTG, it is expected that most enrolled subjects will have a polygenic background. Based on the overall known benefits of lipid-lowering therapy in reducing CVD risk, subjects with elevated lipids of unknown etiology are eligible for inclusion. Subjects are required to continue taking their baseline lipid-lowering medications at the same dose throughout the study until a significant beneficial effect of CTX310 is observed (i.e., target lipid goals are achieved).
[0348] Duration of subject participation All subjects were monitored for safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects for 12 months after infusion in the trial. All subjects were required to participate in a separate long-term follow-up study after completion or withdrawal / discontinuation.
[0349] Table 18: Objectives and endpoints
[0350] Study Design Described herein is a single-arm, open-label, multicenter, ascending single-dose Phase I study that enrolls up to 24 subjects, 18 to 70 years of age, with dyslipidemia and increased levels of TG (>300 mg / dL) and / or LDL-C (>100 mg / dL; for ASCVD, >70 mg / dL) and / or non-HDL-C (>160 mg / dL) and / or ApoB (>100 mg / dL) who are refractory to indicated and available treatments.
[0351] 3-6 subjects were enrolled at each of the following dose levels: 0.1, 0.3, 0.6 and 1 mg / kg of total RNA in LNP formulation. In some embodiments, each subject received a single IV dose of CTX310 and was hospitalized for a minimum of 72 hours after CTX310 infusion (or longer if local regulations or site practices require it), and was closely monitored for adverse events (AEs) defining dose-limiting toxicity (DLT) during the 30-day acute safety evaluation period after infusion. In some embodiments, all subjects received premedication with corticosteroids and antihistamines (H1 and H2 blockers) before receiving CTX310.
[0352] Following CTX310 infusion, subjects were followed for 12 months with physical examinations, periodic laboratory evaluations, and assessment of AEs and effects on ANGPTL3 expression and lipid profiles. After completion of this study, all subjects were required to participate in a separate long-term follow-up study for up to 15 years after infusion. At each dose level, all AEs, including adverse events of special interest (AESI), were reviewed by the Safety Review Committee (SRC) before proceeding to the next cohort. After dose escalation was completed and the recommended dose was determined, an additional 3 to 6 subjects were enrolled at the same dose level to confirm safety and PD effects (confirmatory cohort). Each subject underwent the following phases: (1) screening: 6 weeks, (2) CTX310 infusion (Day 1) and acute safety evaluation period (30 days after infusion), (3) follow-up: each subject was monitored for AEs, AESI, and effects on lipid parameters for a total of 12 months after infusion. Subjects could be transferred to a separate long-term follow-up study for long-term follow-up up to 15 years after infusion.
[0353] Study Treatment Administration of CTX310 In some embodiments, the subject receives a single IV infusion over a 1 hour period on Day 1 administered under medical supervision during inpatient hospitalization.
[0354] Additional treatment prior to infusion Within 1 to 2 hours prior to the administration of the study drug, the subject is administered an additional treatment infusion regimen. In some embodiments, the regimen consists of: IV steroids (e.g., 10 mg dexamethasone or equivalent); IV H1 blocker (e.g., 50 mg diphenhydramine or equivalent) or oral H1 blocker (e.g., 10 mg cetirizine or equivalent); and IV or oral H2 blocker (e.g., 20 mg famotidine or equivalent).
[0355] CTX310 post-infusion monitoring After dosing is completed, in some embodiments, subjects are observed as inpatients for 72 hours, or longer if local regulations or site practices require. In some embodiments, safety and clinical laboratory evaluations are performed, and blood and urine samples are collected for PK analysis. In some embodiments, AEs and concomitant medications are recorded. Inpatient observation can be extended as needed.
[0356] Preparation, Handling, Storage and Liability of Research Products The CTX310 drug product (e.g., nanoparticles comprising a gRNA targeting ANGPTL3 and an mRNA encoding Cas9) is provided as a frozen liquid formulation consisting of 300 mM sucrose in phosphate-buffered saline at a target concentration of 2.0 (±0.4) mg / mL total RNA. In some embodiments, CTX310 must be stored frozen in glass vials at ≤-60°C until the time of use, and stored on site, thawed and reconstituted immediately prior to administration.
[0357] In some embodiments, Inclisiran is not administered starting 60 days prior to CTX310 infusion and until 60 days after Day 1. In some embodiments, an apheresis procedure may not be performed starting 14 days prior to CTX310 infusion and until 14 days after Day 1.
[0358] If a significant decrease in lipids (LDL-C or TG) is observed during the course of the study, i.e., lipid levels are reduced to expected levels (e.g., LDL <70 mg / dL, TG <150 mg / dL, or non-HDL-C <160 mg / dL), adjustments to the frequency of the relevant medications or apheresis procedures may be implemented. In some embodiments, it is contemplated that plans to taper other lipid-lowering medications or apheresis procedures will be individualized for each subject based on response to study treatment, baseline genotype, and assessment of risk factors for future cardiovascular events.
[0359] Study Procedure A description of the study procedures is provided below. In addition to the evaluations described herein, subjects may be followed according to institutional guidelines and unscheduled evaluations may be performed when clinically indicated. Missed evaluations may be rescheduled and performed as close to the original scheduled date as possible, unless the investigator determines that rescheduling becomes medically unnecessary or unsafe because it is too close in time to the next scheduled evaluation. In this case, the missed evaluation is recorded as a protocol deviation and should be abandoned. For the purposes of this protocol, there is no Day 0. All visit dates and windows are calculated using Day 1 as the CTX310 infusion date.
[0360] Screening and inclusion In some embodiments, the logs of all potential subjects examined and evaluated for participating in the study are retained. In some embodiments, the screening period begins on the day when the subject signs the informed consent (ICF), and continues to the qualification confirmation and selected study. In some embodiments, after obtaining the informed consent, the subject is screened to confirm the research qualifications. In some embodiments, all screening evaluations should be completed within 42 days after the subject signs the ICF. The medical monitor can review the qualification data packet and verify the information provided by the place to confirm that the subject is eligible for selection.
[0361] Infusion of CTX310 In some embodiments, all subjects receive the pre-treatment regimen and study treatment as described above. The acute safety evaluation period is 30 days after each subject is infused with CTX310. After the 30-day acute safety evaluation period, the subject can be followed up for another 11 months. In some embodiments, the subject is considered to have completed the study after completing the end of study (EOS) visit at the 12th month. In some embodiments, the end of the study is defined as the time when the last subject completes the 12th month visit, is considered to have lost follow-up, withdraws consent or dies. In some embodiments, in order to comply with local regulatory requirements / guidelines for subjects who are administered gene therapy, it is required that all subjects who receive CTX310 infusion and stop or complete the study participate in a separate long-term follow-up study for up to 15 years after infusion to evaluate long-term safety, persistence and the effect on cardiovascular events.
[0362] Research evaluation and procedures Demographic data can be collected, including date of birth, sex, race and ethnicity. Obtain medical history, including the complete medical history of the subject's disease and the response to treatment since the date of diagnosis. It is also possible to obtain a history of heart disease and a history of surgery. A complete physical examination can be performed when the screening, 30th day and the end of the study (EOS) visit, including general appearance, skin, neck, head, eyes, ears, nose, throat, heart, lungs, abdomen, lymph nodes, limbs and nervous system, and the results are recorded. A simplified physical examination for symptoms can be performed when all other research visits are made. The changes noted in the inspection performed during the screening can be recorded as AEs. It is also possible to obtain weight. In some embodiments, height, body mass index and waist / hip ratio are obtained when the screening and the study are completed.
[0363] In some embodiments, vital signs are recorded at each study visit, and blood pressure, heart rate, respiratory rate, oxygen saturation by pulse oximetry and body temperature may be included. In some embodiments, liver imaging is performed. Standard local procedures can be used for image acquisition and analysis. In some embodiments, fasting for 3 hours before the following imaging procedures is recommended. Liver FibroScan or MRE (depending on availability) can be performed at screening, and the results can be used to exclude patients with cirrhosis consistent with fibrosis signs (see exclusion criteria). Liver MRI-proton density fat fraction or ultrasound (for evaluating fatty liver / fatty degeneration) can be performed at screening and EOS visits. Baseline liver fat status and quantitative changes in liver steatosis can be collected in case report forms (CRFs), and clinically significant findings are reported as medical history or AEs as appropriate.
[0364] One or more transthoracic echocardiograms (for evaluation of left ventricular ejection fraction) may be performed. Additional echocardiograms may be obtained. In some embodiments, a twelve (12) lead ECG is obtained. The corrected QT interval (QTc) and QRS interval are determined from the ECG. Additional ECGs may be obtained.
[0365] Laboratory samples may be collected and analyzed. Laboratory evaluations are listed in Tables 21 and 22.
[0366] Table 21: Local laboratory tests
[0367] Table 22: Center Test
[0368] Immunogenicity CTX310 consists of mRNA encoding SpCas9 and sgRNA targeting a gene of interest (e.g., ANGPTL3) encapsulated in LNPs. In some embodiments, blood samples are collected and stored for potential future immunogenicity evaluation (anti-drug antibodies against LNPs and Cas9), if necessary.
[0369] CTX310 pharmacokinetic analysis In some embodiments, PK analysis of nanoparticle and Cas9 protein levels is performed on the collected blood samples. In some embodiments, samples are collected on day 1 before infusion, within 5 minutes and 1, 2 and 7 hours after the completion of the CTX310 infusion. In some embodiments, a single sample is collected for all other time points.
[0370] ANGPTL3 In some embodiments, plasma samples are obtained to track ANGPTL3 concentrations.
[0371] Exploratory biomarker studies In some embodiments, exploratory biomarker studies may be performed to identify genomic, metabolic, and / or proteomic biomarkers that may indicate or predict clinical response, resistance, safety, PD activity, and / or mechanism of action of treatment. In addition, samples collected for regimen-specific endpoints may be used for exploratory studies, pending the availability of excess samples.
[0372] Whole blood samples can be obtained at screening and stored in PAXgene® tubes (PreAnalytiX GmbH, Hombrechtikon, Switzerland). Plasma samples for storage are obtained at screening. Serum samples are obtained to track exploratory biomarkers (e.g., cytokines).
[0373] Study Supervision Safety Review Committee In some embodiments, the Safety Review Committee (SRC) reviews all available safety data of the last subject included in each queue at the end of the DLT observation period, and is responsible for making decisions about dose escalation or reduction. Throughout the dose escalation, for cases where a certain dose in the queue has been cleared and dose escalation is allowed, it is optionally possible to consult with the SRC to decide to include another number of subjects at the current dose level, totaling up to 6 subjects, to collect other safety data. The SRC continues to hold meetings regularly during the dose escalation phase to discuss toxicity management algorithms and review individual subject cases.
[0374] After discussion with the SRC, the independent Data Safety Monitoring Board (DSMB) may be consulted on urgent safety data and discuss potential revisions to DLT criteria or alternative dosing regimens. Based on the ongoing evaluation of benefits and risks, the SRC may stop dose escalation before the maximum tolerated dose (MTD) is established.
[0375] Data Safety Monitoring Committee An independent data monitoring safety committee (DSMB) was established at the beginning of the study, consisting of at least 3 physicians and 1 statistician with appropriate scientific and medical expertise, and its roles and responsibilities are described in the DSMB section. Throughout the study, the DSMB reviewed the safety and efficacy data of the dose escalation and approved the recommended Phase 2 dose (RP2D). In some embodiments, the DSMB is reminded of any suspicious, unexpected, serious adverse reactions associated with CTX310.
[0376] Recommended starting dose and dose escalation The following doses shown in Table 19 below are recommended for evaluation in the 4 planned dose escalation levels in the study, with a minimum of 3 and a maximum of 6 evaluable subjects for each dose level (DL). The first human starting dose is derived from the no observed adverse reaction level (NOAEL) extrapolated from the NHP good laboratory practice safety and toxicology study. The initial starting dose of 0.1 mg / kg CTX310 refers to the total RNA dose based on the expected NOAEL of 1 mg / kg. Based on the application of total body surface area and a safety factor of 3, a starting dose of 0.1 mg / kg is derived from a one-third allometric scaling from NHP to humans. Emerging clinical data on systemic infusion of LNP-related therapeutics show a relative safety profile. Based on the absence of human liver-related AEs predicted in nonclinical studies, a 3-fold safety factor is recommended. With an expected 3 to 2-fold increment of the dose level, it is expected that the dose escalation will be carried out from 0.1 mg / kg to ≤1 mg / kg. In some embodiments, the overall dose escalation decision is made together with the investigator and SRC based on safety, tolerability and activity data.
[0377] Table 19: Dose escalation of CTX310
[0378] Dosing within dose level cohort Dose escalation was performed using a standard 3+3 design with 3 to 6 subjects treated at each dose level depending on the occurrence of DLTs.
[0379] Based on NHP studies in which transient increases in liver function tests (LFTs) after administration of CTX310 resolved within 14 days, dosing between each subject in the cohort was staggered to evaluate potential toxicity for at least 14 days or until laboratory values (including LFTs) returned to <2× baseline or normal levels, whichever was later. If the subject's safety evaluation is acceptable, the next subject in the cohort can be dosed. When all subjects in the previous dose cohort have completed dosing, the last subject has completed ≥30 days of safety evaluation, and the cumulative safety data of all treated subjects at this dose level show an acceptable safety profile (as determined by the SRC in some embodiments), dose escalation can continue.
[0380] Dose-limiting toxicity evaluation Subjects must receive CTX310 to evaluate DLT. If a DLT evaluable subject (i.e., a subject who has been administered CTX310 and has completed a 30-day DLT evaluation period) has signs or symptoms of potential DLT, the DLT evaluation period is extended according to the window defined by the protocol to allow improvement or regression before the DLT is announced. Each cohort requires a minimum of 3 evaluable subjects. Sufficient intervals are applied between the current lipid-lowering treatment (i.e., monoclonal antibodies and / or inhibitor RNA therapy) that the subject is receiving and the CTX310 infusion to avoid overlapping toxicity. Subjects who experience DLT are considered evaluable. Data from all subjects receiving CTX310 are part of the safety analysis set.
[0381] Dose escalation was performed according to the following rules: (1) if 0 of 3 subjects experienced a DLT, escalate to the next dose level, (2) if 1 of 3 subjects experienced a DLT, expand the current dose level to 6 subjects, (3) if 1 of 6 subjects experienced a DLT, escalate to the next dose level, (4) in DL 2, 3, or 4, if ≥2 of 6 subjects experienced a DLT, decrement to the previous dose level, or if 6 subjects had been tested at the previous dose level, declare the previous dose level MTD, (5) in DL 2, 3, or 4, if ≥2 of 3 subjects experienced a DLT, decrement to the previous dose level, or if 6 subjects had been tested at the previous dose level, declare the previous dose level MTD, (6) the dose was not escalated beyond the study planned or listed highest dose (see Dose Level Table above).
[0382] Based on the analysis of the secondary endpoints, the RP2D is declared to be at or below the MTD, or alternatively, if the MTD is not reached, it is declared to be the optimal biological dose. Before selecting the RP2D, at least 3 additional subjects are administered CTX310 at this dose level (confirmatory cohort). In some embodiments, all cumulative AEs evaluated as related to CTX310 that occur outside the DLT evaluation time period are also discussed with the DSMB.
[0383] Dose-limiting toxicity: rationale and criteria The definition of DLT used in this article is provided by non-clinical studies of CTX310 and published clinical experience reports of LNP-encapsulated CRISPR-Cas-9-based genome editing therapies. AEs that are not reasonably causally related to CTX310 are not considered DLTs. DLTs are graded and recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The criteria for classifying AEs occurring within the first 30 days after administration as DLTs include the following: (1) any CTCAE ≥ grade 3, AE is related to the study drug, (2) any CTCAE grade 3, laboratory abnormalities last ≥ 7 days and are related to the study drug, (3) any CTCAE grade 4, laboratory abnormalities are related to the study drug.
[0384] Research Eligibility Inclusion criteria To be considered eligible for participation in this study, subjects had to meet all of the inclusion criteria listed below: (1) aged ≥18 years and ≤70 years at the time of signing the informed consent form; (2) able to provide written informed consent; (3) diagnosed with persistent dyslipidemia; defined as elevated fasting (and pre-apheresis, if applicable) levels of TG (>300 mg / dL) and / or LDL-C (>100 mg / dL; >70 mg / dL for subjects with ASCVD) and / or non-HDL-C (>160 mg / dL) and / or ApoB (>100 mg / dL); and (4) subjects had to be refractory to the maximum tolerated dose of the indicated standard of care line of therapy available through routine clinical care, which included statins, ezetimibe and / or bepedic acid, icosapent ethyl, and anti-PCSK9 (alirocumab or evolocumab) or ANGPTL3 for at least 26 weeks prior to screening. (5) Subjects with homozygous familial hypercholesterolemia receiving PCSK9-targeted interfering RNA therapy (inclisiran) must have been exposed to refractory disease for at least 365 days prior to screening; (6) Subjects receiving available standard of care treatment lines including statins, ezetimibe and / or bepedic acid and / or PCSK9 and / or ANGPTL3 inhibitors must have been on the maximum tolerated and stable dose for >30 days prior to screening and have no planned dose increases during study participation; (7) Subjects undergoing apheresis should have had the procedure performed at a stable frequency for at least 12 weeks prior to screening and have no planned changes in frequency during study participation. rate; (8) female subjects must be postmenopausal (e.g., women with a uterus who have had amenorrhea for at least 12 consecutive months without alternative medical reasons or surgical infertility (i.e., documented hysterectomy, bilateral salpingectomy, and / or bilateral oophorectomy at least 1 month prior to screening)); (9) all male subjects must agree to use an acceptable and effective contraceptive method, and their female partners should also agree to use an effective contraceptive method as defined in the protocol from consent to 12 months after CTX310 infusion; (10) be willing and able to comply with scheduled visits, treatment plans, laboratory tests, contraceptive guidelines, and other study procedures; and (11) be willing to participate in long-term follow-up studies for up to 15 years after the completion of this study.
[0385] Exclusion criteria To be eligible for study entry, subjects must not meet any of the exclusion criteria listed below: (1) FCS subjects with confirmed genotypes of biallelic LPL or GP1HBP1 mutations; (2) evidence of liver disease (e.g., aspartate aminotransferase, alanine aminotransferase >2 × upper limit of normal (ULN), or total bilirubin value >2 × ULN, or baseline prothrombin time (international normalized ratio) >1.5 × ULN, or liver elastography measurement by FibroScan ≥7.5 kPa, or liver stiffness measurement by magnetic resonance elastography ≥4.15 kPa); (3) complete blood count: white blood cells <2,500 cells / μL; hemoglobin <11 g / dL for men and <10 g / dL for women; or platelet count <100,000 / μL; (4) baseline estimated glomerular filtration rate <60 mL / min / 1.73 m 2, as measured by the Modification of Dietin Renal Disease equation; (5) diagnosis of nephrotic syndrome or albuminuria, >2+ on urine dipstick; (6) inadequately controlled diabetes mellitus with glycated hemoglobin >9%; (7) history of alcohol or drug abuse and nonadherence to abstinence during the study duration; (8) history of significant coagulopathy; (9) uncontrolled or untreated thyroid disease (thyroid stimulating hormone <0.1 mIU / L or >10 mIU / L); (10) left ventricular ejection fraction <50% by echocardiography; (11) peripheral pulse oximetry <90%; (12) uncontrolled hypertension, defined as mean systolic blood pressure >160 mmHg and diastolic blood pressure >90 mmHg; (13) 12-lead electrocardiogram (ECG) findings showing, for example, QTc >450 in men at screening ms, and QTc>470 ms for females and / or any other ECG findings considered clinically significant by the investigator; (14) acute coronary syndrome event within 24 weeks prior to Day 1; (15) central nervous system (CNS) stroke within 24 weeks prior to Day 1; (16) acute pancreatitis within 12 weeks prior to Day 1; (17) current use or use within 365 days from Day 1 of any hepatocyte-targeted small interfering RNA or antisense oligonucleotide molecule (except inclisiran); (18) current use or use within 90 days from Day 1 of any monoclonal antibody therapy (except evolocumab, alirocumab, or ivizumab); (19) participation in another study drug / product within 30 days of Screening or <5 half-lives of the study agent (whichever is longer from Screening). (20) Current use of selective serotonin reuptake inhibitors, chronic systemic corticosteroid therapy, or anabolic steroids; (21) Current use of niacin-based supplements or nutraceuticals that may affect lipid levels at an unstable dose / amount >30 days prior to the screening visit; (22) Previous treatment with gene therapy / editing products; (23) Positive serology for human immunodeficiency virus type 1 (HIV-1) or HIV-2, hepatitis B virus (hepatitis B core antibody or nucleic acid test [NAT]), or hepatitis C virus (NAT); (24) History of any illness or any clinical condition that the investigator believes may confound the study results or impose additional risks on the subject when administering the study drug.This may include, but is not limited to, a history of relevant drug allergies, history of CNS disease, history or presence of clinically significant pathology, history of psychiatric illness, or history of familial cancer syndromes; (25) any prior or current malignancy or myeloproliferative disorder or significant immunodeficiency disorder; (26) females of childbearing potential (post-menarche, with an intact uterus and at least 1 ovary, and less than 1 year since spontaneous amenorrhea) or lactating females; (27) investigator assessment that the subject will not comply with the study procedures outlined in the protocol.
[0386] Statistical methods The study initially included approximately 24 subjects to provide a preliminary evaluation of the safety and effectiveness of CTX310. The safety and tolerability of CTX310 were evaluated in the safety analysis set using descriptive summaries. A summary of AEs, AESIs, clinical laboratory data, and other applicable safety measurements (e.g., ECG) for each dose level and overall of CTX310 is provided. In some embodiments, the summary of AEs focuses on AEs (TEAEs) that occur during treatment. The incidence of TEAEs is summarized by system organ classification and preferred terms, the severity level specified in the protocol, and the relationship with CTX310. The incidence of DLTs, serious adverse events, and AESIs is also summarized. The summary of clinical laboratory data includes the absolute values of selected laboratory parameters at scheduled visits and / or descriptive statistics of changes from baseline. The incidence of clinically significant laboratory abnormalities and other clinically significant safety measurements (e.g., ECG) is summarized.
[0387] The preliminary efficacy of CTX310 was evaluated in the full analysis set using descriptive summaries. Descriptive statistics for each dose level were used to summarize the percentage change in lipid concentrations (including TG, ApoB, non-HDL-C [including LDL, VLDL, IDL and Lp (a)] and HDL-C) over time compared to baseline. A categorical summary of appropriate cutoff values based on selected time points (including 26 weeks and 52 weeks after infusion) can be provided. PK and PD data were evaluated by descriptive and exploratory modeling (if applicable).
[0388] Research objectives and hypotheses In some embodiments, the primary objective is to evaluate the safety and tolerability of a single ascending dose of CTX310 in subjects with refractory dyslipidemia with elevated levels of TG and / or non-HDL-C and / or LDL-C and / or ApoB, and to determine the RP2D. In some embodiments, the secondary objective is to evaluate the preliminary efficacy, PK and PD of CTX310. No formal hypothesis testing was performed.
[0389] Study End Points In some embodiments, the primary endpoints include: the incidence of AEs, including treatment-emergent adverse events (TEAEs), AESIs, DLTs; clinically significant laboratory abnormalities; and clinically significant abnormal vital signs.
[0390] In some embodiments, secondary efficacy endpoints include: percentage change in TG, ApoB, non-HDL-C (including LDL, VLDL, IDL and Lp(a)) and HDL-C concentrations over time compared to baseline. In some embodiments, secondary pharmacokinetic / pharmacodynamic endpoints include: percentage change in plasma levels of LNP, plasma levels of Cas9 protein and ANGPTL3 concentrations over time compared to baseline.
[0391] In some embodiments, exploratory endpoints include: percent change from baseline in FFA levels over time, change in fatty liver disease, and immunogenicity of CTX310 (sampling and evaluating anti-drug antibodies to LNP and Cas9 if necessary).
[0392] Analysis Set In some embodiments, the following analysis set is evaluated and used to present data. In some embodiments, the selected set includes all subjects who signed the informed consent and met the inclusion / exclusion criteria. In some embodiments, the safety analysis set is a subset of the selected set including subjects who received CTX310 infusion. The analysis of safety evaluation is based on the safety analysis set. Subjects in the safety analysis set are classified by the CTX310 dose level received. In some embodiments, the full analysis set (FAS) is a subset of the safety analysis set including subjects who received CTX310 infusion and had at least 1 baseline post-lipid evaluation or stopped earlier. Efficacy analysis is performed based on FAS. Subjects in FAS are classified according to the CTX310 dose level received.
[0393] Sample size The sample size for this study was approximately 24 subjects.
[0394] Interim Analysis In some embodiments, no formal interim analysis of efficacy is planned. Safety and efficacy data are reviewed as needed during the study to monitor stopping rules and provide recommendations regarding inclusion or protocol amendments.
[0395] Planned analysis methods In some embodiments, the primary analysis occurs after all subjects complete 26 weeks of follow-up or stop earlier after CTX310 infusion. The final analysis occurs when all subjects complete or exit the study. In some embodiments, tables are generated for appropriate treatment, demographics, baseline, efficacy, and safety parameters. Unless otherwise stated, all data are listed by subject.
[0396] Efficacy analysis The full analysis set (FAS) is used as the analysis set for efficacy. Descriptive statistics for each dose level are used to summarize the efficacy endpoints of the percentage change in lipid concentration (including TG, ApoB, non-HDL-C (including LDL, VLDL, IDL and Lp (a)) and HDL-C) over time compared to baseline. A categorical summary at selected time points (including 26 weeks and 52 weeks) based on appropriate cutoff values can be provided.
[0397] Security Analysis Safety analysis set is performed. A summary of AEs, AESIs, clinical laboratory data, and other applicable safety measurements (e.g., ECG) for each dose level and overall of CTX310 is provided. In some embodiments, the summary of AEs focuses on TEAEs, which are defined as AEs that start or worsen during or after CTX310 infusion. AEs are graded according to CTCAE v5.0. The incidence of TEAEs is summarized by system organ classification and preferred terms, grades, and relationship with CTX310. Key subsets of TEAEs (including DLT, AESI, ≥ grade 3 AEs, related AEs, and SAEs) are summarized separately. In some embodiments, the summary of clinical laboratory data includes the absolute values of selected laboratory parameters at scheduled visits and / or descriptive statistics of changes from baseline. The incidence of clinically significant laboratory abnormalities and clinically significant abnormal vital signs is summarized. If applicable, the incidence of other clinically significant safety measurement abnormalities (e.g., ECG) can also be summarized.
[0398] Pharmacokinetic and pharmacodynamic analysis Descriptive statistics are used to summarize plasma levels of LNP and Cas9 protein over time. Exploratory analyses can be performed based on applicable PK models. Descriptive statistics are used to summarize the percent change in ANGPTL3 concentrations over time compared to baseline.
[0399] Biomarker analysis Additional exploratory biomarkers, including, for example, FFA levels, one or more fatty liver disease markers, and one or more immunogenicity markers, were summarized using descriptive statistics, if data were available.
[0400] Example 10 ANGPTL3 GLP toxicity study plasma protein levels Data showing reductions in ANGPTL3 plasma protein levels in non-human primates treated using the methods and compositions disclosed herein (e.g., a CTX310 drug product comprising an sgRNA targeting ANGPTL3 and a nucleic acid encoding Cas9) are provided in this Example.
[0401] Table 23 below shows an exemplary study design (see also Fig.29 ).
[0402] Table 23: CTX310 GLP tox nhp study design
[0403] Figure 30-Figure 33 ANGPTL3 plasma protein levels as ng / mL or % change from baseline from 0 to 6 months after administration of CTX310 to NHPs are shown in FIG.
[0404] the term In at least some previously described embodiments, one or more elements used in one embodiment may be interchangeably used in another embodiment, unless such replacement is technically infeasible. It will be appreciated by those skilled in the art that various other omissions, additions and modifications may be made to the method and structure described above without departing from the scope of the claimed subject matter. All such modifications and changes are intended to fall within the scope of the subject matter defined by the appended claims.
[0405] With respect to the use of substantially any plural and / or singular terms herein, those skilled in the art may convert from the plural to the singular and / or from the singular to the plural where appropriate for the context and / or application. For clarity, various singular / plural arrangements may be expressly set forth herein. As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural reminders unless the context clearly indicates otherwise. Unless otherwise indicated, any reference to "or" in this article is intended to encompass "and / or".
[0406] Those skilled in the art will understand that, in general, the terms used herein, and particularly in the appended claims (e.g., the bodies of the appended claims), are generally intended as "open" terms (e.g., the term "including" should be interpreted as "including but not limited to," the term "having" should be interpreted as "having at least," the term "includes" should be interpreted as "includes but is not limited to," etc.). Those skilled in the art will also understand that if a specific number of an introduced claim statement is intended, such an expectation will be expressly stated in the claim, and in the absence of such a statement, no such expectation is present. For example, as an aid to understanding, the following appended claims may contain the use of the prepositions "at least one" and "one or more" to introduce claim statements. However, the use of such phrases should not be construed as implying that the introduction of a claim recitation by the indefinite article "a" or "an" will limit any specific claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the preposition "one or more" or "at least one" and an indefinite article such as "a" or "an" (e.g., "a" and / or "an" should be interpreted as meaning "at least one" or "one or more"); the same applies to the use of definite articles to introduce claim recitations. Furthermore, even if a specific number of an introduced claim recitation is explicitly stated, one skilled in the art will recognize that such a statement should be interpreted as meaning at least the stated number (e.g., merely stating "two statements" without other modifiers means at least two statements, or two or more statements). Furthermore, in those cases where a convention similar to “at least one of A, B, and C, etc.” is used, such syntactic structure is generally intended in a sense that a person skilled in the art would understand the convention to mean (e.g., “a system having at least one of A, B, and C” would include, but is not limited to, systems having only A, only B, only C, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.).In those cases where a convention similar to "at least one of A, B, or C, etc." is used, such syntactic construction is generally intended in a sense that one skilled in the art would understand the convention to mean (e.g., "a system having at least one of A, B, or C" would include, but is not limited to, systems having only A, only B, only C, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). One skilled in the art would also understand that, in practice, any transitional words and / or phrases presenting two or more alternative terms, whether in the specification, claims, or drawings, should be understood to contemplate the possibility of including one of the terms, either of the terms, or both of the terms. For example, the phrase "A or B" should be understood to include the possibility of "A" or "B" or "A and B."
[0407] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0408] As will be understood by those skilled in the art, for any and all purposes, such as in providing written description, all scopes disclosed herein also include any and all possible sub-ranges and combinations of sub-ranges thereof.Any listed scope can be easily identified as fully describing and enabling the same scope to be decomposed into at least equal half, one-third, one-quarter, one-fifth, one-tenth, etc. As a non-limiting example, each scope discussed herein can be easily decomposed into lower third, middle third, and upper third, etc. As will be understood by those skilled in the art, all languages, such as "up to", "at least", "greater than", "less than", etc. include stated numbers, and refer to the scope that can be subsequently decomposed into sub-ranges as discussed above.Finally, as will be understood by those skilled in the art, scope includes each individual member.Therefore, for example, a group with 1-3 articles refers to a group with 1, 2 or 3 articles.Similarly, a group with 1-5 articles refers to a group with 1, 2, 3, 4 or 5 articles, etc.
[0409] While various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims.
Claims
1. A method for treating angiopoietin-like 3 (ANGPTL3)-associated disease or disorder in a subject in need thereof, comprising administering to the subject more than one nanoparticle complexed with: (a) a guide RNA (gRNA) targeting an ANGPTL3 gene or a nucleic acid encoding the gRNA, and (b) a nucleic acid encoding an RNA-guided endonuclease, thereby treating the ANGPTL3-associated disease or disorder in the subject.
2. The method of claim 1, wherein ANGPTL3 expression in the subject is reduced by at least 20%, at least 40%, or at least 70% following the administration.
3. The method of any one of claims 1-2, wherein the concentration of ANGPTL3 protein in the subject's plasma is reduced by at least 20%, at least 40%, or at least 70% following the administration.
4. The method of any one of claims 2-3, wherein the reduction is relative to (a) ANGPTL3 expression or concentration of ANGPTL3 protein in the subject's plasma prior to administration of the more than one nanoparticles; (b) ANGPTL3 expression or concentration of ANGPTL3 protein in one or more untreated subjects; and / or (3) a reference level of ANGPTL3 expression or concentration of ANGPTL3 protein in healthy subjects.
5. The method of any one of claims 1-4, wherein the subject's plasma levels of one or more of non-high-density lipoprotein (non-HDL) lipids are reduced by at least 20%, at least 40%, or at least 70% following the administration.
6. The method of claim 5, wherein one or more of the non-HDL lipids are triglycerides, very low density lipoprotein (VLDL), low density lipoprotein (LDL), or a combination thereof.
7. The method of any one of claims 5-6, wherein the reduction in non-HDL levels is relative to (a) the non-HDL level in the subject's plasma before administration of the more than one nanoparticle; (b) the non-HDL level in one or more untreated subjects; and / or (3) a reference non-HDL level in a healthy subject.
8. The method of any one of claims 1-7, wherein the concentration of apolipoprotein B (ApoB) protein in the subject's plasma is reduced by at least 20%, at least 40%, or at least 70% after the administration.
9. The method of claim 8, wherein the reduction is relative to (a) the concentration of ApoB protein in the subject's plasma prior to administration of the more than one nanoparticle; (b) the concentration of ApoB protein in one or more untreated subjects; and / or (3) a reference level of ApoB protein concentration in healthy subjects.
10. The method of any one of claims 2-9, wherein the reduction in the concentration of the ANGPTL3 protein, the level of one or more of the non-high-density lipoprotein (non-HDL) lipids, and / or the concentration of the ApoB protein is at least 20%, at least 40%, or at least 70% three weeks, four weeks, five weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, or more after the administration.
11. The method of any one of claims 2-9, wherein the reduction in the concentration of the ANGPTL3 protein, the level of one or more of the non-high-density lipoprotein (non-HDL) lipids, and / or the concentration of the ApoB protein by at least 20%, at least 40%, or at least 70% is sustained for four weeks, two months, three months, six months, one year, three years, six years, ten years, or more after the administration.
12. The method according to any one of claims 1-11, wherein the subject in need thereof has a triglyceride level greater than 300 mg / dL, a non-high-density lipoprotein (HDL) level greater than 160 mg / dL, a low-density lipoprotein cholesterol (LDL-C) level greater than 100 mg / dL, an ApoB level greater than 100 mg / dL, or a combination thereof.
13. The method of any one of claims 1-11, comprising measuring blood levels of one or more of ANGPTL3, ApoB, triglycerides, very low density lipoprotein (VLDL), low density lipoprotein (LDL), LDL-C, HDL, and non-HDL lipids in the subject before, during, and / or after the administration.
14. The method of any one of claims 1-13, comprising identifying a subject in need of said treatment.
15. The method of any one of claims 1-14, wherein the ANGPTL3-related disease or disorder is a metabolic disease, a cardiovascular disease, a lipid metabolism disease, or a combination thereof.
16. The method of any one of claims 1-15, wherein one or more symptoms of the ANGPTL3-related disease or disorder in the subject are reduced or alleviated.
17. The method of any one of claims 1-16, wherein the ANGPTL3-related disease or disorder is obesity, diabetes, atherosclerosis, dyslipidemia, coronary heart disease, non-alcoholic fatty liver disease (NAFLD), hyperfatty acidemia, metabolic syndrome, or a combination thereof.
18. The method of claim 17, wherein the dyslipidemia is hyperlipidemia, and optionally the hyperlipidemia is hypercholesterolemia, hypertriglyceridemia, or both.
19. The method of claim 18, wherein the ANGPTL3-related disease or disorder is familial hypercholesterolemia, familial combined hyperlipidemia, familial chylomicronemia syndrome, multifactorial chylomicronemia syndrome, elevated Lp(a), or a combination thereof.
20. The method of claim 17, wherein the NAFLD is hepatic steatosis or steatohepatitis.
21. The method of claim 17, wherein the diabetes is type 2 diabetes or type 2 diabetes with dyslipidemia.
22. The method of any one of claims 1-21, wherein administering the more than one nanoparticle to the subject reduces dyslipidemia, cardiovascular risk, likelihood of death related to a cardiovascular event, or a combination thereof.
23. The method of any one of claims 1-22, wherein the RNA-guided endonuclease is a Cas9 endonuclease.
24. The method of any one of claims 1-23, wherein the nucleic acid encoding the RNA-guided endonuclease is an mRNA of the RNA-guided endonuclease.
25. The method of claim 23, wherein the Cas9 endonuclease is Streptococcus pyogenes (S. Pyogenes) Cas9, Staphylococcus aureus (S. aureus) Cas9, Neisseria meningitidis (N. meningitides) Cas9, Streptococcus thermophilus (S. thermophilus) Cas9, Streptococcus thermophilus 3 Cas9, Treponema denticola (T. denticola) Cas9 or a variant thereof.
26. The method of any one of claims 1-25, wherein the gRNA is a single guide RNA (sgRNA).
27. The method of any one of claims 1-26, wherein the gRNA targets exon 1 of the ANGPTL3 gene.
28. A method according to any one of claims 1-26, wherein the gRNA comprises a spacer sequence of any one of SEQ ID NOs: 3-9 and SEQ ID NOs: 20-26.
29. The method of any one of claims 1-28, wherein the gRNA or the nucleic acid encoding the gRNA and the nuclease guided by the RNA are encapsulated in the nanoparticle; and optionally wherein the nanoparticle is a lipid nanoparticle.
30. The method of any one of claims 1-29, wherein the subject is a primate, and optionally the subject is a human.
31. The method according to any one of claims 1-30, further comprising determining the level of one or more of (i) alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), bilirubin, alkaline phosphatase (Alk Phos), and albumin in the subject before, after, or both of the administration; (ii) prothrombin time (PT) and / or (iii) partial thromboplastin time (PTT).
32. The method of claim 31, wherein the determining comprises determining (i), (ii) and / or (iii) in the subject once, twice, three times, or daily until day 28 after the administering.
33. The method of claim 31, wherein the determining comprises determining (i), (ii) and / or (iii) in the subject daily, weekly or monthly for at least 3 months, at least 6 months or at least 12 months after the administering.
34. The method of any one of claims 1-33, wherein the more than one nanoparticle is administered to the subject at a single dose of about 0.1 mg / kg, 0.3 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 1 mg / kg, 1.5 mg / kg, 2.0 mg / kg, 2.5 mg / kg, or 3.0 mg / kg of nucleic acid (a) and (b).
35. A method for treating angiopoietin-like 3 (ANGPTL3)-associated disease or disorder in a subject in need thereof, comprising administering to the subject more than one nanoparticle complexed with (a) and (b) at a single dose of about 0.1 mg / kg, 0.3 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 1 mg / kg, 1.5 mg / kg, 2.0 mg / kg, 2.5 mg / kg or 3.0 mg / kg of nucleic acid (a) a gRNA targeting an ANGPTL3 gene (ANGPTL3 gRNA) and (b) Cas9 mRNA, thereby treating the ANGPTL3-associated disease or disorder in the subject.
36. The method of any one of claims 1-35, wherein the method comprises a single administration of the more than one nanoparticle to the subject.
37. The method of claim 36, wherein the more than one nanoparticle is administered to the subject in the single administration at or about 0.5 mg / kg, 0.6 mg / kg, 1 mg / kg, 1.5 mg / kg, 2.0 mg / kg, 2.5 mg / kg, or 3.0 mg / kg of nucleic acid (a) and (b).
38. The method of any one of claims 1-37, wherein the more than one nanoparticle is administered to the subject two or more times, and optionally wherein each two of the two or more administrations are separated by about two weeks to about four weeks, or wherein each two of the two or more administrations are separated by at least about 1 year, about 2 years, or about 5 years.
39. The method of any one of claims 1-38, wherein an additional treatment is administered to the subject, wherein the additional treatment comprises administration of a corticosteroid, an anti-H1 antihistamine, an anti-H2 antihistamine, or any combination thereof.
40. The method of claim 39, wherein the additional treatment is administered to the subject 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, or more prior to administering the more than one nanoparticle to the subject.
41. The method of claim 39, wherein the additional treatment and the more than one nanoparticles are administered simultaneously.
42. A method according to any one of claims 1-41, wherein the gRNA comprises a spacer sequence of SEQ ID NO: 3, SEQ ID NO: 20 or SEQ ID NO:
12.
43. A method according to any one of claims 1-42, wherein the gRNA comprises a sequence of SEQ ID NO: 10 or SEQ ID NO:
13.
44. The method of any one of claims 1-43, wherein a single dose of the more than one nanoparticle is complexed with (a) about 1.5 mg / mL of ANGPTL3 gRNA and (b) about 0.5 mg / mL of Cas9 mRNA; and optionally, the single dose of the more than one nanoparticle is about 58.2 mg / mL.
45. A composition comprising more than one nanoparticle complexed with (a) a guide RNA (gRNA) targeting an ANGPTL3 gene (ANGPTL3 gRNA) and (b) an mRNA encoding a Cas9 endonuclease, wherein the gRNA comprises a spacer sequence of SEQ ID NO: 3, SEQ ID NO: 20, or SEQ ID NO:
12.
46. A composition according to claim 45, wherein the gRNA comprises a sequence of SEQ ID NO: 10 or SEQ ID NO:
13.
47. The composition of any one of claims 45-46, wherein the Cas9 endonuclease is a Streptococcus pyogenes Cas9 endonuclease.
48. The composition of any one of claims 45-47, wherein the concentration of the more than one nanoparticle is about 58.2 mg / mL and is complexed with a total of about 2 mg / mL of nucleic acid of (a) the ANGPTL3 gRNA and (b) the Cas9 mRNA.
49. The composition of any one of claims 45-47, wherein the concentration of the more than one nanoparticle is about 58.2 mg / mL and is complexed with (a) about 1.5 mg / mL of the ANGPTL3 gRNA and (b) about 0.5 mg / mL of the Cas9 mRNA.
